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Zusammenfassung 
Die Parkinson-Krankheit ist die zweithäufigste neurodegenerative Erkrankung und betrifft 1-2% der 
Bevölkerung älter als 55 Jahre. Bis heute sind die Mechanismen der Neurodegeneration in dieser 
Erkrankung unklar. Vieles deutet auf eine Beteiligung von α-Synuclein, ein präsynaptisch 
hochexprimiertes neuronales Protein. Fehlgefaltetes und aggregiertes α-Synuclein stellt die 
Hauptkomponente von Lewy-Körpern, charakteristischen pathologischen Ablagerungen in Gehirnen 
von Parkinson Patienten, dar. Insofern stellt die Reduktion der Expression von α-Synuclein durch eine 
erhöhte Degradation ein interessantes therapeutisches Ziel dar. Allerdings sind die genauen 
Mechanismen dieses intrazellularen Abbaus von α-Synuclein unklar. In vitro wird monomeres α-
Synuclein sowohl proteasomal als auch lysosomal katabolisiert.  α-Synuclein ist als ein Substrat der 
Chaperon-vermittelten Autophagie (CMA) beschrieben, ein Prozess in dem zum Abbau vorgesehene 
Proteine direkt LAMP2A-vermittelt in das Lumen von Lysosomen translozieren. Eine Mutation des 
CMA-Erkennungsmotivs (∆CMA) von α-Synuclein erhöht dessen Halbwertszeit; ebenso führt eine 
Reduktion der LAMP2A Expression in primären Neuronen zu erhöhter  α-Synuclein Expression. 
Pathogene Mutanten von α-Synuclein (A30P, A53T) sind zudem als Inhibitoren des LAMP2A 
Rezeptors beschrieben und könnten daher den lysosomalen Abbau von α-Synuclein hemmen. Das 
Ziel dieser Studie war es, die Auswirkungen einer CMA-Motiv-Mutation auf dessen Expression in in 
vitro-und in vivo-Modellen zu untersuchen: 
(1) Für die in-vitro-Studien sind in induzierbaren Zelllinien (nicht-neuronalen und neuronalen) 
verschiedene C-terminal verkürzte (∆CT) α-Synuclein Varianten (WT und A53T) mit dem normalen 
(Wildtyp) oder mutierten CMA-Motiv exprimiert worden (∆CMA). Durch den Vergleich der 
kinetischen Abbaukurven des  α-Synucleins in diesen Zelllinien fanden wir – unerwartet – das die 
Mutation des CMA-Motivs nicht zu signifikanten Unterschieden in der Kinetik des Abbaus führt. Die 
zur Kontrolle analysierten Volllängenkonstrukte (Wildtyp und A53T-Mutante) zeigten -  in 
Übereinstimmung mit früheren veröffentlichten Daten – eine verlangsamte Degradation bei der 
A53T-Mutante (im Vergleich zum Wildtyp Konstrukt).  
(2) Für die in-vivo-Studien sind zwei transgene Mausmodelle mit Expression von  C-terminal 
verkürzten α-Synuclein in zerebellären Purkinje-Zellen (PZ) (Konstrukt 1: A53T-∆CT, Konstrukt 2: 
A53T-∆CMA) generiert wurden. Die Analyse dieser Tiere fand mit histologischen und biochemischen 
Methoden sowie in Verhaltensexperimenten statt. α-Synuclein wurde stark in den präsynaptischen 
Bereichen der Purkinje-Zellen exprimiert, sowie im Perikaryon und den Neuriten der PZ. Es konnten 
jedoch keine α-Synuclein Aggregate (resistent gegen Proteinase K) erkannt werden; ebenso konnte 
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kein signifikanter Verlust an Purkinje-Zellen nachgewiesen werden. Auch morphologischen 
Veränderungen der Purkinje-Zellen war nicht nachweisbar. Interessanterweise zeigten transgene 
Mäuse Beeinträchtigungen im Motorverhaltenstests (Pole Test und Open-Field). Die Korrelation 
dieser Verhaltensauffälligkeiten mit α-Synuclein bleibt unklar. Die in unseren beiden transgenen 
Linien beobachteten ähnlichen Motorphänotype und sowie fehlende Unterschiede in der α-
Synuclein Expression legen allerdings nahe, dass die Mutation des α-Synuclein CMA Motiv keinen 
Einfluss auf die Abbaukinetik dieses Proteins in vivo hat. Folglich konnte keine wesentliche 
pathologische Rolle des CMA-System im in-vivo-Modell nachgewiesen werden.  
Zusammen genommen zeigen die in vitro und in vivo Daten, dass das CMA-System in Zusammenhang 
mit der Überexpression eines C-terminal verkürzten α-Synuclein keinen Einfluss auf die Abbaukinetik 
von α-Synuclein hat. Das Fehlen einer offensichtlicher Pathologie in unserem Tiermodell begrenzt 
jedoch die Interpretation der in vivo Daten in Bezug auf eine eventuell unterschiedliche 
Bildungskinetik aggregierten α-Synucleins. 
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Summary 
Parkinson's disease (PD) is the second most common neurodegenerative disease and affects 1-2% of 
the population older than 55 years. To date, the mechanisms of neurodegeneration in PD remain to 
be elucidated. Strong evidence suggests that aggregation of α-Synuclein, a small membrane-bound 
protein abundantly present in presynaptic regions of neuronal cells, is highly involved in the process 
of neurodegeneration. Misfolded and aggregated structures of α-Synuclein are the main components 
found in Lewy bodies and are characteristic pathological features in parkinsonian brains. Therefore, 
down-regulating of α-Synuclein levels by enhancing its degradation represents an interesting 
therapeutic target. However, the exact mechanisms of intracellular α-Synuclein clearance are 
unclear. In vitro, monomeric α-Synuclein is degraded by both proteasomal and lysosomal systems, 
but α-Synuclein oligomers are thought to block these degradation pathways. Recently, α-Synuclein 
has also been demonstrated to be a substrate of the chaperone-mediated autophagy (CMA), a 
pathway in which proteins are directly translocated into the lysosome lumen via the lysosomal 
membrane receptor LAMP2A. Mutation of the CMA-motif (∆CMA) of α-Synuclein increases its half-
life and down-regulation of LAMP2A leads to increased α-Synuclein levels in primary neurons. 
Pathogenic mutants of α-Synuclein (A30P, A53T) have also been proposed to act as blockers of 
LAMP2A and therefore might inhibit the lysosomal degradation pathways in cellular models thereby 
increase cytotoxicity. The impact of these mutations in vivo remains to be explored.  
The aim of this study was to determine the impact of CMA-motif mutation using in vitro and in vivo 
models:  
(1) In in vitro studies, we generated inducible cell lines (non-neuronal and neuronal) expressing 
different C-terminal truncated (∆CT) α-Synuclein (WT and A53T) containing wild-type or mutated 
CMA motif (∆CMA). By comparing kinetic degradation curves of α-Synuclein in these cell lines using 
western-blot, we found that, unexpectedly, CMA mutation did not lead to significant differences in 
the kinetics of degradation. There was also no difference in α-Synuclein clearance between cell lines 
expressing WT or A53T constructs. To further understand this, we generated two additional cell lines 
expressing full-length (FL) α-Synuclein (WT and A53T). Interestingly, we found that A53T mutation 
slowed down the degradation of overexpressed α-Synuclein compared to WT in agreement with 
previous published data.  
(2) In in vivo studies, two transgenic mouse models expressing C-terminal truncated α-Synuclein in 
cerebellar Purkinje cells (PCs) (construct 1: A53T-∆CT, construct 2: A53T-∆CMA) were generated. The 
analysis of these animals using histological, biochemical and behavioral approaches was conducted in 
parallel. α-Synuclein was highly expressed in the presynaptic areas, and in the cell perikaryon and 
neurites of PCs. However, the presence of α-Synuclein oligomers (resistant to proteinase K) was not 
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detected and there was no significant loss of PC numbers compared to control lines. Moreover, no 
morphological changes in neuritic layer of PCs were observed. Interestingly, transgenic mice showed 
impairments in motor behavioral tests (pole-climbing test and open-field). The correlation of these 
phenotypes with α-Synuclein related pathology remains unclear. On the other hand, the similar 
motor behavior and α-Synuclein protein levels observed in our two transgenic lines suggest that 
mutation of the α-Synuclein CMA motif does not affect the clearance kinetics of this protein and 
consequently does not play a significant pathological role in the in vivo model. 
Taken together, in vitro and in vivo data showed that overexpression of C-terminal truncated α-
Synuclein ∆CMA does not affect the degradation kinetics of α-Synuclein. ∆CMA also does not result 
in a differentiation of pathological development in animal models. However, absence of obvious 
pathology in our animal models limits the interpretation from in vitro to in vivo.  
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1 Introduction 
1.1 Generalities 
The symptoms of Parkinson’s disease (PD) have been described since ancient times. The disease was 
named in honor of James Parkinson, a London physician, who was the first one to describe the 
clinical features of this disorder in his monograph entitled “An Essay on the Shaking Palsy” appeared 
in 1817 (Figure 1.1). The term “Shaking Palsy” or “Paralysis Agitans” was defined in his manuscript as 
follows:  
“Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when 
supported; with a propensity to bend the trunk forwards, and to pass from a walking to a running 
pace: the senses and intellects being uninjured…”  
PD is the second most common neurodegenerative disorder with an average onset age of about 60 
years. Around 5 million people throughout the world get PD; the prevalence of PD in industrialized 
countries is estimated at 0.3% of the population and 1-2% of those older than 60 years. Reported 
standardized incidence rates of PD are 8-18 per 100 000 person-years. In addition to age, several 
prospective studies found evidence for a higher incidence of PD in men than in women. Interestingly, 
cross-cultural variations in the prevalence of PD suggest differences in environmental exposure or 
distribution of susceptibility genes. In the same manner, PD has been reported to be less common in 
African and Asian people than in the Caucasian population. The mortality rate is consistently 
reported to be about two-fold higher for PD patients than the general population (reviewed in 
Wirdefeldt et al., 2011). Socioeconomic impact of the disease is important, direct and indirect costs 
spent for PD are estimated at around $23 billion in United States and €14 billion in Europe. These 
costs are predicted to increase in upcoming years due to an oncoming wave of world-wide aging 
population (reviewed in Mhyre et al., 2012; Olanow et al., 2009).  
Parkinsonism is defined as a combination of four specific motor features: low-frequency resting 
tremor, rigidity of the skeletal muscles of the face and hands, slowness of movement (bradykinesia), 
gait dysfunction or postural instability. PD is the most common form of Parkinsonism representing 
about 75% of diagnosed movement disorder cases. Not all of these features need to be present but 
at least two of those are required to be diagnosed for Parkinsonism. Although mainly defined as a 
movement disorder, the disease can be associated with many non-motor symptoms such as 
autonomic dysfunction, pain and sensory disturbances, mood or sleep disorders and dementia 
(Mhyre et al., 2012; Olanow et al., 2009).  
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1.2 Etiology of PD 1.2.1 Genetic factors 
To date, 5 to 10% of patients with PD have a familial inheritance. At least 16 loci are associated with 
both autosomal dominant and autosomal recessive forms of monogenetic PD. These genes are 
designated as PARK1 to PARK16 (Table 1.1). The knowledge of monogenetic factors in PD is 
constantly evolving and the functions of all of these genes have not been fully elucidated. Functional 
studies of these genes have progressively revealed key converging molecular pathways involving 
mechanisms leading to neuronal cell death in PD. Impairments of lysosomal pathways and 
mitochondrial dysfunction are most prominent in PD pathogenesis (Figure 1.2). 
Mutations of the two autosomal dominant PD genes SNCA (encoding α-Synuclein) and LRRK2 
(encoding Leucine-rich repeat kinase 2) produce classical, late onset disease with α-Synuclein-
positive Lewy bodies. Accumulation of  α-Synuclein aggregates and other proteins in Lewy bodies is 
the main histopathology feature of PD. Interestingly,  α-Synuclein mutants are suggested to impair 
proteolytic systems such as ubiquitin proteasome system (UPS) (Stefanis, 2001) or autophagy-
lysosomal pathways (ALP) (Cuervo et al., 2004) which subsequently prevent protein degradation 
(reviewed in Xilouri M, 2009) (Figure 1.3).  
Figure 1.1: Historical beginning of Parkinson‘s disease (PD) research.
In 1817, James Parkinson described the clinical features of this disorder in his manuscript “An Essay on the
Shaking Palsy”. In 1886, Sir William Richard Gowers documented on PD in in his book “A Manual of Diseases of
the Nervous System”.
A Manual of Diseases of the Nervous System 
(William Richard Gowers,1886)
Dr James Parkinson (1755-
1824)
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LRRK2 encodes a large (280 kDa) kinase protein of the ROCO family which is widely expressed in 
diverse tissues and cell types. ROCO proteins contain a characteristic Ras-of-Complex (ROC) GTPase 
domain. Interestingly, all of LRRK2 gene mutations are located in or near the “enzymatic core” of the 
protein. The native substrates and normal function of LRKK2 remain however largely unknown. 
Interestingly, LRRK2 had been identified in vitro to be implicated in diverse pathways including 
regulation of autophagy-lysosomal pathways (reviewed in Cookson, 2012;Manzoni, 2012).  
Mutations of other PARK genes are also linked to ALP. Mutations of the PARK9 gene ATP 13A2 
encoding a large trans-membrane lysosomal ATPase is associated with Kufor-Rakeb syndrome (KRS), 
a form of recessively inherited atypical Parkinsonism. Certain studies suggest that loss of functional 
ATP 13A2 might lead to lysosomal dysfunction and impairs autophagic pathways (Usenovic et al., 
2012a;Usenovic et al., 2012b). The most definitive evidence for lysosomal function in sporadic PD 
came from the discovery that GBA mutation carriers develop also Parkinsonism (Cullen et al., 2011). 
Mutations of GBA encoding glucocerebrosidase (GCase) cause Gaucher's disease, a lysosomal storage 
disorder while GCase enzymatic activity is crucial for lysosomal function (reviewed in Tofaris, 2012). 
In contrast to autosomal dominant genes, mutations of autosomal recessive PARK genes like PARKIN, 
PINK1 and DJ1 tend to cause earlier onset Parkinsonism with or without α-Synuclein positive Lewy 
pathology and generally with a more slowly evolving, more clinically manageable disease. Parkin and 
Figure 1.2: Hypothesis of pathogenesis pathways in PD.
Schema attempts to illustrate that many factors, and not a individual one, might contribute to events leading to
neuronal cell death in PD (adapted from Olanow et al., 2007).
Genetic 
factors
Environment 
factors
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PINK1 (PTEN-induced novel kinase -1) have been shown to regulate the process of mitochondria 
degradation by autophagy (mitophagy). PINK1 exists as a dimer present at mitochondrial membrane 
and might play a pivotal role in regulation of mitochondrial quality control. Parkin is a cytosolic E3 
ubiquitin ligase capable of ubiquitination of mitofusins localized on mitochondrial surface and 
promotes mitochondrial fusion. Recruitment of Parkin requires the kinase activity of PINK1 under 
mitochondrial membrane depolarization (Rakovic et al., 2011; Shiba-Fukushima et al., 2012). DJ-1 is 
known as a chaperone protein which might function as a redox sensor helping to protect 
mitochondria against oxidative stress (Mullett et al., 2013;Ramsey et al., 2010). Similar pathology 
symptoms of mutation carriers of these genes and their close intracellular location suggest an 
interconnection between Parkin, PINK1 and DJ-1 playing a role in maintaining mitochondria integrity 
(reviewed in Cookson, 2012). 
 
 
Proteolytic equilibrium
Proteolytic stress Aggresome Lewy body
Figure 1.3: A model for Lewy body (LB) formation.
Under normal physiological conditions, there is a dynamic balance between the production of unwanted proteins
and their degradation. In PD, proteolytic stress is induced as a result of impaired degradation or excess
production of unwanted proteins (mutant, misfolded, denatured, and damaged proteins). These proteins begin to
accumulate and aggregate and are actively transported along microtubules to the perinuclear centrosome.
Sequestered components are encased by cytoskeletal elements such as neurofilaments to form an aggresome
with a distinct core and a peripheral halo. If sequestered proteins are successfully degraded, proteolytic
equilibrium is restored. However, if the proteolysis in aggresomes fails as a result of defects in the protein
degradation machinery or the overwhelming production of abnormal proteins, the aggresome continues to expand
and form an insoluble mass of proteins—a Lewy body (adapted from Olanow etal., 2004)
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 1.2.2 Environmental factors 
While genetic factors may explain disease risks for PD, the majority of PD cases are sporadic. This 
indicates that environmental factors or life styles represent potential risks for disease development. 
Interest in environmental factors has been raised over the past decades since the anecdotal report 
that intravenous injection of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced 
Parkinsonism in a 23-year-old man (Davis et al., 1979). MPTP is a neurotoxin precursor of MPP+ 
which is taken up by dopaminergic neurons via the dopamine transporter and provokes 
dopaminergic neuron loss in the substantia nigra in the brain (reviewed in Przedborski et al., 2004). 
MPTP has been largely used to generate various animal models for the disease studies (reviewed in 
Gene/locus Chromosomal 
location
Mode of 
inheritance
Distinctive clinical features Reference
SNCA
(PARK1/ 
PARK4)
4q21 Dominant Relatively early onset, less 
tremor, rapid progression
Polymeropoulos, 
1997
Singleton,2003
Parkin
(PARK2)
6q25 Recessive Early-juvenile onset, dyskinesia, 
dystonia,  slow progression
Kitada, 1998
PARK3 2p13 Dominant Dementia Gasser, 1998
UHCL-1 
(PARK5)
4p14 Dominant None Leroy, 1998
PINK1 
(PARK6)
1p35-36 Recessive Early onset, slow progression Valente, 2004
DJ-1  
(PARK7)
1p36 Recessive Early onset, dystonia,
psychiatric symptoms 
Bonifati, 2003
LRKK2 
(PARK8)
12q12 Dominant None Paisan-Ruiz, 2004 
Zimprich, 2004
ATP13A2 
(PARK9)
1p36 Recessive Early onset, rapid progression, 
pyramidal signs, dementia
Ramirez, 2006
PARK10 1p32 - None Hicks, 2002
GIGYF2 
(PARK11)
2q36-37 - None Pankratz, 2002
Lautier, 2008
PARK12 Xq21-25 - None Pankratz, 2003
Omi/HtrA2 
(PARK13)
2p12 Dominant None Strauss, 2005
PLA2G6 
(PARK14)
22q12-13 Recessive Early onset, dystonia, pyramidal 
signs
Paisan-Ruiz, 2004
FBXO7 
(PARK15)
22q12-13 Recessive Early onset, pyramidal signs Shojaee, 2008
PARK16 1q32 - None Satake, 2009
Table 1.1: Parkinson‘s disease genes and loci (adapted from Wirdefeldt et al., 2011)
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(Porras et al., 2012). Although the exposure risk to MPTP is rare for humans, MPTP structure is very 
similar to paraquat which is widely used as herbicide. Similarly, another compound frequently used 
as pesticide or insecticide, rotenone, was also identified to increase the risk of developping PD 
(reviewed in Tieu, 2011). Supporting this, epidemiological studies have correlated rural living, 
farming profession and well water use with higher risks of developing PD. However, a causal 
relationship between pesticides and PD has not been fully established. 
Parallel to environmental "neurotoxic" factors, certain "neuroprotective" factors such as smoking, 
coffee or tea consuming, antioxidants or physical activities have been suggested. Both nicotine (Quik 
et al., 2012) and caffeine (Kalda et al., 2006) have been identified as neuroprotective factors. 
Interestingly, nicotine inhibits formation of α-Synuclein fibrils in vitro (Ono et al., 2007). 
Mechanistically, nicotine may exerts it effects by acting on nicotinic receptors (nAChRs) which are 
widely distributed throughout the brain by enhancing calcium signaling, that activates neuronal 
survival pathways and decrease apoptotic signals (reviewed in Wirdefeldt et al., 2011). Caffeine may 
act as an adenosine receptor antagonist. The enrichment of adenosine receptors in basal ganglia 
offers an interesting, unique non-dopaminergic target for the treatment of PD (reviewed in 
Wirdefeldt et al., 2011). The role of antioxidants has also been extensively studied based on the 
hypothesis that an increase in oxidative stress could be harmful to neurons. However, only few links 
are presently established nowadays between the intake of antioxidants and a lower risk of PD 
(vitamin E, B6, folic acid and others) and the beneficial effects of some antioxidants risk remain 
controversial (reviewed in Wirdefeldt et al., 2011). 
1.3 Neuropathological features of PD 
60-70% of dopaminergic neurons are lost in the substantia nigra pars compacta (SNpc or black 
substance) at the presence of motor symptoms (reviewed in Olanow et al., 2009). Histology studies 
from PD patients show that the disease is characterized by intracytoplasmic formation of inclusions, 
also known as Lewy bodies (LBs) or Lewy neurites (LNs) (Figure 1.4). The first descriptions of these 
inclusions were done by Heinrich Lewy in 1912. Later, the works from Russian neuropathologist 
Tretiakoff confirmed the presence of these inclusions which were termed as “corps de Lewy”. 
Immunohistochemical staining showed that these inclusions are composed of a variety of proteins, 
with a majority of α-Synuclein, ubiquitin (Ub) and neurofilaments (Lennox et al., 1989; Schmidt et al., 
1991; Spillantini et al., 1997; Spillantini et al., 1998). They also contain components of the ubiquitin-
proteasome system and heat-shock proteins Hsp70 and Hsp90 (Auluck et al., 2002;McNaught et al., 
2002). Within LBs, proteins may be oxidized, nitrated, ubiquitinated or phosphorylated (Castellani et 
al., 2002; Fujiwara et al., 2002; Good et al., 1998). Proteomic studies have demonstrated 296 
proteins in cortical LBs, whereas 90 proteins have been identified in brainstem LBs (Leverenz et al., 
2007). Other than proteins, these inclusions are enriched in lipids, but carbohydrates and nucleic 
22 
 
acids have not been detected (Gai, 2000). The presence of LBs is, however, not related to cell toxicity, 
it remains to be elucidated their physiological role in neuron survival and whether their formation is 
neuroprotective or harmful. 
 
Although LBs are found typically in dopaminergic neurons of the SNpc, they are also detected in 
other brain areas, spinal cord or peripheral nervous system. Other neurological disorders are also 
linked to the presence of LBs, such as dementia with Lewy bodies (DLB), Multiple System Atrophy 
(MSA) or Alzheimer’s disease (AD). Braak’s and collaborators have established six characteristic 
stages of the disease, the so-called “Braak’s staging” (Braak, 2003). According to the authors, α-
Synuclein aggregate structures may appear and spread throughout the nervous systems in a “prion-
like” manner, following a caudo-rostral progression (Figure 1.5). Recent evidence support this 
hypothesis: spreading and in vivo seeding of α-Synuclein aggregation was first demonstrated by the 
Figure 1.4: Neuropathology features in PD.
A: Schema representing loss of dopaminergic neurons in substantia nigra (SN) in PD compared to healthy brain.
B: Lewy body in SNc neurons stained with Hematoxylin and Eosin (Olanow and McKnaught, 2011). Structurally,
classical LBs are spherical, 8-30 µm in diameter and have pink color with heamatoxylin and eosin staining. They
are characterized by a central core intensively stained in contrast to peripherical halo which are slightly stained.
Under electronic microscopy observation, their center contains dense granular material whereas the outer regions
are composed of ordered arrangement of radiating filaments of 7-20 nm in diameter (Olanow et al., 2004)
A
B
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induction of Lewy bodies within normal neuronal stem cells transplanted into Parkinson’s disease 
patients (Kordower et al., 2008; Li et al., 2008). This paradigm was subsequently replicated in mice 
(Desplats et al., 2009; Hansen et al., 2011; Luk et al., 2009). Moreover, α-Synuclein exhibits a seeding 
behavior when introduced into cultured cells (Desplats et al., 2009; Hansen et al., 2011; Nonaka et 
al., 2010). 
In addition to profound dopaminergic cell loss and presence of Lewy pathology, post-mortem 
analysis of PD brains show increased glial cell (astrocytes and microglia) number and activation state  
(McGeer et al., 1988). Activation of these cells responds inflammatory signals (Colton, 2009). The 
exact role of glial cell activation in PD pathogenesis is still debated, however evidence suggests that 
they might be both "initiators" and "progressors" of neurodegeneration (Halliday and Stevens, 2011).  
 
 
 
1.4 Neurobiology of α-Synuclein  1.4.1 α-Synuclein genetic and primary structure 
α-Synuclein aggregates are the principal components of Lewy bodies which are considered as the 
pathology hallmark of PD. α-Synuclein is encoded by the SNCA or PARK 1/4 gene located on 
Figure 1.5: The Braak’s staging system of Parkinson’s disease.
Braak’s stages showing the initiation sites in the olfactory bulb and the medulla oblongata, through to the later
infiltration of Lewy pathology into cortical regions.
Two main subtypes of LBs may exist: classical brainstem LBs and cortical LBs. They are made of un-branched a-
Synuclein filaments at around 200-600 nm of length and 5-10 nm of width. Cortical LBs are eosinphilic, rounded,
angular or reniform structures without a halo.
At stage 1, the first a-Synuclein positive structures occur in the olfactory bulb and/or the dorsal motor nucleus of
the glossopharyngeal and vagal nerves. During this stage the patients usually don’t manifest motor impairment
(pre-motor stage). At stage 2, Lewy pathology develops in the medulla oblongata and the pontine tegmentum. At
stage 3, the pathology reaches the amygdala and the substantia nigra. During this stage 3, the motor symptoms
of PD start to appear (in general bradykinesia with at least one of three cardinal features of PD such as rigidity,
resting tremor or gait disturbance). At stage 4, a-Synuclein inclusions reach the temporal cortex and the pathology
worsens. The end stages 5 and 6 corresponding to the most severe ones, a-Synuclein inclusions are present in
neocortex relating to cognitive problems in most advanced PD patients.
Permission obtained from John Wiley and Sons © Halliday,G. et al. Mov. Disord. 26, 1015–1021 (2011)
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chromosome 4q21-q23. This is the first gene identified in familial inheritance of PD causing 
autosomal dominant PD (Figure 1.6). 
 
Synuclein was first isolated from Pacific electric ray Torpedo california and was cloned in 1988 
(Maroteaux et al., 1988). The name Synuclein was proposed due to its localization in the nuclear 
envelope of neurons and in presynaptic nerve terminals. In 1993, Uéda et al. detected the non-Aβ- 
component amyloid (NAC) fragment of Alzheimer’s disease (AD) and interestingly, this fragment 
corresponds to the central part of α-Synuclein (aa 61-95). From 1996 to 1998, successive work 
demonstrated that α-Synuclein is a major component of the proteinaceous inclusions such as Lewy 
bodies or Lewy neurites in brains of patients with PD or DLB (Arima et al., 1998; Forno et al., 1996; 
Spillantini et al., 1997; Spillantini et al., 1998). The key years of α-Synuclein discovery were marked 
by the findings of two familial mutations of PD in 1997 by Polymeropoulos et al. (substitution of Ala 
53 by Thr or A53T) and 1998 by Kruger et al. (substitution of Ala 30 by Pro or A30P). Later, a third 
point mutation (substitution of Glu 46 Lys or E46K) was identified (Zarranz, 2004). Point mutations of 
SNCA gene remain extremely rare: A53T mutation has been found in only 15 Greek/Italian families 
who probably have a common ancestor and in two other Korean and Swedish PD families, but on 
different halotype backgrounds. A30P and E46K were each found in one single family, German and 
Spanish respectively. Clinically, patients with A53T mutation represent relative young onset with 
rapid progression of the disease, whereas A30P mutation patients correspond to sporadic PD 
patients with mild phenotype. Patients with E46K mutations have the most severe Parkinsonism with 
early onset age and diffuse Lewy body dementia (reviewed in Corti et al., 2011). Furthermore, 
duplication and multiplication of the gene locus encoding α-Synuclein have been associated with 
inherited forms of autosomal dominant PD (Chartier-Harlin et al., 2004; Ibanez et al., 2004; Singleton, 
2003) leading to the hypothesis of a dose relationship between α-Synuclein levels and severity of the 
Figure 1.6: α -Synuclein gene and primary structure (adapted from Weinreb et al., 1996 and Dickson et al.,
2001)
Amphipathic region
(1-70)
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disease. The most common genetic predisposition of PD is due to Synuclein since it is found in 
around 15 families worldwide (reviewed in Corti et al., 2011). 
Since its discovery, α-Synuclein is widely accepted as being a monomeric, unfolded or disordered 
protein adopting a helical conformation when it binds to phospholipid membrane (Weinreb et al., 
1996). However, this concept has been recently challenged by (Bartels et al., 2011;Wang et al., 
2011b) who suggested that native forms of α-Synuclein from human cell lines and red blood cells 
exist predominantly as structured (ordered) tetramers which may better resist aggregation. 
Structurally, α-Synuclein is composed of three distinct domains: (1) The N-terminal (residues 1-70) is 
basic and highly conserved containing 7 imperfectly repeated hexamer (KTKEGV) motifs contributing 
essentially to its capacity to bind to lipid membranes, (2) The central part or NAC domain (residues 
61-95) is variable and highly hydrophobic playing a determinant role in the oligomerization and 
fibrillization of α-Synuclein. This NAC domain itself is able to form amyloid fibrils and its deletion or 
disruption can abolish the ability of α-Synuclein to form fibrils as in the case for β-Synuclein, (3) The 
C-terminal (residues 96-140) is less well conserved, highly acidic and might function as a protein 
scaffold to recruit additional proteins (Davidson et al., 1998; George, 2002) (Figure 1.6). 1.4.2  Synuclein family 
The Synuclein family is a highly conserved family of small proteins. Members of synuclein family are 
only found in vertebrate and not in prokaryotic organisms. Thus, these proteins are widely accepted 
as having novel roles in eukaryotic cells without having ancestors from prokaryotic organisms. The 
apparition of these proteins probably corresponds to the requirement for novel sophisticated 
regulation of CNS processes such as synaptic transmission and plasticity, in vertebrate organisms 
during evolution. 
The human α-,β-,γ- Synuclein genes are mapped respectively to chromosomes 4q21.3-q22, 5q35 and 
10q23. α-Synuclein gene is organized in seven exons (five protein-coding exons), β-Synuclein has six 
exons (five protein-coding exons) and γ-Synuclein has five protein-coding exons. The translation start 
codon ATG is encoded by exon 2 and the stop codon TAA is encoded by exon 6. The NAC domain is 
encoded by exon 4. The predominant isoform of α-Synuclein in humans is composed of 140 aa. The 
three other α-Synuclein isoforms are composed of respectively 112, 126 and 98 aa (reviewed in 
Surguchov, 2008). The last one is overexpressed in the frontal cortices of LB disease and AD brains 
and is supposed to have very high amyloidogenic properties. β- and γ- Synuclein differ from α-
Synuclein by a lower propensity to form amyloid fibrils due to the absence of the NAC domain in β-
Synuclein and the higher structural stability of γ-Synuclein (reviewed in Surguchov, 2008). 
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1.4.3 Localizations and physiological functions  
α-Synuclein is abundantly expressed in nervous system and accounts for 1% of total soluble cytosolic 
protein (Iwai et al., 1995). For a long time, α-Synuclein was considered mainly as an intracellular 
protein since it lacks the peptide signal for secretion. However, growing evidence shows the 
presence of extracellular α-Synuclein supporting the hypothesis of cell-to-cell transfer of α-Synuclein 
and the theory of prion-like spreading of α-Synuclein in PD (Desplats et al., 2009; Luk et al., 2009; 
Volpicelli-Daley et al., 2011). α-Synuclein is highly expressed in erythrocytes, platelets or 
lymphocytes. The mechanism of α-Synuclein secretion has been reviewed and discussed by 
(Marques and Outeiro, 2012). In brain tissue, the protein is predominantly present at presynaptic 
terminals and less apparent in soma (Kahle, 2008). Due to structural similarities to fatty-acid binding 
proteins, especially the amphipathic feature of the N-terminal region, α-Synuclein is prone to bind 
lipid vesicle membranes. Indeed, monomeric α-Synuclein fluctuates both between free and 
membrane-bound state and the amount of membrane-bound α-Synuclein was estimated to be 
around 15% in rat brain (Lee et al., 2002). The affinity of different α-Synuclein mutants for lipidic 
membranes is variable: A30P is known for its low affinity whereas E46K is more tigthly bound. A53T 
and WT α-Synuclein however have similar affinities to membranes (Bussell and Eliezer, 2004;Choi et 
al., 2004).  
Due to its abundant presence in the pre-synaptic regions and its lipid-binding properties, the main 
physiological function of α-Synuclein is thought to be involved in the regulation of synaptic vesicle 
turnover and neurotransmitter release. Knock-down of α-Synuclein in primary hippocampal neurons 
seems to reduce the reserve vesicle pool (Cabin et al., 2002;Murphy et al., 2000). α-Synuclein-
depleted mice are viable, fertile and do not show obvious pathological abnormalities (Abeliovich et 
al., 2000). However the absence of  α-Synuclein in mice results in reduced dopamine content in the 
striatum, but no loss of dopaminergic neurons (Al-Wandi et al., 2010). In the same manner, α-,β-,γ- 
Synuclein triple knock-out mice show decrease in the synaptic size in the CA3 hippocampus of old 
mice (Al-Wandi et al., 2010), decrease levels of dopamine and its metabolites in the striatum and 
impaired motor behavior (Anwar et al., 2011). There is substantial proof that α-Synuclein has an 
important role in the biology of SNARE proteins which are responsible for facilitating membrane 
fusion events. Knock-down of Cysteine-string protein α (Cspα), a co-chaperone promoting the SNARE 
complex assembly at synapses, leads to severe neurodegeneration, whereas overexpressing of α-
Synuclein in these mice rescues the motor impairment (Chandra et al., 2005). In vitro, α-Synuclein 
binds to Synaptobrevin-2 and directly catalyzes SNARE complex assembly, whereas there is a 
decrease in SNARE markers during aging in Synuclein triple knock-out mice (Burré et al., 2010). 
Other than the roles in regulation of synaptic vesicle dynamics, some other physiological functions of 
α-Synuclein have been reported. Indeed, α-Synuclein is implicated in the biosynthesis of dopamine 
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(DA) since it indirectly reduces the activity of tyrosine hydroxylase, the rate-limiting enzyme in DA 
synthesis (Perez et al., 2002) by activating protein phosphatase 2A (PP2A) (Peng et al., 2005). α-
Synuclein is also implicated in the regulation of endoplasmic reticulum (ER) or Golgi vesicle trafficking 
(Cooper et al., 2006). A chaperone-like activity of certain enzymes such as esterases and alcohol 
dehydrogenase has also been proposed for α-Synuclein (Ahn et al., 2006; Rekas et al., 2012; Souza et 
al., 2000b).  1.4.4 Propensity of α-Synuclein for oligomerization and aggregation 
α-Synuclein can adopt different conformation states and aggregated morphologies including small 
aggregates, oligomers, protofibrils and fibrils. The aggregation process initially forms oligomeric 
species that are relatively soluble, these oligomers can then self-assemble to fibrillar structures 
which become more and more insoluble (Conway et al., 1998;Giasson et al., 1999). In vitro, α-
Synuclein fibrillization can be visualized by atomic force microcospy (AFM) (Khurana et al., 2003) 
(Figure 1.7) and these amyloid fibrils can be stained with fluorescent probes such as Thioflavin T or 
Congo Red (Naiki et al., 1989). In brain tissues, α-Synuclein fibrils can be immunolabelled (Games et 
al., 2013;Spillantini et al., 1998) or visualized by electronic microscopy (Tofaris et al., 2006). Insoluble 
α-Synuclein oligomers have been sequentially extracted from brain lysates by ultracentrifugation 
(Kahle et al., 2001). Insoluble α-Synuclein fibrils are resistant to proteinase-K digestion and can be 
immunolabelled after digestion using specific antibodies (Neumann et al., 2002).  1.4.4.1 Factors modulating α-Synuclein aggregation 1.4.4.1.1 Physical properties 
Physiscally, the α-Synuclein monomer has a typical random coil conformation at neutral pH (Uversky 
et al., 2001b). In vitro, the unfolded structure of α-Synuclein has relatively low hydrophobicity, but 
this structure is labile and flexible depending on pH and temperature of the environment: for 
example at pH 3.0 or at high temperature, α-Synuclein gains some ordered secondary structure and 
becomes more compact or adopts a partially folded conformation (Uversky et al., 2001a). 1.4.4.1.2 Genetic mutations 
Familial mutant forms of α-Synuclein accelerate its aggregation in vitro at different manners. Indeed, 
in dilute solution the A30P and A53T mutants have similar disordered structures like the WT but at 
higher concentrations both mutants rapidly aggregate, with the A53T mutant showing the highest 
acceleration compared to the WT. No fibrillizations but just oligomer formation was observed for 
A30P (Conway et al., 1998; Li et al., 2001). The third familial mutant E46K accelerates fibrillization 
(Greenbaum et al., 2005; Lewis et al., 2010). These observations might explain the pathogenicity of 
α-Synuclein genetic mutations during PD pathogenesis (Figure 1.7). 
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 1.4.4.2 Post-translational modifications (PTMs) 1.4.4.2.1 Phosphorylation 
Phosphorylation is one of the major PTMs of α-Synuclein. In human brain, phosphorylated α-
Synuclein exists naturally and is concentrated in the regions of the nucleus basalis of Meynert (MN) 
and substantia nigra (SN) (Muntané et al., 2012). The level of phosphorylated α-Synuclein is 
increased in pathological stages. In patient brains with PD, 90% of α-Synuclein in LB or inclusions is 
phosphorylated at Ser129 (Anderson et al., 2006; Fujiwara et al., 2002). An additional 
phosphorylation site is mapped at Ser87 in vitro (Okochi et al., 2000). A recent report from Lashuel’s 
lab showed that phosphorylation at position Ser87 is increased in brains of transgenic models of 
synucleopathies and patients with AD, DLB and MSA (Paleologou et al., 2010). Whether 
phosphorylation promotes or prevents aggregation is still a matter of debate. In vitro 
phosphorylation at Ser 129 (P-Ser129) inhibits fibrillization while mutants with substitution of Ser by 
Ala (S129A) form more fibrils (Paleologou et al., 2008). Mimicking phosphorylation of Ser87 by 
expressing mutant S87E also inhibits fibril formation in a rat model (Oueslati et al., 2012). 
Interestingly, in flies expressing the S129A mutant there are five times more insoluble, proteinase K 
resistant inclusions (Chen and Feany, 2005; Azeredo da Silveira et al., 2009). On the other hand, 
expression of S129A in SH SY5Y cells has been reported to dramatically decreases eosinphilic 
Figure 1.7: Atomic force microscopy images.
Solutions of α-Synuclein were incubated for 3 weeks at a concentration of 300 µM (a, WT; b, A30P; c, A53T) or 8
weeks at 50 µM (d, A53T) (from Conway etal., 1998)
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cytoplasmic inclusions (Smith et al., 2005) or at least does not increase inclusions (Gorbatyuk et al., 
2008;McFarland et al., 2009). 1.4.4.2.2 Ubiquitination 
Ubiquitination of α-Synuclein is found in LBs (Gomez-Tortosa et al., 2000; Spillantini et al., 1998), 
(Sampathu et al., 2003; Tofaris et al., 2003). Purified protein from LBs confirmed that a fraction of α-
Synuclein is ubiquitinated (Anderson et al., 2006; Sampathu et al., 2003; Tofaris et al., 2003). 
Interestingly, the majority of α-Synuclein found in LBs is mono-ubiquitinated. In vivo and in vitro α-
Synuclein is ubiquitinated by E3-ligases: Parkin, UCHL-1 and SIAH (Lee et al., 2008;Liani et al., 
2004;Rott et al., 2008). The protein sequence of α-Synuclein contains 15 lysine sites which can be 
potentially ubiquitinated (Nonaka et al., 2004; Rott et al., 2008). Another study using semi-synthetic 
monoubiquitin-modified α-Synuclein showed that this ubiquitination site influences the aggregation 
rate (Meier et al., 2012). 1.4.4.2.3 Truncation 
Truncation of α-Synuclein is a normal event in human brains and its concentration is directly 
proportional to the amount of full-length α-Synuclein found in each brain region (Muntané et al., 
2012). Several cleaved species of α-Synuclein from LB including both N- and C-terminal truncations 
have been detected (Anderson et al., 2006; Chen and Feany, 2005).Importantly, in vitro truncation of 
C-terminus at different cleavage sites leads to faster fibrillization of α-Synuclein (Liu et al., 
2005b;Murray et al., 2003).  
The C-terminal region (from residues 95 to 140) of α-Synuclein is highly acidic and negatively 
charged. These negative charges are essential for the regulation of the kinetics of fibril formation: 
decreases in C-terminus charges shifts α-Synuclein to wards fibrillar species (Hoyer et al., 
2004;Levitan et al., 2011). Hong et al. (2011) proposed that C-terminal region forms bisulfide bonds 
with other regions inside of the α-Synuclein monomer structure stabilizing it. Therefore in the 
absence of this C-terminus, aggregation is enhanced. In the same direction, Izawa et al. (2012) 
demonstrated that Tyr residues at the C-terminal region, especially Tyr136, are particularly 
implicated in the regulation the fibrillization kinetics and mutation of these residues dramatically 
decreases the time and rate of fibril formation.  
In vivo data support these in vitro observations. Expression of α-Synuclein (∆CT 1-110 and ∆CT 1-120) 
in SH-SY5Y cell increases cell death (Liu et al., 2005b). Expression of C-terminal truncated α-Synuclein 
(∆CT, 1-120) in Drosophila increases oligomer levels and reduces the number of dopaminergic 
neurons (Periquet et al., 2007). Pathological changes in the olfactory bulb and substantia nigra have 
been observed in mice expressing α-Synuclein (∆CT, 1-120) driven by TH promoter (Tofaris et al., 
2006). Remarkably, expression of α-Synuclein (∆CT, 1-130) controlled by the same TH promoter 
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causes selective cell loss in the SNc and abnormal motor behavior. More interestingly, homozygote 
expression of α-Synuclein (∆CT, 1-130) causes embryonic death (Wakamatsu et al., 2008). (Daher et 
al., 2009) have reported a reduction of striatal dopamine release without loss of dopaminergic 
neurons in mice expressing inducible α-Synuclein (∆CT, 1-119) under the control of the ROSA26 
promoter. 
In addition to phosphorylation and ubiquitination, other PTMs of α-Synuclein have also been 
explored, such as nitration (Souza et al., 2000a), sumoylation (Dorval and Fraser, 2006) and or 
methionine-oxidation (Glaser et al., 2005). Their potential influences on α-Synuclein aggregation 
remain to be elucidated (reviewed in Surguchov, 2008 and Myhre et al., 2012). 
1.5 Current therapies in PD 
Pathologically, PD is characterized by profound loss of dopaminergic neurons in substantia nigra pars 
compacta (SNpc) which modulate motor circuits. Although there are therapies available to treat 
motor symptoms, an effective cure of PD does not exist. Dopamine replacement (L-DOPA and 
dopamine agonists) remains the most common therapy in PD treatment. The introduction of 
levodopa (L-DOPA) in the late 1960s was a major progress in improving life quality of PD patients 
(Carlson, 1959; Schwab et al., 1969). L-DOPA is a precursor of dopamine which is able to cross the 
blood-brain barrier. In the body, L-DOPA is converted to dopamine under action of DOPA 
decarboxylase (Figure 1.8). However, treatment with L-DOPA causes later complications such as 
motor-fluctuations or dyskinesia (Shannon et al., 1987). Alternatively, surgical techniques have been 
developed in an attempt to control motor symptoms using deep brain stimulation (DBS) for patients 
who do not respond well to medications (Benabid et al., 1987). Lack of knowledge in the neuronal 
circuitries to be targeted remains a major limit of this technique.  
In the near future, based on current concepts of pathogenesis of cell death in PD, many putative 
neuroprotective agents are being proposed for clinical trials. However, most of the encouraging pre-
clinical investigations have unfortunately so far not been translated successfully from animal models 
to PD. Absence of a well established biomarker and detailed knowledge of the pathogenesis 
pathways of PD remain principal limiting factors in PD research (reviewed in Olanow et al., 2009; 
Mhyre et al., 2012). 
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1.6 Animal modeling for PD research  
Lack of good animal models mimicking the pathogenesis the disease is problematic in PD research. 
An ideal model should reproduce the main pathological and clinical features of PD consisting of cell 
loss in the dopaminergic and non-dopaminergic systems with motor or non-motor symptoms. 
Moreover, the age-dependent onset and progressive apparition of the symptoms are appreciable 
criteria. Unfortunately, at this stage of advancement, none of current animal models display all these 
key PD features (reviewed in Chesselet and Richter, 2011; Magen and Chesselet, 2010)). 
Current animal models of PD can be divided into two categories: neurotoxic and genetic models. 
Each group of models has strengths and weaknesses. Neurotoxic animal models are produced by 
lesioning dopaminergic systems using specific targeting drugs (neurotoxin models). These models 
have advantages as they induce rapid and robust nigrostriatal cell loss accompanied by severe motor-
symptoms. The disadvantages are that they do not mimic either the progressive nature of the 
disease or the late age-onset or non-motor symptoms (reviewed in Bové and Perier, 2012;Tieu, 
2011). The most common neurotoxins used to generate nigrostriatal lesions in PD animals models 
are 6-Hydroxydopamine (6-OHDA) (Senoh et al., 1959), MPTP (Davis et al., 1979), paraquat (Snyder 
and D'Amato, 1986) and rotenone (Heikkila et al., 1985) (Table 1.2). 
Figure 1.8: Dopamine synthesis and activity in neurons.
L-DOPA is converted to Dopamine catalyzed by DOPA decarboxylase enzymes (blocked by Carbidopa). Induced
dopamine is either used in synaptic vesicles, degraded by MAO or COMT enzymes or transformed into
noradrenaline (adapted from Olanow et al., 2009)
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DOPA 
Decarboxylase
Dopamine Noradrenaline
Dopamine    
β-hydroxylase
Breakdown by 
MAO and COMT
Packaged into 
vesicles and 
used at synapse
Carbidopa
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Alternatively, progress in genetic studies has linked some key genetic mutations to the pathogenesis 
of PD which have permitted lead to the production of an increasing number of transgenic models. 
Several transgenic animal models have been generated; the most common overexpress WT or 
mutant human α-Synuclein in mice ("humanized models") using different exogenous promoters. The 
use of exogenous promoters is often helpful as they drive high transgene expression. However, 
distribution and expression of human α-Synuclein differs from endogenous level. Mouse and human 
Models Nigro-striatal damage Behavioral alterations Lewy-bodies/ α-
Synuclein inclusions
Reference
6-OHDA (unilateral
injection into 
rodent MFB)
• 90% loss of dopaminergic
neurons
• Dose-dependent loss of 
striatal dopamine innervation
• Quantifiable turning
behavior after 
systemic 
administration of a 
dopaminergic agonist
• Bradykinesia and 
impaired paw use on 
contralateral side
No intracellular 
inclusions
Przedborski, 1995
6-OHDA (unilateral
injection into 
rodent striatum)
• 30-75% loss of dopaminergic
neurons
• Circumscribed loss of striatal
dopamine innervation at 
injection site
•Quantifiable turning
behavior after 
systemic 
administration of a 
dopaminergic agonist
• Bradykinesia and 
impaired paw use on 
contralateral side after 
multiple injections
No intracellular 
inclusions
Kirik, 1998
MPTP (acute mouse 
model)
• 70% loss of dopaminergic
neurons
• Reduced dopamine levels in 
the striatum
Motor and 
coordination
impairments in 
challenging situations
No intracellular 
inclusions
Jackson-Lewis, 1995
MPTP (chronic 
mouse model)
• 30-50% loss of dopaminergic
neurons
• Reduced dopamine 
innervation in the striatum
Motor and 
coordination
impairments in aged 
mice
•Increase α-Syn
immunoreactivity in the 
SN
•No intracellular 
inclusions
Perier, 2007
MPTP (non human 
primate model)
• 60-90% loss of dopaminergic
neurons
•Reduced dopamine 
innervation in the striatum
• Motor impairments 
resembling PD 
symptoms
• Cognitive 
impaiments
Inclusions resembling 
LBs in locus coeruleus of 
old monkeys
Langston, 1984
Rotenone (in 
rodents)
• 20-75% loss of dopaminergic
neurons
• Reduced dopamine 
innervation in the striatum 
(rat)
• Reduced TH levels in the 
striatum (mouse)
• Reduced motor 
activity (rats) and 
endurance time in 
rotarod (mouse)
α-Syn aggregation in 
dopaminergic and other 
neuron populations
Betarbet, 2000
Paraquat (in mice) • <20% loss of dopaminergic
neurons
• Little changes in dopamine 
innervation in the striatum 
• No clear motor 
impairments
•Increase α-Syn
immunoreactivity in the 
SN
•No intracellular 
inclusions
Thiffault, 2000
Table 1.2 : Representative neurotoxic animal models (adapted from Bove and Perier, 2012)
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promoters differ too, leading to differences in expression in mouse model compared to the situation 
in humans. Additionally, different genetic backgrounds between animal models potentially result in 
different histopathologies or phenotypes. At this stage, no mouse model is known to develop true 
LBs, although α-Synuclein oligomeric structures can be detected. Behavior impairments are also 
variable between models and do not always mimic the progression of motor decline seen in patients 
(reviewed in Chesselet et al., 2010 and 2011). To overcome obstacles due to the use of exogenous 
promoters, bacterial artificial chromosomes (BAC) that allow expression of α-Synuclein under its 
normal promoter are being used to generate transgenic mice, and these models will hopefully shed 
light on the physiological functions and pathological pathways of α-Synuclein (reviewed in Lu, 2009) 
(Table 1.3). 
 
 
Transgene Promoter Histology Biochemistry Neurochemistry Behavior Reference
WT SNCA PDGFβ • Marked somal and
neuritic
accumulation of 
transgenic α-Syn
• Amorphous 
inclusions
Detergent-
insoluble 
transgenic α-
Syn
Non progressive 
reduction of TH+ 
neurons and 
terminals
Mild reduction 
of locomotor
activity
Masliah, 2000
WT SNCA CaM-tTA • Somatodendritic
accumulation of 
transgenic α-Syn
• Highest expression 
in the forebrain
Trend of 
reduction of TH+ 
neurons in SN
• Young onset
• Progressive 
reduction of 
locomotor
activity
Nuber, 2008
A53T SNCA CaM-tTA • Somatodendritic
accumulation of 
transgenic α-Syn
• Gliosis
Phosphorylated
, ubiquitinated
transgenic α-
Syn
- Memory 
impairment
Lim, 2011
WT SNCA mThy-1 Somatodendritic
accumulation of 
transgenic α-Syn
- - Very young 
onset 
sensorimotor
impairments
Fleming, 2006
A53T SNCA mThy-1 • Marked somal and
neuritic
accumulation of 
transgenic α-Syn
• Amorphous 
inclusions
- - Fulminant
progressive   
neuromuscular 
junction loss
Van der
Putten, 2000
A30P SNCA mThy-1 • Somatodendritic
accumulation of 
transgenic α-Syn
• Argyrophilic, 
thioflavin S-positive 
fibrillar inclusions
• Detergent-
insoluble 
transgenic α-
Syn aggregates
• Progressive 
proteinase K 
resistant
Normal Progressive 
cognitive and 
locomotor
decline
Kahle, 2000
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1.7 Reduction of α-Synuclein burden is a potential therapeutic strategy for 
PD 
Although pathophysiology mediated by α-Synuclein misfolding and aggregation is not fully 
understood, reduction of α-Synuclein burden by preventing formation of α-Synuclein oligomers and 
fibrils appears to be a convincing strategy. Unfortunately, there are no validated inhibitors of α-
Synuclein oligomerization in clinical trials. In this context, maintaining α-Synuclein homeostasis might 
Transgene Promoter Histology Biochemistry Neurochemistry Behavior Reference
A53T SNCA mPrion • Somatodendritic
accumulation of 
transgenic α-Syn
•Argyrophilic, 
thioflavin S-positive 
fibrillar inclusions
• Gliosis
• Neurodegeneration
Detergent-
insoluble 
transgenic α-
Syn aggregates
Normal Progressive 
locomotor
decline
Giasson, 2002
A30P SNCA hamPrion • Somatodendritic
accumulation of 
transgenic α-Syn
• Gliosis
α-Syn
aggregates
Normal Progressive 
locomotor
decline
Gomez-Isla, 
2003
WT SNCA ratTH • Somatodendritic
accumulation of 
transgenic α-Syn
• No fibrillar
inclusion
- Normal Normal Richfield,
2002
A30P SNCA ratTH • Somatodendritic
accumulation of 
transgenic α-Syn
Normal Normal - Rathke-
Hartlieb, 2001
A53T SNCA ratTH • Somatodendritic
accumulation of 
transgenic α-Syn
- - - Richfield,
2002
A30P +A53T 
SNCA
ratTH • Somatodendritic
accumulation of 
transgenic α-Syn
• No fibrillar
inclusion
- Reduction of TH+ 
neurons and DA 
levels upon aging
Mild reduction 
of locomotor
activity upon 
aging
Matsuoka, 
2001
Truncated 1-
120 WT SNCA
ratTH • Somatodendritic
accumulation of 
transgenic α-Syn
• Thioflavin S-
positive fibrillar
inclusions
Detergent-
insoluble 
transgenic α-
Syn
Very young onset, 
non progressive 
DA reduction
Progressive
locomotor
decline
Tofaris, 2006
Truncated 1-
130 A53T 
SNCA
ratTH Somatodendritic
accumulation of 
transgenic α-Syn
- Embryonal, non 
progressive DA 
reduction
Reduction 
locomotion
Wakamatsu, 
2008
A53T SNCA α-Syn
(BAC)
α-Syn expression in 
brain and in colon
Proteinase K-
resistant 
aggregates in 
enteric neurons
- • Reduction of 
colonic motility
• Progressive
reduction of 
locomotion
Kuo, 2010
Table 1.3: Representative α -Synuclein transgenic animal models (adapted from Kahle, 2008 and
Chesselet etal., 2011)
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be an attractive approach. However the mechanisms by which α-Synuclein is degraded under normal 
and pathological conditions remains largely unknown. Theoretically, ubiquitin-proteasome system 
(UPS) and autophagy-lysosomal pathways (ALP) are the major degradation systems of intracellular 
proteins and their implication in neurodegenerative diseases have been investigated extensively 
(reviewed by Ciechanover, 2013; Ihara et al., 2012). 1.7.1 α-Synuclein has been proposed to be a substrate of both UPS and ALP 1.7.1.1 α-Synuclein was firstly described to be degraded by UPS 
Due to its crucial role in regulating the intracellular protein burden, the UPS is being extensively 
researched in human disease therapies including neurodegenerative diseases (Ciechanover, 2013). 
The first link between α-Synuclein and UPS in cell culture was established by (Bennett et al., 1999) 
who showed that inhibition of UPS in SH-SY5Y cells by β-lactone increased the amount of non-
degraded α-Synuclein. Interestingly, the authors also noticed that the pathogenic mutant A53T has a 
longer half-life than the WT α-Synuclein. α-Synuclein can be digested by proteasome 20S in vitro 
producing different C-terminal truncated forms (Liu et al., 2005a) and this can be inhibited by adding 
a proteasome inhibitor (MG132).  
Overexpression of α-Synuclein mutants also enhances cytotoxicity by compromising the function of 
UPS (Stefanis, 2001; Tanaka et al., 2001; Tofaris et al., 2001). In parallel, (McNaught and Jenner, 
2001) reported that proteasomal enzyme activities (chymotryptic, tryptic and postacidic) are 
decreased in SN of idiopathic PD brains. In the same manner, inhibition of the proteasome leads to 
increased α-Synuclein inclusion formation and neurotoxicity in vivo (McNaught et al., 2002; Rideout 
et al., 2001;Sawada et al., 2004). The impairment of UPS function might come from aggregated α-
Synuclein itself (Chen et al., 2006; Emmanouilidou et al., 2010; Snyder et al., 2003; Zhang et al., 
2008). Interestingly, overexpression of Parkin reduces toxicity in an α-Synuclein toxicity-induced 
model (Haywood and Staveley, 2006; Oluwatosin-Chigbu et al., 2003) suggesting that activating UPS 
pathways might be protective. Taken together, these observations seem to indicate that UPS is 
implicated in the regulation of α-Synuclein homeostasis. 1.7.1.2 Degradation of α-Synuclein by UPS is conflicting 
Evidence for α-Synuclein degradation by UPS has been challenged by other studies. Indeed, α-
Synuclein is not ubiquitinated in stably transfected TSM1 neurons and inhibition of the proteasome 
does not change the  α-Synuclein level in HEK293 cells (Ancolio et al., 2000). Although inhibition of 
the proteasome leads to inclusion formation, (Rideout et al., 2001) did not see an upregulation of  α-
Synuclein levels. α-Synuclein found in LBs indeed can be ubiquitinated and its ubiquitination is a 
hallmark of α-Synuclein aggregation. However, the ubiquitinated states of α-Synuclein from LB do 
not necessarily determine its targeting to the proteasome system since non-ubiquitinated α-
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Synuclein can be degraded by the proteasome and α-Synuclein in LBs are essentially mono-
ubiquitinated, not poly-ubiquitinated (Anderson et al., 2006; Tofaris et al., 2003). Moreover 
ubiquitination of α-Synuclein by SIAH, an α-Synuclein E3 ligase, does not lead to its degradation by 
the proteasome, but rather increases aggregation and cell death (Lee et al., 2008; Liani et al., 2004; 
Rott et al., 2008). The presence of SIAH together with mono-ubiquitinated α-Synuclein in LBs 
reinforces the thesis that mono-ubiquitinated α-Synuclein is not degraded by proteasome (Liani et 
al., 2004). 1.7.1.3 Increasing evidence for α-Synuclein degradation by ALP 
Autophagy plays a key role in maintenance of cell homeostasis, and in neuronal cells, disruption of 
autophagy leads to devastating consequences (Figure 1.9). Actually, in vivo depletion of the Atg5 
gene provokes neuronal cell loss, progressive motor deficits and accumulation of ubiquitin-positive 
inclusions (Hara et al., 2006). In the same manner, depletion of the Atg7 gene causes severe cell loss 
in the cerebral and cerebellar cortices, motor impairments and inclusion formation. These mice also 
show axonal swelling and die at around 28 weeks (Komatsu et al., 2006; Komatsu et al., 2007). In 
many neurodegenerative disorders such as AD, HD or PD, the role of autophagy is crucial to degrade 
abnormal inclusions (reviewed by Wong and Cuervo, 2010).  
 
Figure 1.9: Three main routes to entering lysosomal lumen.
A. Macroautophagy represents the formation of autophagosome and fusion with lysosome for protein degradation.
Autophagosome formation is a highly conserved process including several steps. The first step consists of
isolation of the unique membrane (called “phagophore”) which sequesters a portion of cytoplasm, organelles or
other substrates. The second step consists of complete elongation and fusion of phagophore extremities forming
“autophagosome” which is typically a double-membrane organelle. During its maturation, autophagosome can
fusion with other endosomes and no degradation occurs. Autophagosomes are docking and fusing in the last step
with lysosome forming “autolysosome”, its content is then delivered to lysosome lumen and is degraded by
lysosomal hydrolases. (Mizushima,2007; Tanida, 2011).
B. Microautophagy consists of a non specific uptake of substrates or organelles into the lysosome vacuole directly
by invagination of the lysosome membrane.
C. Chaperone-mediated autophagy, in difference to micro- and macro-autophagy, is a selective process which
doesn’t require the formation of autophagosome.
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The first link between autophagy and PD was established by (Anglade et al., 1997) who observed 
apoptosis and autophagic vacuole accumulation in nigral neurons of patients with PD. This was 
supported by (Crews et al., 2010) who observeded increasing levels of mTOR and decreasing levels of 
Atg7 in patient brains with DLB. Interestingly, autophagic cell death is accompanied by increasing α-
Synuclein levels in human neuroblastoma SH-SY5Y cells (Gómez-Santos et al., 2003). In the same 
year, (Webb, 2003) reported that α-Synuclein can be degraded by both autophagy (activated by 
rapamycin and inhibited by bafilomycin) and the proteasome (inhibited by exopomicin or lactone) 
using PC12 cells that inducible expressed α-Synuclein. Inhibition of lysosomes with ammonium 
chloride slows down the degradation of α-Synuclein even more than inhibiting the proteasome with 
exopomicin in cultured midbrain neurons (Cuervo, 2004). 
In animal models, disrupting autophagy by abolishing Atg7 gene in mouse dopaminergic neurons 
promotes presynaptic accumulation of α-Synuclein (Friedman et al., 2012). In view of the conflicting 
results concerning the role of proteasome in α-Synuclein degradation these observations suggest 
that the lysosomal autophagic pathway may be an alternative mechanism of α-Synuclein 
degradation. 
 
 
substrate proteins
KFERQ-motif
lysosome
membrane receptor
lamp2a
proteases
lys-hsc70
cytosolic chaperone(s)
hsc70/cochaperones
Figure 1.10: Mechanism of CMA degradation pathway.
Step 1: CMA substrates possess in their sequence the pentapeptide “KFERQ” which is specifically recognized by
chaperones Hsp70 and co-chaperones.
Step 2: Complex substrate-chaperone is transferred to the lysosome surface and binds to the lysosome-
associated membrane protein type 2A (LAMP-2A).
Step 3: CMA substrate is translocated one-by-one through the LAMP-2A complex to the lysosomal lumen to be
degraded (Kaushik and Cuervo,2012).
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1.7.1.4 CMA: a new player in α-Synuclein degradation 
Chaperone-mediated autophagy, in contrast to micro- and macro-autophagy, is a selective process 
which does not require the formation of autophagosome (Figure 1.10). The protein sequences of 
CMA substrates contain the pentapeptide “KFERQ” (~30% of cytosolic proteins) which is specifically 
recognized by chaperones Hsp70 and co-chaperones. The substrate-chaperone complex is 
transferred to the lysosome surface and binds to the lysosome-associated membrane protein type 
2A (LAMP-2A). The substrate is then translocated one-by-one through the LAMP-2A complex to the 
lysosomal lumen for degradation. LAMP-2A is the rate limiting-step of CMA and is organized as a 
dynamic structure which rapidly switches from a monomeric form (~100 kDa) at a basal level to a 
high molecular weight complex of about 700 kDa when bound to a substrate. Once the substrate is 
released into the lumen, the LAMP-2A complex disassembles into monomers. The stability of LAMP-
2A is crucial for an effective translocation of the substrate. Several factors may regulate this stability. 
Interestingly, declining of lipid binding profile of the lysosomal membrane is correlated with 
physiological aging that associates CMA with aging diseases (Kaushik and Cuervo, 2012). 
Recently, (Cuervo, 2004) noticed that α-Synuclein carries in the sequence a pentapeptide sequence 
95VKKDQ99 corresponding to the CMA motif. Recognition of this motif by chaperones such as Hsp70 
might target α-Synuclein directly to the lysosomal lumen via binding to LAMP-2A. Experiments of 
binding with purified lysosomes confirmed the prediction that α-Synuclein is a substrate of CMA. 
Interestingly, mutation of the CMA motif by replacing 98DQ99 by AA (∆DQ or ∆CMA mutant) showed 
impairment of translocation of this mutant into the lysosomal lumen and therefore led to a slower 
degradation (Figure 1.11A). Wild-type α-Synuclein is able to bind LAMP-2A whereas the ∆CMA 
mutant cannot. Supporting this, inducible overexpression of wild-type and ∆CMA mutant in SHSY-5Y 
and PC12 cells revealed a slower turn-over of α-Synuclein. Importantly, down-regulation of LAMP-2A 
in PC12 leads to slower degradation of α-Synuclein and α-Synuclein interacts physically with LAMP-
2A rat cortical and midbrain neurons (Vogiatzi et al., 2008). Moreover, in vivo α-Synuclein-induced 
mice with paraquat treatment  increased expression of CMA-markers such as LAMP-2A or Hsp70 in 
nigral neurons suggesting that α-Synuclein is degraded in vivo via CMA (Mak et al., 2010). 
In brains of PD or DLB patients CMA markers LAMP-2A and Hsp70 levels are reduced suggesting that 
defects in CMA lead to α-Synuclein accumulation (Alvarez-Erviti et al., 2010; Alvarez-Erviti et al., 
2013). In the same manner, CMA activity is reduced in brain regions that are most vulnerable to α-
Synuclein inclusions (for example in brain stem and spinal cord of transgenic mice overexpressing 
A53T α-Synuclein under the control of the PrP promoter (Giasson, 2002; Malkus and Ischiropoulos, 
2012). Recently, overexpression of LAMP-2A enhances CMA activity and boosts the degradation of α-
Synuclein in cell culture. Interestingly in the same study, overexpression of LAMP-2A also rescues the 
toxicity induced by α-Synuclein in a rat model (Xilouri et al., 2013a) (Figure 1.11C). Taken together, 
39 
 
these data indicate that CMA participates, at least in part, in the degradation of intracellular α-
Synuclein.  
 
 
Interestingly CMA does not appear to degrade all α-Synuclein monomeric forms. Pathogenic forms of 
α-Synuclein including genetical mutants or post-translational modified variants may affect the 
efficiency of CMA degradation. Compared to the WT α-Synuclein, the two familial mutants A30P and 
A53T bind more strongly to LAMP-2A and are less efficiently translocated into the lysosome lumen. 
This tight binding prevents the proteolysis of other CMA substrates (such as GAPDH) in vitro and 
significantly slows down their own degradation kinetics in PC12 cells (Cuervo, 2004). Thus, these 
mutants are supposed to act as uptake blockers at the “entry gate” to the lysosome and binding to 
LAMP-2A is a limiting step of CMA pathway (Figure 1.11B). These observations were confirmed by 
(Xilouri et al., 2009) who observed that an inhibition of lysosomal degradation in cells expressing 
A53T mutant has little effect on long-lived protein degradation, whereas in cells expressing double 
mutant A53T-∆CMA, inhibiting lysosome leads to increase of non-degraded protein. This result 
Figure 1.11: Evidence for α -Synuclein degradation by CMA in vitro and in vivo
A. Mutation of CMA targeting motif leads to slower turn-over in SHSY-5Y cells overexpressing α-Synuclein
(Vogiatzi et al., 2008)
B. Familial mutants of α-Synuclein block their internalization into lysosomal lumen (Cuervo et al., 2004)
C. Enhancing CMA pathways by overexpression of LAMP-2A rescue α-Synuclein-induced neurotoxicity in animal
model (Xilouri et al., 2012).
A B
C
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suggests that A53T may block the degradation of long-lived proteins by blocking their translocation 
to lysosomes. Various post-translational modified variants can not undergo CMA. (Martinez-Vicente 
et al., 2008) reported that phosphorylation and nitration alter the degradation of α-Synuclein by 
CMA reducing its binding and uptake into lysosomes. Interestingly, dopamine-modified α-Synuclein, 
as A53T and A30P, binds more strongly to lysosomes and blocks CMA suggesting an explanation for 
the vulnerability of dopaminergic neurons in synucleopathies. Remarkably in the same paper, 
Martinez-Vincente showed that only α-Synuclein monomers and dimers, but not oligomers, are 
efficiently taken up by lysosomes although oligomers do not themselves inhibit CMA. This result is 
inconsistent with previous observation that oligomeric α-Synuclein overlaps with LAMP-2A in cell 
culture models (Lee et al., 2004), but predicts however, that oligomers may still undergo lysosomal 
degradation, probably through autophagosomes, since α-Synuclein aggregates are seen in lysosome 
lumen and inhibiting lysosomal degradation with bafilomycin or 3MA stabilizes the oligomer level of 
α-Synuclein (Lee et al., 2004; Webb, 2003). These primary observations suggest that 
macroautophagy and CMA may function in a synergistic manner to maintain the balance of 
intracellular α-Synuclein. On the other hand, the capacity of macroautophagy to degrade pathogenic 
species of α-Synuclein is still under debate. Overexpression of A53T impairs macroautophagy in a 
cellular model (Winslow, 2010). Recently, Tanik et al. (2013) showed that transfection of preformed 
fibrils (Pffs) in HEK293 cells impairs macroautophagy and clearance of α-Synuclein aggregates. This 
observation however contradicts similar experiments from (Watanabe et al., 2012) who reported 
that the incorporation of α-Synuclein aggregates into autophagosomes depends on the presence of 
p62. Nevertheless, induction of macroautophagy remains an efficient strategy to reduce the 
accumulation of α-Synuclein species (Gonzalez-Polo et al., 2007; Hebron et al., 2013; Klucken et al., 
2012; Steele et al., 2012; Wang et al., 2011a). 
 
α-SynucleinLC3 Merge
α-SynucleinLAMP2A Merge Figure 1.12: Evidence for α -
Synuclein degradation by
ALP in PD and DLB patients
A. α-Synuclein is colocalized
with CMA marker (LAMP-2A)
in some abnormal inclusions
but not in LBs in PD and DLB
patients (Alvarez-Erviti et al.,
2010)
B. Most of α-Synuclein
colocalized with an general
marker of lysosome (LC3) in
inclusions including LBs in PD
and DLB patients (Alvarez-
Erviti et al., 2010)
A
B
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1.8 PhD thesis: Studying the role of α-Synuclein lysosomal degradation 
using in vivo and in vitro approaches 
The overall aim of my thesis was to determine the role/contribution of lysosomal degradation, in 
particular CMA autophagy in the regulation of α-Synuclein homeostasis using both in vitro and in vivo 
approaches.  
In vitro studies:  
Mutation of the CMA motif (∆CMA) by replacing 98DQ99 with AA has been shown to prevent 
translocation of α-Synuclein into lysosomes in vitro (Cuervo, 2004), and results in increases of α-
Synuclein protein levels in cell culture models (Vogiatzi et al., 2008). In these studies, to validate our 
in vivo concepts, inducible cell lines (non-neuronal and neuronal) using the Tet-inducible system 
were generated following approaches applied in the development of previous cell culture models 
(Vogiatzi et al., 2008; Xilouri M, 2009). These cell lines express four different C-terminal truncated 
(∆CT) α-Synuclein constructs (construct 1: WT-∆CT, construct 2: WT-∆CMA, construct 3: A53T- ∆CT, 
construct 4: A53T- ∆CMA). By comparision of kinetic degradation curves of α-Synuclein in these cell 
lines established by quantitative western-blot, we wanted to answer the following questions:  
(1) Does mutation of CMA motif affect the kinetics of α-Synuclein degradation?  
(2) Do kinetics of degradation differ in cell lines expressing WT and A53T α-Synuclein constructs? 
(3) Does overexpression of our α-Synuclein constructs enhance cell toxicity?  
These data from cell culture served as base element for the discussion of our in vivo studies that 
were conducted in parallel. 
In vivo studies: 
The effects of α-Synuclein CMA motif mutation have not yet been verified in vivo. For these studies, 
two conditional transgenic mouse lines overexpressing truncated (1-130) A53T α-Synuclein: line 1 
overepxressing α-Synuclein containing "normal" CMA motif (A53T-∆CT line), line 2 overexpressing α-
Synuclein containing "mutated" CMA motif (A53T-∆CMA line) were generated. Expression of α-
Synuclein transgene is targeted specifically to cerebellar Purkinje cells (PCs) under the control of Pcp2 
promoter. The level of mRNA transcription is comparable in these two transgenic lines since α-
Synuclein transgene is targeted to a defined locus (ROSA26). The animal pathologies were analyzed 
using standard methods including histology, biochemistry and behavior. The objectives are to 
response to following questions: 
(1) Does mutation of the CMA motif affect the kinetics of α-Synuclein degradation in vivo? 
(2) Does mutation of the CMA motif change the disease onset in animal models? 
(3) Does overexpression of α-Synuclein lead to pathological development (aggregation, 
neuroinflammation or neurotoxicity) in the cerebellum? 
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2 Results 
2.1 Kinetics of α-Synuclein degradation in HEK293 cells 
To investigate if CMA is the major route for α-Synuclein degradation, we examined whether 
mutating the CMA motif (replacing 98DQ99 by AA) in the α-Synuclein primary structure induces 
changes in the kinetics of α-Synuclein clearance. To do this in vitro, we applied a cellular approach 
using stable Doxicycline (Dox) inducible cell lines as previously described (Vogiatzi et al., 2008). We 
generated four cell lines expressing C-terminal truncated WT and A53T α-Synuclein with or without 
CMA motif mutation (line 1: WT- ∆CT; line 2: WT- ∆CMA; line 3: A53T- ∆CT and line 4: A53T- ∆CMA). 
A caveat when studying the kinetics of soluble protein degradation in stable cell lines is how to 
obtain comparable expression of the protein of interest. In addition to influencing the expression 
level, the insertion locus may alter the physiology of the cells. To test this possibility, α-Synuclein was 
expressed in HEK293 (derived from Human Embryonic Kidney) with the Flp-In™ host system (Life 
technologies). The host cells contain a single, stably integrated FRT (Flp Recombinase Target) site at a 
transcriptionally active genomic locus. Targeted integration of the Flp-In™ expression vector ensures 
high-level expression of the gene of interest. The Flp-In™ T-REx™-293 cell line contains pFRT/lacZeo 
and pcDNA™6/TR (from the T-REx™ System) stably integrated (Tet-on). Co-transfection of the Flp-In™ 
cell lines with Flp-In™ expression vector and the Flp recombinase vector, pOG44, results in targeted 
integration of the expression vector to the same locus in every cell, ensuring homogeneous levels of 
gene expression (Annex 1). To verify expression levels, RT-qPCR was performed to compare mRNA 
transcription in cells fully induced to express α-Synuclein (cells were cultured in presence of 1µg/mL 
Dox during 7 consecutive days with media changes every 2-3 days). The comparison of relative mRNA 
amounts estimated by ∆∆Ct method showed highly comparable mRNA expression between cell lines 
(Figure 2.1A). Equal α-Synuclein expression was further confirmed by western-blot using 15G7 
antibody (specific for human α-Synuclein). Interestingly, a weak band was observed at the same 
molecular weight in non-induced cells (in the absence of Dox in the culture medium). This residual 
expression of α-Synuclein suggests a "leaky" expression which is commonly observed in Tet inducible 
systems (Figure 2.1C). Importantly, these cell lines showed a high expression level of α-Synuclein at a 
concentration of 1µg/mL Dox, and this expression was not efficiently decreased when Dox was 
removed from the medium by two washes with PBS (data not shown). This observation suggested 
that the system might well be activated by lower Dox concentrations. After testing lower Dox 
concentrations, it was found that efficient induction to express highest protein expression level could 
be attained from 10ng/mL Dox (Figure 2.1B). 
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Figure 2.1: Generation of Tet-on HEK293 Trex Flip-In inducible cell lines overexpressing α -Synuclein.
A: RT-qPCR comparing relative α-Synuclein mRNA level using ∆∆Ct method, expression of GAPDH is used as
internal control.
B: Optimization of Dox concentration inducing highest α-Synuclein protein level. Western-blot showing α-
Synuclein protein level after 5 days of induction at different concentrations of Dox, antibody 15G7 anti- α-
Synuclein, GAPDH is used as loading control.
C: Control of inducibility of cell clones chosen for further studies. Cells were cultured with or without Dox
(10ng/mL) in enriched culture media (containing 10% of FCS) during 5 days and total protein was solubilized in
Triton lysis buffer.Western-blot showing α-Synuclein level using antibody 15G7 anti- α-Synuclein.
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Figure 2.2: α -Synuclein steady-state levels at 0h and 48h after removing Dox in Tet-on HEK293 cells.
Cells are cultured in enriched culture media (10% of FCS) containing Dox (10ng/mL) during 5 days. Cells are
washed twice in PBS and immediately processed for total protein extraction in Triton lysis buffer for time point 0h
(in A) or transferred into new culture dishes for 48h in absence of Dox (in B). Above: Western-blot showing α-
Synuclein level using 15G7 antibody, β-Actin is used as loading control. Below: Quantification of α-Synuclein
level, data is presented as the mean ±SEM of ratio α-Synuclein/β-Actin (signal obtained from Odyssey software)
from n=4 independent experiments.
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To determine α-Synuclein degradation kinetics using the inducible cell lines, western-blots were used 
to measure the amount of remaining α-Synuclein in each cell line after terminating α-Synuclein 
mRNA transcription. Firstly, maximum expression of α-Synuclein was obtained by culturing in 
enriched medium containing 10% of FCS and then transcription was stopped by removing Dox from 
culture media. Cells continued to be cultured in serum-enriched medium and total protein extracts 
were prepared at different time points; time point "0" was defined as time when Dox was removed. 
Protein levels for each time point were calculated by normalizing the signal of the α-Synuclein band 
to the signal of the β-Actin band [α-Syn/ β-Actin] of the same well (Odyssey quantification method). 
Firstly, to assess the steady state protein levels in the different cell lines, their protein levels were 
compared at time point 0 in fully induced cells. All four cell lines showed similar α-Synuclein protein 
levels at this time point (Figure 2.2A), confirming homogenous steady state expression (Figure 2.1). 
On the other hand, this result also indicates that there is no apparent difference in α-Synuclein 
turnover between the lines because a difference in protein degradation would be expected to alter 
steady state levels, given that the protein synthesis was comparable between the lines. In the same 
manner, no significant changes in protein levels were observed at 48 hours after stopping expression 
of α-Synuclein (Figure 2.2B). In contrast with an early report (Vogiatzi et al., 2008), mutating the CMA 
motif does not affect the turnover of α-Synuclein. To confirm this, kinetic curves of α-Synuclein 
degradation were determined for each cell line by quantifying the amount of α-Synuclein protein at 
various time points (0, 24, 48 and 72 and 96 h) in three independent experiments (a triplicate per cell 
line was made per experiment). α-Synuclein protein level per time point in each experiment was 
calculated as the mean of [α-Syn/ β-Actin]. To determine the degradation rate at each time point, we 
normalized all time points to time point 0 (100%). These data served to estimate the corresponding 
α-Synuclein protein half-life in each cell line. No significant difference in protein degradation rates 
either between WT- ∆CT and WT- ∆CMA or between A53T- ∆CT and A53T- ∆CMA (Figure 2.3A,B). 
This result confirmed the precedent observation in Figure 2.2. Surprisingly, the rate of protein 
degradation in the WT- ∆CT line seemed even to be higher, although not significantly, than in WT- 
∆CMA. Although in contradiction with published data suggesting that mutating CMA motif slows 
degradation rate of WT α-Synuclein (Vogiatzi et al., 2008). The present results indicate that mutating 
CMA in either the WT or A53T mutant has no effect on the α-Synuclein degradation rate.  
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Figure 2.3: Kinetics of α -Synuclein degradation in Tet-on HEK293 cells.
A and B: Degradation under enriched culture media of wild-type (A) and A53T mutant (B) α-Synuclein. Cells were
cultured in medium (10% of FCS) containing Dox (10ng/mL) during 5 days. Cells were washed twice in PBS and
immediately processed for total protein extraction in Triton lysis buffer for time point 0h or transferred into new
culture dishes in absence of Dox and repeating the process for different time points (24, 48 and 72h). Culture
medium is refreshed every 24 hours. For each image (A or B): Left: Western-blot showing α-Synuclein level using
15G7 antibody, β-Actin is used as loading control. Right: Quantification of α-Synuclein level. A triplicate per
experiments is done. Data are presented as the mean of ratio α-Synuclein/β-Actin of time points (24, 48 or 72h)
compared to ratio α-Synuclein/β-Actin of time point 0, calculated in % (signal obtained from Odyssey software)
from n=3 independent experiments.
C and D: Degradation under starvation condition of wild-type (C) and A53T mutant (D) α-Synuclein. Cells were
cultured in medium (10% of FCS) containing Dox (10ng/mL) during 5 days. Cells were washed twice in PBS and
immediately processed for total protein extraction in Triton lysis buffer for time point 0h or transferred into new
culture dishes containing serum-reduce medium (0.5% FCS) in absence of Dox and repeating the process for
different time points (24, 48 and 72h). Data are collected and presented as in A and B.
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α-Synuclein has been reported to have a relatively long half-life varying from 16.8-24h and depends 
on multiple factors including genetic background and culture conditions (number of passages, cell 
confluence, frequency of media change...) (Cuervo, 2004; Vogiatzi et al., 2008; Rott et al., 2011). CMA 
is also more active when cells are cultured in serum-free medium, thereby accelerating degradation 
rates (Cuervo, 2004). Since our observations did not confirm with the initial hypothesis that CMA 
motif mutation leads to slower degradation kinetics, the experiment was repeated with reduced 
serum (0.5% instead of 10% of FCS) in the culture medium.  
Since four of the α-Synuclein constructs lack the C-terminus which has been suggested to play a role 
in the physiology of α-Synuclein (Choi et al., 2012), two control cell lines expressing WT and A53T 
full-length (Control 1: WT- FL, Control 2: A53T- FL) were generated to establish base-line controls for 
α-Synuclein degradation rates. The degradation kinetics were calculated using the previous 
experimental design except that after removing Dox from medium, cells were cultured in medium 
containing 0.5% FCS (instead of 10 % FCS). Media were refreshed every 24 hours. In this reduced-
serum culture condition, the degradation rates of WT- FL and A53T- FL were first compared and 
found that interestingly, A53T- FL showed constantly higher % of non-degraded protein than WT- FL 
up to 96h and the difference between these cell lines is significant (Figure 2.4A). Quantification of 
steady state levels of WT-FL and A53T-FL α-Synuclein also demonstrated that A53T-FL α-Synuclein 
exhibited higher protein levels than WT-FL at 0h and 48h (Figure 2.4B). This observation correlated 
with previous published data (Cuervo, 2004) suggesting that, A53T α-Synuclein itself might prevent 
its entry into the lysosome lumen. However, no significant in difference of degradation rates was 
observed either between WT- ∆CT and WT- ∆CMA or between A53T- ∆CT and A53T- ∆CMA (Figure 
2.3C,D) confirming our observation in cells cultured with serum-enriched medium (Figure 2.3A,B). 
Based on their kinetic curves, the half-life of A53T-FL α-Synuclein is estimated to be about 16 h 
greater than WT-FL α-Synuclein whereas half-life of all four ∆CT α-Synuclein is very similar (Table 
2.1). 
In conclusion, these results with non-neuronal HEK293 cell lines showed that mutating of CMA motif 
did not slow down the kinetics of ∆CT α-Synuclein in two culture conditions (enriched serum and 
reduced serum). This observation raised the questions about the part of CMA in regulation of α-
Synuclein turn-over under normal physiological condition. The significant difference in half-life 
between FL α-Synuclein also suggests that α-Synuclein C-terminus might be crucial in regulating the 
CMA pathway. 
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2.2 Kinetics of α-Synuclein degradation in BE(2)-M17 cells 
The use of HEK293 cells has the advantage of maintaining the homogenous transcription levels, but 
these cells do not reflect neuronal cell properties. Therefore, in parallel with these experiments, four 
stable, inducible Tet-off BE(2)-M17 cells (derived from a neuroblastoma) were generated. They were 
designed to express C-terminal truncated WT and A53T α-Synuclein mutants with or without CMA 
motif mutation (line 1: WT- ∆CT; line 2: WT- ∆CMA; line 3: A53T- ∆CT and line 4: A53T- ∆CMA). For 
these cell lines, the traditional method for stable cell line generation based on random integration 
into the cellular genome was used. To ensure comparable expression levels, clones which showed 
similar mRNA levels were chosen after full induction during 7 days (in absence of Dox in culture 
medium). Unfortunately, the four cell lines did not have the same expression level. For subsequent 
studies, clones with comparable mRNA levels between line 1 and line 2 (WT- ∆CT vs WT- ∆CMA) and 
between line 3 and line 4 (A53T- ∆CT vs A53T- ∆CMA) were selected. The mRNA levels in cells 
expressing A53T α-Synuclein were 3-4 fold higher than in cells expressing WT α-Synuclein (Figure 
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Figure 2.4: Exploring the impact of C-terminus and the presence of CMA-motif mutation on the regulation
of α -Synuclein half-life.
A. Kinetics of full-length α-Synuclein degradation under starvation condition (culture media containing 0.5% of 
FCS) in Tet-on HEK293 cells. Cells were cultured in medium containing Dox (10ng/mL) during 5 days. 
Cells were washed twice in PBS and immediately proceed for total protein extraction in Triton lysis buffer 
for time point 0 or transferred into new culture dishes in absence of Dox and repeating the process for 
different time points (24, 48,72 and 96h). Left: Western-blot showing α-Synuclein level using 15G7 
antibody, β-Actin is used as loading control. Right: Quantification of α-Synuclein level. A triplicate per 
experiment is done. Data are presented as the mean of ratio α-Synuclein /β-Actin of time points (24, 48,72 
or 96h) compared to ratio α-Synuclein /β-Actin of time point 0, calculated in % (signal obtained from 
Odyssey software) from  n=3 independent experiments (∗∗P < 0.01 ∗P < 0.05, Student’s t test).
Β. α-Synuclein steady-state level at 0h and 48h after removing Dox in Tet-on HEK293 cells. Diagram  
showing the mean of protein level from experiments in A at 0h and 48h. Data are presented as the mean 
±SEM of ratio α-Synuclein /β-Actin of time points 0h and 48h from n=3 independent experiments.
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2.5A). However, protein levels observed by western-blot in cells expressing A53T α-Synuclein were 
constantly 2-fold higher than in cells expressing WT α-Synuclein. This might be interpreted in part as 
"leaky" expression that was also observed in non-induced cells when cells re cultured in medium 
containing 1µg/mL Dox (Figure 2.5B).  
 
As previously done with HEK293 cell lines, steady state protein levels were examined in the four cell 
lines. At time points 0 and 48h after adding Dox, protein levels in cells expressing WT- ∆CT and A53T- 
∆CT were significantly higher than ones express WT- ∆CMA and A53T- ∆CMA respectively (Figure 
2.6). The kinetics of degradation curves of α-Synuclein were established in these cell lines and their 
estimated half-lives are presented in Table 2.1. No significant differences in degradation kinetics 
kinetics were observed between WT-∆CT and WT-∆CMA or between A53T-∆CT and A53T-∆CMA up 
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Figure 2.5: Generation of Tet-off BE(2)-M17 inducible cell lines expressing α -Synuclein .
A: RT-qPCR comparing relative α-Synuclein mRNA level using ∆∆Ct method, expression of GAPDH is used
internal control.
B: Control of inducibility of cell clones chosen for further studies, cells are cultured with or without Dox (1µg/mL) in
enriched culture media (containing 10% of FCS) during 5 days and total protein are solubilized in Triton lysis
buffer.Western-blot showing α -Synuclein level using antibody 15G7 anti- α-synuclein.
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to 96h in culture conditions with serum-reduced medium (0.5%FCS) (Figure 2.7). Interestingly, in 
BE(2)-M17 cell lines, the estimated half-lives of ∆CT α-Synuclein are about 1 day longer than the ones 
in HEK-293 cells (Table 2.1). Once again, in neuronal BE(2)-M17 α-Synuclein with mutated CMA motif 
did not exhibit a slower turnover than α-Synuclein-∆CT with a normal CMA motif. 
 
 
Construct Half-life (h)±SEM
WT- FL 20.20±2.41
WT-∆CT 29.17±4.88
WT-∆CMA 25.21±4.80
A53T-FL 36.25±7.06
A53T-∆CT 26.89±3.84
A53T-∆CMA 25.10±3.84
Construct Half-life (h)±SEM
WT-∆CT 50.66±8.41
WT-∆CMA 57.84±16.43
A53T-∆CT 43.60±14.17
A53T-∆CMA 60.44±3.523
HEK293 cells BE(2)-M17 cells
Table 2.1: Recapitulation of α -Synuclein half-life in different cell lines.
Half-lives are represented as the mean±SEM of half-life values calculated from each independent experiment
(n=3) after correction of the degradation curves using “Nonlinear regression (curve fit), one phase decay”
(GraphPrism,version 5).
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Figure 2.6: α -Synuclein steady-state level at 0 and 48h after adding Dox in Tet-off BE(2)-M17 cells.
Cells were cultured in enriched culture media (10% of FCS) in absence of Dox (10ng/mL) during 5 days. 1µg/mL
of Dox was added to culture medium and total protein is immediately extracted in Triton lysis buffer for time point
0 (in A) or cells were cultured under starvation condition (medium containing 0.5% FCS) during 48 h in presence
of Dox (in B). For each image (A or B): Above: Western-blot showing α-Synuclein level using 15G7 antibody, β-
Actin is used as loading control. Below: Quantification of α-Synuclein level, data are presented as the mean of
ratio α-Synuclein/β-Actin (signal obtained from Odyssey software) from n=3 independent experiments.
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2.3 Generation of transgenic models overexpressing α-Synuclein 2.3.1  Pcp2 promoter drives α-Synuclein expression in cerebellar Purkinje cells (PCs) 
To study the long-term effect of the CMA motif mutation in animal models, two transgenic mouse 
lines expressing respectively A53T-∆CT (1-130) and A53T-∆CMA (1-130) were generated (Figure 
2.8A). Two large cohorts (30-40 animals per line) were obtained by crossing the driver line Pcp2-tTA 
(at the 6th backcross with wild-type C57BL/6 mice) with TetO-SNCA animals. These animal cohorts 
served for pilot studies using standard techniques such immunohistochemistry and western-blot. 
These preliminary stuides aimed to: (1) confirm the efficiency and validate strategies of α-Synuclein 
overexpression, (2) optimize and standardize technical approaches which would be used for 
subsequent studies, (3) detect eventual age-dependent pathological changes in transgenic animals.  
The distribution of transgene expression under the control of Pcp2 promoter which expresses tTA 
(transactivator) specifically in cerebellar Purkinje cells was assessed. Expression of tTA, in the 
absence of Dox, activates expression of the transgene which is preceded by the TetO sequence. The 
inducibility of transgene expression by Pcp2-tTA driver line was previously checked by crossing it with 
Tet-O-LacZ mice. LacZ gene encodes for β-galactosidase which can be detected by its enzymatic 
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Figure 2.7: Kinetics of α -Synuclein degradation in Tet-off BE(2)-M17 cells under starvation condition in
presence or absence of CMA-motif mutation for wild-type (A) and A53T mutant (B) α -Synuclein .
Cells were cultured in medium (10%FCS) without Dox during 5 days. 1µg/mL of Dox is added to culture medium
(0.5% FCS) and total protein is immediately extracted in Triton lysis buffer for time point 0h (in A) or cells were
kept in culture under starvation condition (medium containing 0.5% FCS) for additional time periods (24, 48,72 or
96h). Medium culture is refreshed every 24 hours. For each image (A or B): Left: Western-blot showing α-
Synuclein level using 15G7 antibody, β-Actin is used as loading control. Right: Quantification of α-Synuclein level.
A triplicate per experiments is done. Data are presented as the mean of ratio α-Synuclein/β-Actin of time points
(24, 48, 72 or 96h) compared to ratio α-Synuclein/β-Actin of time point 0h, calculated in % (signal obtained from
Odyssey software) from n=3 independent experiments.
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activity revealed by the presence of X-gal. Expression of β-galactosidase was found to appear 
specifically in Purkinje cell perikaryon in transgenic mice from around post-natal (P25) day 25. No 
leaky expression was observed in other brain regions. This transgene expression could be completely 
abolished by feeding adult mice (at 2 months) Dox (chow) for 18 days (Cawthorne et al., 2007) (Annex 
2). These results indicated that overexpression of transgene under direction of the Pcp2-tTA line 
satisfied criteria for specifically localizing and inducing transgene expression. 
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To further confirm these results in α-Synuclein transgenic lines, sagittal brain sections from young 
adult animals at 2-3 months of age were immunostained for α-Synuclein. As brain tissues were 
embedded in paraffin blocks, a step of antigen retrieval after tissue deparaffinization was necessary 
to enhance the quality of the labeling signal.  Pre-treatment by prolonged heating (around 20min) of 
tissue sections at 90°C in citrate buffer (pH 7.6) produced optimal α-Synuclein staining using 15G7 
and LB509 antibodies (specific for human α-Synuclein) or Syn-1 antibody (specific for mouse and 
human α-Synuclein). Additional pretreatment with formic acid 88% during 5 min at room 
temperature increased the specific signal of α-Synuclein. Immunostaining using 15G7 antibody 
indicated specific α-Synuclein expression in cerebellum of transgenic mice compared to control non- 
transgenic mice for human α-Synuclein (Pcp2-tTA mice, Figure 2.8C). This expression was particularly 
concentrated in the Purkinje cell layer (PCL), and the molecular layer (ML) which is the projection 
area of PC dendrites and the deep cerebellar nuclei (DCN) which contains axonal extensions of PCs 
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Figure 2.8: Overexpression of human C-terminal truncated α -Synuclein driven by mouse Pcp2 promoter.
A: Diagram representing the crossing procedure (Pcp2: Purkinje cell protein-2, tTA: tetracycline-controlled
transactivator). Two transgenic lines expressing α-Synuclein were generated (A53T-∆CT, A53T-∆CMA). Pcp2-
tTA mice are used as non-transgenic control.
B: Diagram showing strategy of generating TetO-SNCA mice: TetO-SNCA sequences are targeted specifically at
ROSA26 locus ensuring isogenic insertion
C: Expression of α-Synuclein is specifically targeted to cerebellum: immunostaining of 7-μm thick sagittal
cerebellar sections and western-blot of brain and peripheric tissue homogenates from 4- month-old mice, antibody
15G7 anti- α-Synuclein, (Red), DAPI (Blue).
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(Figure 2.8C). Some weak leaky expression of α-Synuclein was found in olfactory bulb (OB), but not 
observed in any other brain regions, in sagittal or coronal sections (Figure 2.8C, coronal sections not 
shown). This result was further confirmed by western-blot using the same 15G7 antibody: we could 
detect a distinct band of α-Synuclein at around 16kD was evident in cerebellum homogenate, but no 
signal was detected in other brain regions or in non-brain tissue homogenates (Figure 2.8B). These 
results validated the strategy of α-Synuclein overexpression directed by Pcp2 promoter in 
cerebellum without significantly inducing leaky expression in other brain regions.  
 
Next we further characterized the distribution pattern of overexpressed α-Synuclein to determine its 
cellular localization, by focusing on the two main regions ofabundant α-Synuclein expression (at 
A53T-∆CMA, 6moA53T-∆CT, 6mo
Pcp2-tTA, 6mo
Pcp2-tTA, 6mo
A
B
A53T-∆CMA, 6moA53T-∆CT, 6mo
5µm
5µm
Figure 2.9: Localization of
overexpressed human α -Synuclein
driven by mouse Pcp2 promoter by
immunostaining of 7-μm thick
sagittal cerebellar sections from 6-
month-old mice (6mo), antibody 15G7
anti-α -Synuclein.
A: Overexpressed human α-Synuclein is
located in neurites and Purkinje cell
perikaryon (enlargement of Purkinje cell
layer area).
B: Overexpressed human α-Synuclein is
located axon terminals of Purkinje cells
(enlar in Deep cerebella nuclei area).
Abbreviations: PCL: Purkinje cell layer,
DCN: Deep cerebellar nuclei, ML:
molecular layer, WM: white matter,
GCL:granular cell layer).
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higher magnification). In the PCL, we observed that overexpressed α-Synuclein was principally in 
Purkinje cell bodies. Surprisingly, the protein level of overexpressed α-Synuclein was not 
homogenous, but varied in a mosaic-like manner between the cells. Unexpectedly, strong α-
Synuclein signal was observed in the PC dendrite arborescence in the ML. Anatomically, PC dendrites 
form synapses and receive excitatory input directly from nuclei via climbing fibers or indirectly via 
granule cells located in the granule cell layer (GCL) which project their bifurcated parallel fibers in ML 
region. We found numerous punctuate of overexpressed α-Synuclein around Purkinje cell bodies 
although its precise intracellular location remained unclear (Figure 2.9A). In DCN, abundant "dots" 
corresponding to α-Synuclein signal were observed. These α-Synuclein dots were widely distributed 
in the DCN and some of them are clustered around cell bodies of DCN neurons. DCN are known as 
output areas where PCs make inhibitory synapses with relay neurons which are inter-connected with 
motor-cortex neurons in the thalamus. As α-Synuclein is known to be abundant in pre-synaptic 
regions, these α-Synuclein dots might well correspond to PC pre-synaptic regions (Figure 2.9B). 
To confirm the cellular type overexpressing α-Synuclein, sections were double immunostained for α-
Synuclein and specific marker for PCs, Calbindin-D28K. Calbindin-D28K is a calcium buffer protein 
which is highly expressed in all PCs and only at low levels in other cerebellar cell types such as in 
parallel fibers of granule cells. Immunostaining of Calbindin confirmed that PCs can be clearly 
distinguished from other cell types in the cerebellum. In sagittal sections, Calbindin signal 
concentrated in PC perikaryons (PCL), dendritic arborescences (ML) and deep cerebellar nuclei (DCN). 
The Calbindin signal in the ML is particularly intensive, clearly separating the cerebellar cortex (PCL + 
ML) from the cerebellar white matter (Figure 2.10A). However, within the cerebellar white matter   
Calbindin labelled axonal fibers of PCs which depart from the PCL and project to the DCN. The human 
α-Synuclein and Calbindin signals perfectly overlap in PCs in ML, PCL and DCN, confirming 
overexpressed α-Synuclein is localized in PCs. In PCL and ML, the overlapping signals were 
particularly strong in Purkinje cell perikaryon and cytoplasm, but also in dendrites confirming the 
presence of overexpressed α-Synuclein in post-synaptic regions. Numerous punctuate staining of α-
Synuclein around Purkinje cell bodies are overlapped with Calbindin signals at the region of axonal 
departure or dendritic connection even though the latter are not as intensively stained for Calbindin. 
This observation suggested that α-Synuclein "dots" around PC are rather intracellular than secreted 
(Figure 2.10B). Interestingly, not all PCs with strong Calbindin staining showed strong signal of α-
Synuclein confirming our observation that overexpression of α-Synuclein was not homogenous 
between the cells and followed a random mosaic distribution. In DCN, the Calbindin staining was 
homogenous and diffusely distributed, whereas α-Synuclein presented a rough, coarse pattern of 
wasdistribution. α-Synuclein and Calbindin are perfectly overlapped in this region with comparable 
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signal intensities, a portion of Calbindin signal however did not co-stain with α-Synuclein confirming 
the mosaic pattern of α-Synuclein expression. Localization of α-Synuclein with Calbindin in DCN 
demonstrated that overexpressed α-Synuclein was abundant in pre-synaptic regions of PCs. 
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 2.3.2 Mutation of the CMA motif does not affect the steady-state level of α-Synuclein in 
vivo 
The effect of CMA-motif mutation on the α-Synuclein turnover in vivo had not been previously 
elucidated. In vitro, the A53T mutant has been shown to act as a blocker at the entrance gate of the 
lysosomes and to prevent its translocation to the lysosomal lumen (Cuervo, 2004). Expression of 
A53T α-Synuclein has been reported to partially inhibit total protein degradation in the lysosome 
while expression of A53T-∆CMA had no effect in proliferating SHSY-5Y cells. In contrast, 
overexpression of both mutants blocked lysosomal degradation in differentiated SHSY-5Y cells in the 
same study (Xilouri et al., 2009). In current animal models, similar staining intensities and 
intracellular distributions were observed for both mutants by immunohistochemistry intensity 
(Figure 2.11C). To further explore this, the mRNA levels of α-Synuclein of each transgenic line were 
measured by RT-qPCR and these results confirmed that expression levels were similar (data not 
shown). This indicated that the isogenic insertion strategy by knocking-in TetO-SNCA transgene at the 
ROSA26 locus created transgenic animals with identical genetic backgrounds (Figure 2.8B). In these 
transgenic lines at 4-months of age, western-blot analyses revealed no differences in protein 
expression levels (Annex 4). As well, α-Synuclein migrated as a single band as in non-transgenic 
controls (data not shown). The means of ratios [α-Synuclein/GAPDH] were compared. No significant 
difference in α-Synuclein protein levels was found in both lines (Figure 2.11A,B). This suggests that 
the deletion of the CMA-motif had no effect on α-Synuclein turnover in vivo. Therefore, we should 
expect from this result no great difference in disease onset or behavior in our two transgenic mouse 
lines. 
 
 
Figure 2.10: Co-localization of α -Synuclein and specific marker of PCs, Calbindin D28-K.
Immunofluorescent staining of 7µm- thick sagittal cerebellar sections from 6-month old transgenic mice.
A: α-Synuclein and Calbindin D28-K are co-localized in molecular layer (ML), Purkinje cell layer (PCL) and Deep
cerebellar nuclei (DCN) in A53T-∆CT and A53T-∆CMA lines. Antibody anti-human α-Synuclein (15G7, Red),
antibody anti-mouse Calbindin D28-K (Green).
B: Co-localization of α-Synuclein and Calbindin D28-K in PCL at high magnification view. Antibody anti-human
α-Synuclein (15G7,Red), antibody anti-mouse Calbindin D28-K (Green).
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2.4  Analysis of transgenic animals overexpressing α-Synuclein 
Overexpression of α-Synuclein in rodents has been reported to cause pathological conditions, but 
the severity probably varies between models depending on different factors: the promoters used for 
driving transgene expression, the α-Synuclein transgene construct, the level of overexpression, the 
genetic background of the host animal, the location of the transgene insertion, the absence or 
presence of α-Synuclein aggregates. These variable factors contribute to the diversity in the age of 
disease-onset observed in different animal models (Table 1.3 and reviewed in Chesselet et al., 2011). 
In general, overexpression of α-Synuclein causes progressive behavior changes with onset starting 
between 8 and 12 months. These behavioral dysfunctions may be preceded or followed by 
histopathological features. The difficulty in determinating the onset of the disease constitutes major 
Figure 2.11: Similar α -Synuclein protein levels in both transgenic lines despite mutation of the
Chaperone-mediated autophagy motif in A53T-∆CMA line.
A: Western-blot showing in α-synuclein level in cerebellum tissue homogenates from 4-month old transgenic
mice,antibody 15G7 anti- α-Synuclein, GAPDH is used as loading control.
B: Quantification of α-Synuclein protein level from A. Diagram representing the mean of signal ratio α-
Synuclein/GAPDH of transgenic lines (signal obtained from Odyssey software, no-background quantification
method), data are expressed as the mean ±SEM;n= 8.
C: Immunostaining of 7-μm thick sagittal cerebellar sections from 3- month-old mice (3mo), antibody 15G7 anti- α-
Synuclein followed by chromogenic revelation method.
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challenge when analyzing new α-Synuclein transgenic models. For this reason, two lines of 
investigation were carried out in parallel: one surveying behavior changes and the second examining 
the histopathology of the cerebellum at different ages. 2.4.1 Transgenic mice overexpressing of α-Synuclein in PCs show decline in locomotor 
performance compared to non-transgenic mice 
Transgenic mice overexpressing α-Synuclein did not show any particular phenotype up to 5 months 
of age. To further investigate animal behavior, we generated new cohorts of animals by crossing 
Pcp2-tTA mice (from 7th backcrossing to C57BL/6) with TetO-SNCA mice. Two age-matched cohorts 
of control non-transgenic animals were used: control 1: WT= purchased C57BL/6 mice, control 2: 
Pcp2-tTA at 8th generation of backcrossing. Any behavioral deficits, once identified, are predicted to 
depend on the degree of neurodegeneration. Concretely, pronounced PC degeneration should affect 
motor coordination or motor balance in our transgenic animals (Donald et al., 2008;Komatsu et al., 
2007). Therefore, a broad range of motor coordination behavior was evaluated using standard tests: 
rotarod, pole test and beam-walk. In addition, basal locomotor activities (ambulatory and rearing) 
were recorded using open-field test (automatic home-cage).  
In open-field, locomotor activities of animals were recorded every 6 weeks using Actimot system 
(TSE). Two main parameters which featured locomotor activities, ambulatory activity (reflected by 
traveling distance) and rearing frequency were extracted from the raw data. The mean of each 
parameter in each group at each time point is plotted in a graph to establish the cumulative activity 
curves (total recordings) (Figure 2.12 A, B). To facilitate the analysis, data from transgenic groups 
were normalized to the control group Pcp2-tTA (100% correspond to ~ 3000-3500 meters of traveling 
distance and ~ 1500-2000 rearing times) (Annex 6).  Both parameters, traveling distance and rearing, 
from all animal groups were relatively stable over time indicating that locomotion does not decline in 
an age-dependent manner up to 16.5 months. Interestingly, the A53T-∆CMA line showed 
significantly lower traveling distances and rearing activities compared to the control Pcp2-tTA. 
Although the A53T-∆CT line showed a lower trend towards rearing activities compared to the control 
Pcp2-tTA, this was not statistically significant. No difference in the ambulatory activities of the A53T-
∆CT and control Pcp2-tTA lines were detected. Interestingly, WT (C57BL/6) mice exhibited 
significantly higher rearing activities compared to all other lines (Pcp2-tTA, A53T-∆CT and A53T-
∆CMA) (Annex 6). 
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In pole climbing test, the time necessary for animals to turn downward (t-turn) and total time to 
descend the pole (t-total) were measured. The pole test has been used to detect bradykinesia and 
motor coordination in PD mouse models (Fleming et al., 2006;Glajch et al., 2012;Price et al., 2010). 
Behavioral deficits in the pole test have been ameliorated by dopamine agonist treatment in MPTP 
mice and in a Parkinsonian genetic mouse model (Luchtman et al., 2012;Ono et al., 2009;Park et al., 
2013). Experiments were done with animals at young and mid-advanced ages of 5, 7, 10 months. 
Starting from 14 months, animal performance was regularly assessed every 6 weeks. Data per animal 
in each experiment was represented as the mean (t-turn and t-total) of five trials. Since the t-turn is 
proportional to t-total, only data here representing t-total are shown. In young animals, there was no 
significant difference in total time to descend the pole. Curiously, occasionally some transgenic 
animals could not turn downward or slide-off the pole (t-total was counted as 60s). Starting from 14 
months of age, there was an increase in the number of animals in the transgenic groups that slide-off 
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Figure 2.12: Locomotor activities of animals recorded by Open-field test during active phase.
(Pcp2-tTA: n=22, A53T-∆CT: n=16, A53T-∆CMA: n=18)
A: Left: Typical curve of ambulatory movement. Data represented the mean ±SEM of traveling distance (in
meters) recorded every 60min. Right: Total traveling distance from ages of 6 to 22.5 months. Data mean traveling
distance normalized to Pcp2-tTA group.
B: Left: Typical curve of vertical movement. Data represented the mean ±SEM of rearing times recorded every
60min. Right: Total rearing activities from ages of 6 to 22.5 months. Data mean rearing activities normalized to
Pcp2-tTA group.
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the pole (7 animals from A53T-∆CT line and 7 animals from A53T-∆CMA line). These animals were 
called "symptomatic" animals. However, there was no progressive increase between 14 and 22.5 
months. Other transgenic animals continued to perform the test well and did not show an increase in 
the total time to descend the pole (7 animals from A53T-∆CT line and 9 animals from A53T-∆CMA 
line) (Figure 2.13A). These were called "non-symptomatic" animals. Performance of the non-
transgenic group Pcp2-tTA was stable over time and was similar to "non-symptomatic" transgenic 
animals. There was no significant difference in the time to descend the pole in aged animals 
compared to young animals in the control group. Interestingly, re-analyzing the open-field data 
revealed that "symptomatic" animals clearly exhibited a decreased trend for rearing activities 
starting from around 15 months. Compared to control Pcp2-tTA mice, the rearing activities of 
"symptomatic" A53T-∆CMA and A53T-∆CT are 29.98 % 7.73 and 51.11% 11.13, respectively. The 
same activity in "non-symptomatic" animals remained stable (Figure 2.13B). However, there was no 
substantial decrease in traveling distance between "symptomatic" groups and "non-symptomatic" 
groups (Annex 7). 
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In rotarod, motor coordination capacity was measured by the duration in which animals were still 
able to run on an accelerating rotarod (latency to fall). The mean of latency to fall of each group at 
each time point is plotted in a graph to establish cumulative curves. To avoid variation between 
experiments, the scores of transgenic groups were normalized to the ones of Pcp2-tTA group (100 % 
corresponding to ~80-120 s of latency on rod). A mild, progressive, age-dependent diminishing motor 
performance was observed in all animal groups (Annex 8A). However, no significant difference in the 
latency to fall could be detected up to 19.5 months of age between transgenic lines and Pcp2-tTA 
control group (Figure 2.14A). The retention time on rotarod of the two sub-groups "symptomatic" 
and "non-symptomatic" defined as precedent from pole climbing test was also re-analyzed. 
Interestingly, transgenic "symptomatic" animals again showed a difference of 20 s of retention time 
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Figure 2.13: Motor coordination and motor balance phenotyping.
A: Latency of animals on pole . Data represented the mean of total time to descend the pole (in s) in five trials of
individual animals (Pcp2-tTA:n=22,A53T-∆CT: n=16, A53T-∆CMA: n=18).
B: Post-analysis of vertical movement activities for “symptomatic” (left) and “non-symptomatic” (right) groups .
Data represents the mean ±SEM of total rearing times ages of 6 to 21 months normalized to Pcp2-tTA group
(Pcp2-tTA: n=22,A53T-∆CT: n=7, A53T-∆CMA: n=7).
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on rotarod at 13, 15 and 16.5 months of age compared to Pcp2-tTA control line. No clear difference 
was observed in "non-symptomatic" groups (Annex 8B). 
In beam-walk, the total time that animals needed to cross the challenge beam in a single walk was 
measured, a maximal allowed duration of crossing was fixed at 60s. Experiments were conducted at 
three time points: 15, 17 and 19 months. On the day of test, five trials per animal were done and the 
mean of five scores was considered as the crossing time. Animals that failed in 3 or more of the 5 
times to cross the beam ("fallen-out") were counted as 60s. Interestingly, transgenic groups at 15 
months took significantly longer time to cross the beam than non-transgenic control group. However, 
no significant difference was observed at later time points (17 and 19 months) suggesting a certain 
adaptation of transgenic animals to the task (Figure 2.14B). 
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Figure 2.14: Motor coordination and motor balance phenotyping.
A: Latency of animals on rotarod. Data represent the mean of total time to stay on accelerating rod (in s)
normalized to Pcp2-tTA group (Pcp2-tTA: n=22, A53T-∆CT: n=16,A53T-∆CMA: n=18).
B: Ability to cross the beam.Data represented the mean of total time to cross the beam in four trials.
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Taken together, this behavioral data suggested a certain tendency of locomotor and motor 
coordination deficits in transgenic animals. In terms of specificity, vertical movement (rearing, pole 
climbing) seems to be more affected than horizontal movement (traveling distance, latency on 
rotarod, beam crossing). These deficits however did not clearly decline in an age-dependent manner. 
In addition it should be noted that not all animal in transgenic groups were affected to the same 
degree and only some animals in each transgenic group were sensible to the behavioral tests. 2.4.2 Analysis of PC neurodegeneration 
Our primary immunohistochemistry results obtained from analyses of pilot groups did not show 
prominent neurodegeneration in the cerebellum (data not shown). To clarify pathological changes in 
transgenic animals and to identify a link between phenotype and molecular pathologies, detailed 
histological and biochemical studies were performed on the animal groups which had been used for 
behavioral tests. All animals were sacrificed and transcardiacally perfused with PBS at 23 months of 
age, the right hemisphere of cerebellum was used for immunohistochemical staining and the left 
hemisphere was used for western-blot. Transgenic lines- A53T-∆CT and A53T-∆CMA were compared 
with non-transgenic lines- WT and Pcp2-tTA. 2.4.2.1 PC morphology 
To determine whether overexpression of α- Synuclein lead to neurodegeneration of PCs, number of 
Purkinje cells was counted in cerebellum sections stained with antibody anti-Calbindin-D28K. 
Sections were cut at 12µm of thickness and staining was revealed by chromogenic method to reduce 
the risk of autofluorescence detection due to accumulation of lipofuscin in old brain tissues (Figure 
2.15A). Triplicate staining was made for each animal and only cells with well-shaped cell body (as 
shown in Figure 2.15B) were taken in account. The mean of triplicate is defined as the PC number of 
corresponding animal. No significant difference in PC number was found between Pcp2-tTA and the 
two transgenic lines A53T-∆CT and A53T-∆CMA. Interestingly, PC number in WT line (205.3 ± 31.77, 
n=11) showed a non-significant trend for more PCs than the Pcp2-tTA (154.7 ± 11.79, n=12), A53T-
∆CT (180.4 ± 14.24, n=14) and A53T-∆CMA (169.3 ± 15.02, n=14) (Figure 2.15B). The A53T-∆CT line 
also tended to have more PCs than the A53T-∆CMA line. In two sub-groups "symptomatic" vs. "non-
symptomatic" within the same transgenic line, no significant difference in PC numbers in these sub-
groups was observed (Figure 2.15B).  
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Changes in Purkinje cell dendrite morphology has been reported to induce deficits in motor 
coordination (Donald et al., 2008). Using the same sections, the number of visible main trunks of 
dendrites was counted. Only trunks directly connected to cell bodies were taken in account, the ones 
which were not linked to cell bodies were considered as unordered structures. There was a 
significant difference in the number of visible main trunks in WT line (215.1 ± 33.42, n=10) and the 
trangsenic animal lines but not between Pcp2-tTA (159.6 ± 12.04, n=10), A53T-∆CT (171.3 ± 10.67, 
n=11) and A53T-∆CMA (162.1 ± 12.57, n=11) lines. Again, there was a higher but non-significant 
trunk number in A53T-∆CT line compared to A53T-∆CMA line. Within the same transgenic line, the 
trunk number in "symptomatic" and "non-symptomatic" within the same transgenic line (Figure 
2.15B) in agreement with the analysis of Purkinje cell number. 
Since α-Synuclein overexpression has been reported to induce abnormabilities in axon terminals 
(Komatsu et al. 2007). No remarkable morphological changes or abnormal redistributions of 
Calbindin was observed in cerebellar nuclei in any of the animal groups. This suggests that the 
Calbindin D28K
GAPDH
Figure 2.15: Change in number of Purkinje cells is independent of α -Synuclein overexpression in 23-
month old animals .
A: Immunostaining of Purkinje cells in 12-μm thick sagittal cerebellar sections from 23- month-old mice (23mo),
antibody anti-Calbindin D-28K (chromogenic stain)
B: Counting of PCs with sharped cell bodies and visible main trunk of neuritic arborization (arrowed). Data are
expressed as the mean of PCs ±SEM; n= 7 per animal group, 3 slices per animal.
C. Western-blot showing Calbindin protein level in cerebellum tissue homogenates from the same animals
(antibody anti-Calibindin D-28K, GAPDH is used as loading control) and diagram comparing relative protein level
of Calbindin, data expressed as the mean of ratio Calbidin/GAPDH ±SEM;n= 7 per animal group .
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evelated expression of α-Synuclein in pre-synaptic regions, does not provoke massive axonal 
degeneration of PC before 23 months of age (Figure 2.15A). 
To validate these histological studies, western-blot analysis was also performed. We compared 
protein level of Calbindin in cerebellum homogenates from the same animals which were used for 
immunohistostaining. Calbindin was detected by the same antibody anti-Calbidin-D28K used in 
histological studies. As shown in Figure 2.15C, the Calbindin protein levels between were similar in 
cerebellum homogenates from the four lines. Taken together, the absence of significant differences 
in PC numbers and Calbindin levels between transgenic lines and Pcp2-tTA control line indicates that 
there is no massive PC loss. In addition, the quantification of visible main trunks did not reveal any 
disorganization of dendritic trees of PCs in transgenic mice compared to non-transgenic control 
animals. Furthermore, the presence of excess α-Synuclein in axonal terminals did not dramatically 
alter either axonal morphology or pre-synaptic density in cerebellar nuclei. However, the fact that 
WT line showed consistently higher PC numbers and more homogenously organized dendritic 
structures imply that overexpression of tTA itself is unexpectedly toxic for PCs.  2.4.2.2 Synaptic density markers 
PC dendrites form synapses with parallel fibers in the molecular layer and PC degeneration may be 
linked to loss of synaptic connections in this region. Overexpressed α-Synuclein was also found in 
dendritic trees suggesting that PC degeneration, when it occurs, might also happen in dendritic 
spines. To further explore this possibility, synaptic density in the molecular layer (ML) reflected by 
synaptic marker expression level was examined using a synaptic marker, the glutamate receptor 
mGluR1 which is concentrated in PC dendritic spines innervated by parallel fibers. Glutamate 
receptor mGluR1 is localized at high level in PC dendritic spines where PCs are innerved by parallel 
fibers. mGluR1 has been previously used to characterize PC degeneration (Zu et al., 2004; Komatsu et 
al., 2007). Immunohistochemistry revealed a high concentration of mGluR1 widely distributed in the 
ML, clearly distinguishing the cerebellar cortex from the rest of the cerebellum. The staining intensity 
and distribution of mGluR1 was comparable in transgenic mice and control mice suggesting that no 
dramatical change in dendritic spine density occurs in the ML (Figure 2.16A). However, this method 
was not quantitative since dendritic spine could not be visualized with high precision under 
microscope at low magnification. In addition, the localization of another synaptic marker, Syntaxin 
which is a component of the SNARE complex was examined. Immunolocalization of Syntaxin revealed 
a similar distribution to mGluR1 in the ML (data not shown). To quantify synaptic densities, Syntaxin 
levels in cerebellar homogenates from the trangenic animal lines were compared by western-blot. 
Equivalent levels of syntaxin were found in all lines (Figure 2.16B), again indicating that 
overexpression of α-Synuclein does not affect synaptic density in the ML (Figure 2.16A). 
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 2.4.2.3 GABA neurotransmitter release 
The involvement of α-Synuclein in regulating neurotransmitter release remains controversial. Some 
findings suggest that overexpression of α-Synuclein in old mice elevates dopamine levels at the pre-
synaptic region of nigrostriatal dopaminergic cells and induces abnormal accumulation of dopamine 
vesicles reserve pool prior to neurodegeneration (Kurz et al., 2010). PCs are known as GABAergic 
inhibitory neurons which make synapses with relay neurons in deep cerebellar nuclei (DCN). To 
evaluate the effect of α-Synuclein overexpression on GABA transmission, GABA releasing terminals 
were immunostained for the vesicular GABA transporter (VGAT) (Mandolesi et al., 2012), in particular 
the DCN where PC axon terminals are concentrated. The signals for VGAT and α-Synuclein observed 
in this region highly overlapped in transgenic mice confirming that the majority of axon terminals 
were from PCs (Figure 2.17A). Nevertheless, the densities of VGAT signals were highly comparable in 
transgenic mice and non-transgenic control animals. Using this approach, no notable accumulation or 
redistribution of VGAT dots in transgenic animals was found in contrast to previous studies (Halliday 
et al., 2011). This observation suggests that despite the presence of overexpressed α-Synuclein and 
GABA vesicle, GABA vesicle homeostasis is maintained in PC axon terminals (Figure 2.17A). 
GABAergic synaptic inputs in cerebellum do not exclusively come from PCs, but also from Golgi cells 
which synapse on mossy fibers in the granule cell layer and from other inter-neurons which synapse 
on soma or dendrites of PCs in the ML (Mandolesi et al., 2012). Thus immunostaining of VGAT also 
reveals afferent PC inputs. VGAT was widely distributed in punctate, but was less dense than mGluR1 
revealed a widely punctuate distribution of this marker in ML but with lower density as observed 
with mGluR1 staining (Figure 2.17B). As predicted, punctuate VGAT staining was also present on PC 
soma as expected. Similarly to mGluR1, no obvious change in VGAT density either in ML or on PC 
soma in transgenic mice compared to control animals. Once again this supports the view that there is 
no clear-cut reduction in the direct innervation of PCs by other cells in the ML and PCL on PC (Figure 
2.17B). 
Figure 2.16: Overexpression of α -Synuclein doesn’t lead to changes in synaptic density up to 23 months
of age.
A.Immunofluorescent co-labeling of glutamate receptor (mGluR1/5) and α-Synuclein in the molecular layer from
7µm- thick sagittal cerebellar sections. Antibody anti-mouse mGluR1/5 (Green) and antibody anti-human α-
Synuclein (15G7, Red).
B. Western-blot showing protein level of synaptic marker protein Syntaxin in cerebellar tissue homogenates from
the same animals (antibody anti-Syntaxin, GAPDH is used as loading control) and diagram comparing relative
protein levels of Syntaxin, data expressed as the mean of ratio Syntaxin/GAPDH ±SEM; n= 4 per animal group
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 2.4.2.4 Neuroinflammation markers 
Activation of glial cells is widely recognized as a feature of neurodegeneration although molecular 
mechanisms underlining this activation are not fully understood. Glial activation accompanying with 
PC degeneration has been reported in previous studies (Mandolesi et al., 2012;Zhao et al., 2011). 
Overexpression of α-Synuclein in transgenic animal model commonly showed an increase in glial cell 
activation (Lim et al., 2011;Nuber et al., 2008). In order to check whether overexpression of α-
Synuclein in our animal models increased inflammation, immunohistochemistry of glial fibrillary 
acidic protein (GFAP) and Iba-1 to characterize astrocyte activation (astrogliosis) and microglia 
activation (microgliosis) respectively was performed. 
Immunostaining of GFAP revealed a ubiquitous distribution of astrocytes throughout the cerebellum 
with a high concentration of cells in cerebellar white matter along PC axonal beams. Astrocytes were 
also seen at a lower density in cerebellar nuclei. These cells were present in high quantity in all 
animals and expression was comparable between the lines (non-transgenic and transgenic) 
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Figure 2.17: Overexpression of α -Synuclein doesn’t lead to change of pre-synaptic vesicle density up to
23 months of age.
A: Immunofluorescent co-labelling vesicular GABA transporter (VGAT) and α-Synuclein in deep cerebellar nuclei
of 7µm- thick sagittal cerebellar sections. Antibody anti-mouse VGAT (Green) and antibody anti-human α-
Synuclein (15G7,Red).
B: Staining of VGAT in Purkinje cell layer and molecular layer of 7µm- thick sagittal cerebellar sections.
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suggesting that overexpression of α-Synuclein in transgenic lines does not significantly enhance 
astrogliosis (Figure 2.18). 
 
Immunolabeling of Iba-1 showed a uniform distribution of microglia in cerebellum. Microglial cells 
were more concentrated in the cerebellar nuclei. The cells exhibited both resting state (small cell 
bodies with long ramifications) and activated state (round, dense cell body with small extensions). 
From our general observation, there were more resting cells than activated cells in all animal groups. 
Similarly to GFAP, Iba-1 expression was comparable between animal lines indicating that 
overexpression of α-Synuclein was probably not the cause for microglia activation (Figure 2.19). 
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Figure 2.18: Astrogliosis in cerebellum at 23 months of age.
Immunofluorescent labelling glial fibrillary acidic protein (GFAP) from 7µm- thick sagittal cerebellar sections.
Antibody anti-mouse GFAP (Green) and Hoerscht staining (Blue).
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Taken together, overexpression of α-Synuclein in our transgenic models up to 23 months of age did 
not show enhanced astrogliosis or microgliosis indicating that neuroinflammation is not induced, in 
agreement with the absence of neurodegeneration in these models.  2.4.2.5  Absence of amyloid-like feature of overexpressed a-Synuclein  
Amyloid-like (Lewy body-like) deposits of α-Synuclein resulting from the oligomerization and 
aggregate formation process are "hallmarks" of α-Synuclein pathologies. α-Synuclein oligomers are 
characterized by multiple features: abnormal accumulation, insolubility, resistance to enzymatic 
digestion (for example with proteinase K) and reactivity to Thioflavin S. They have also been shown 
to be phosphorylated or ubiquitinated (Neumann et al., 2002; Rieker et al., 2011). Based on these 
criteria, the development of pathological species of α-Synuclein (with amyloid features) in the 
transgenic models was examined by immunohistochemistry ans western-blot.  
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Figure 2.19: Microgliosis in cerebellum at 23 months of age.
Immunofluorescent co-labelling microglial cells and α-Synuclein in deep cerebellar nuclei from 7µm- thick sagittal
cerebellar sections.Antibody anti-Iba1 (Green) and antibody anti-human α-Synuclein (15G7,Red).
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Oligomeric forms of α-Synuclein could be detected in Triton soluble fractions by western-blot. Using 
15G7 antibody, the presence of high-molecular-weight bands in brain homogenates were regularly 
checked from animal at different ages. The presence of relevant high-molecular-weight bands 
specific for α-Synuclein oligomers in brain homogenates of transgenic animals up to 23 months of 
age was not detected. High-molecular-weight bands could be inconsistently observed in 
immunoblots using 15G7 antibody as well as in absence of primary antibody showing non-specificity 
of secondary binding (Annex 4).  
In immunohistochemistry, it was observed that overexpressed α-Synuclein in our transgenic models 
showed similar sub-cellular distribution pattern and there was not remarkable variation of this 
distribution at 3, 12 or 21 months (Figure 2.20). As previously mentioned, α-Synuclein labeling using 
15G7 antibody showed punctuate, dot-like immunoreactivity that could lead to think about abnormal 
accumulation of the protein (Figure 2.9). Nevertheless, these dots were already detected at early age 
(1 month, data not shown) and there was not a broad spreading of dots over time. Together with the 
observation in co-labeling with Calbindin-D28K, we supposed that dot-like α-Synuclein corresponds 
rather to the normal localization of overexpressed α-Synuclein than an abnormal accumulation 
(Figure 2.10). 
Further, α-Synuclein resistance to PK digestion in cerebellum of our transgenic animals was assessed. 
For this, PK digestion of paraffin sections from mouse brains at 18 months after transferring sections 
on PVDF membrane (PET-Blots) was performed according to Neumann et al. (2002) protocol. As 
positive control, brain sections from mice overexpressing A30P α-Synuclein under the control of Thy-
1 promoter (Thy-1 A30P mice) which showed strong phenotype (15-17 months) were used (Kahle et 
al., 2001). After paraffin de-waxing, tissues were digested in 50µg/mL of PK solution at 37°C during 
15 hours. α-Synuclein detection was done with 15G7 antibody. Numerous remaining spherical or 
longitudinal structures of α-Synuclein in brain sections from Thy-1 A30P mice were observed 
whereas no background staining was seen (data not shown). This observation proved that α-
Synuclein structures in Thy-1 A30P mice could resist robust digestion by PK. However, none of 
remaining α-Synuclein structure in our transgenic models was seen. In order to check how resistant 
overexpressed α-Synuclein in our transgenic models was, milder digestion conditions were applied 
(in 50µg/mL of PK solution at 37°C during 1 h) to treat brain sections from animals at 3, 12 and 21 
months. This time, the staining on glass slides without transferring the brain tissues onto PVDF 
membrane was performed (adapted from Wagner et al., 2013). By this approach, there was still 
remaining homogenous background signal after 1 hour of digestion but no clear deposits α-Synuclein 
was seen (Figure 2.20). This observation suggested that α-Synuclein overexpression did not develop 
prominent aggregates in our transgeninc models. 
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We asked whether overexpression of α-Synuclein enhanced disease-associated post-translational 
modifications such as phosphorylation or ubiquitination. Phosphorylation at Ser129 residue of α-
Synuclein is widely accepted as one of pathological modifications found in α-Synuclein inclusions in 
human cases but also in animal models (Kahle et al., 2002; Chen and Feany, 2005). Additional 
immunostaining in brain sections of animals from behavior groups as precedent were performed.  
Monoclonal antibody recognizing specifically phosphorylated α-Synuclein at Ser129 residue was used 
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Figure 2.20: α-Synuclein at 3, 12 and 21 months of age doesn’t resist to proteinase K digestion.
Cerebellar sections on glass slides are incubated in 50µg/mL of proteinase K at 37°C during 10 min. Immunostaining of α-
Synuclein in PC and molecular layers from 3µm- thick sagittal cerebellar sections, Antibody anti-human α-Synuclein (15G7)
(chromogenic stain).
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(Table 4.1). This antibody was first tested in brain sections from Thy-1 A30P mice which exhibited 
strong motor phenotype (15-17 months). Abundant fibrillar and spherical structures of α-Synuclein 
showing that we were able to detect phosphorylated α-Synuclein using this approach could be 
detected (data not shown). To localize overexpressed α-Synuclein, co-lableling on the same sections 
α-Synuclein using 15G7 antibody was performed . Staining of phosphorylated α-Synuclein at Ser129 
showed diffuse cytoplasmic signal, except for unspecific autofluorescence signal emitted by 
accumulation of lipofuscin usually seen in old brain tissues. No up-regulation or abnormal 
accumulation of phosphorylated α-Synuclein signal was observed either in Purkinje cell bodies or 
cerebellar nuclei in transgenic animals compared to non-transgenic control animal (WT and Pcp2-
tTA). Overlapped images confirmed that there was no relevant co-localization of overexpressed α-
Synuclein and phosphorylated α-Synuclein, we supposed that yellow signals were resulted from the 
overlapping lipofuscin autofluorescence (Figure 2.21A,B). 
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In a parallel study, the question whether overexpressed α-Synuclein in our transgenic models was 
conjugated to ubiquitin was asked. Ubiquitination of α-Synuclein is also one of the pathological 
modifications of α-Synuclein which is accumulated in Lewy bodies (LBs) (Gomez-Tortosa et al., 2000; 
Sampathu et al., 2003). As previously for detection of phosphorylated α-Synuclein, co-staining of 
ubiquitin and human α-Synuclein using 15G7 antibody was performed on brain sections of animals 
from the same precedent cohorts. Similarly, the efficiency of the antibody was tested on brain 
sections from Thy-1 A30P mice and could also detect positive signal, although with less abundance, 
showing existence ubiquitinated α-Synuclein structures in this line. Using the same approach, it was 
observed that there was homogenous, diffuse signal in cell bodies but no remarkable accumulation 
of ubiquitin signal was detected in our transgenic animals. In the same manner than in 
immunostaining of phosphorylated α-Synuclein, there was no observation of up-regulation of 
Figure 2.21: No clear evidence of increased phosphorylated α -Synuclein level at 23 months of age .
A: Immunofluorescent co-labelling phosphorylated α-Synuclein at Ser-129 and α-Synuclein in PC and molecular
layers from 7µm- thick sagittal cerebellar sections, scale bar 100µm. Antibody anti-phosphoSynuclein (Green) and
antibody anti-human α-Synuclein (15G7,Red)
B: High-magnification pictures comparing phosphorylated α-Synuclein staining in PCL between non-transgenic
mouse and transgenic mouse, scale bar 20µm. Antibody anti-phospho α-Synuclein (Green) and antibody anti-
human α-Synuclein (15G7,Red), Hoerscht (Blue).
Phospho.−α-Synuclein Mergeα-Synuclein (15G7)
A5
3T
-∆
CT
23
m
o
Pc
p2
-t
TA
23
m
o
B
20µm
79 
 
ubiquitin signal in transgenic animals compared to non-transgenic control animals neither in PCL nor 
in DCN where overexpressed α-Synuclein was abundantly found. Background signal caused by 
accumulation of autofluorescence from lipofuscin was also detectable (Figure 2.22). Overlapped 
image demonstrated that there was no significant co-localization between overexpressed α-
Synuclein and ubiquitin, yellow signals might come from overlapping of lipofuscin autofluorescence. 
Our result of western-blot validated this observation: using the same antibody anti-ubiquitin, there 
was not dectection of obvious change of ubiquitin protein level in both brain homogenate fractions 
(triton soluble and non-soluble) comparing transgenic and non-transgenic mice (data not shown). 
 
 
Taken together, our results of immunohistochemistry and PK-PET blots indicate that overexpression 
of α- Synuclein in transgenic animal models did not lead to the buid-up of insoluble, oligomeric 
structures which could resist PK digestion. This result was also supported by absence of other 
pathological posttranslational modifications as described for α-Synuclein inclusions such as 
phosphorylation at Ser129 or ubiquitination.  
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Figure 2.22: No clear up-regulation of ubiquitination in transgenic animals at 23 months of age .
Immunofluorescent co-labelling ubiquitin and α-Synuclein in PC and molecular layers from 7µm- thick sagittal
cerebellar sections.Antibody anti-Ubiquitin (Green) and antibody anti-human α-Synuclein (15G7,Red).
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3 Discussion 
3.1 In vitro studies: Establishing cellular paradigms to study protein 
degradation  
α-Synuclein is central in PD since it is accumulated in LBs which constitute the main histopathological 
feature of the disease. Enhanced clearance of α-Synuclein is a potential therapeutic strategy 
(reviewed in Verkrellis and Stefanis, 2012). Although efforts have been made to determine the main 
degradation pathways of α-Synuclein a consensus on how α-Synuclein is degraded has not yet been 
achieved (Bennett et al., 1999; Ancolico et al., 2000; Rideout et al., 2002). The lack of consistency 
from previous studies including our own is due to various factors including the choice of cell type 
used for the studies (neuronal vs non neuronal cells) or culture conditions (proliferation vs. 
differentiation, starvation vs. non-starvation, duration of treatment with inhibitors…) (Figure 2.3). 
Discovery of CMA degradation of α-Synuclein has opened new interesting perspectives, since 
enhancing CMA activity rescued toxicity induced by α-Synuclein in animal model a recent study 
(Xilouri et al., 2013).  
The main foundation of our study is based on previous findings showing that CMA is one major route 
of degradation for numerous intracellular proteins including α-Synuclein. Indeed, this protein is also 
described as a substrate of this process since it contains the consensus KFERQ motif in its sequence 
(Cuervo, 2004). This conserved motif is recognized by chaperones Hsp70 and protein substrates are 
delivered directly to lysosomal vacuole. Inducible cell culture models examining the impact of CMA 
motif mutation on kinetics of α-Synuclein turnover have been previously established and analyzed 
(Vogiatzi et al., 2008; Xilouri M, 2009). Modifying the composition of CMA motif such as substitution 
of 98DQ99 by AA (∆DQ) in α-Synuclein sequence was sufficient to slow the turn-over of this protein in 
different cell culture models (Vogiatzi et al., 2008). However, in these studies α-Synuclein full-length 
constructs were expressed, in contrast to our animal models which overexpress C-terminal truncated 
α-Synuclein (1-130). Recent report has suggested that post-translational modifications in α-Synuclein 
C-terminus might influence its own degradation pathways (Choi et al., 2012).  
In this in vitro study, we have generated cell lines using Tet-inducible system as in our animal models 
and previous cell culture models (Vogiatzi et al., 2008; Xilouri M, 2009). We have compared the 
kinetics of α-Synuclein degradation in cell lines expressing WT and A53T (full-length and C-terminal 
truncation).To study the impact of CMA on α-Synuclein degradation in our cell lines, we mutated 
CMA motif in ∆CT α-Synuclein constructs by replacing 98DQ99 by AA. These data from cell culture gave 
us a side-by-side control for our animal models to determine whether mutation of CMA motif really 
affects the kinetics of degradation of α-Synuclein. 
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3.1.1 Mutation of CMA motif doesn't slow down α-Synuclein degradation  
Surprisingly, we found that the absence of the CMA recognition motif did not result in significant 
difference in degradation rate of α-Synuclein for both WT and A53T constructs compared to 
expression of α-Synuclein with normal CMA motif. These observations were consistent in two 
different culture conditions in enriched (Figure 2.3A,B) or serum-reduced medium (Figure 2.4B,C). 
We also confirmed that there was no significant difference in α-Synuclein protein steady state levels 
in independent experiments (Figure 2.2A) between these cell lines. Similar to HEK293 cells, we could 
also not detect a significant difference in the degree of non-degraded α-Synuclein in Tet-off BE(2)-
M17 cell lines at various time points even though steady-state level of α-Synuclein in these cells 
differed significantly. Together, our data of HEK293 and BE(2)-M17 cells for kinetics of α-Synuclein 
degradation suggest that in our cellular models, CMA might not play a determining role in regulation 
of intracellular α-Synuclein protein level. 
Difficulties one could meet when studying the kinetics of protein degradation in tissue culture is how 
to maintain comparable culture conditions between experiments. Variation or lack of consistency in 
determination of protein half-life in former studies might be due to degree of transgene 
overexpression, frequency of media change, exposure time to pharmacological treatment, method of 
revelation or quantification. A key difference between our studies and the work by Vogiatzi et al. 
(2008) is that we chose to overexpress α-Synuclein transgene in HEK293 Flip-In system allowing a 
unique, isogenic insertion of transgene promoted by Flp recombinase. Vogiatzi et al. chose to 
overexpress α-Synuclein in PC12 and SHSY-5Y cells using random integration method. Using isogenic 
insertion method, we could generate stable Tet-on cell lines with comparable levels of transcription 
and protein translation (Figure 2.1A,C). Moreover, these cell lines have indentical genetic 
background. Nevertheless, as HEK293 cells might not exhibit all properties of neuronal cells, we 
generated additionally neuroblastome-derived Tet-off cells, BE(2)-M17, overexpressing the same ∆CT 
α-Synuclein constructs. In contrast to HEK293 cells, these cell lines have disadvantage that they were 
generated by random transgene insertion (similar to Vogiatzi et al.) which could not guaranteeing 
comparable genetic background and expression levels between the lines (Figure 2.5A,B). 
The fate of α-Synuclein seems to depend on different degradation pathways (Rott et al.,2011; 
Vogiatzi et al.,2008; Webb et al., 2003). Although substantial evidence has shown that CMA 
participate in α-Synuclein degradation process (Cuervo et al., 2004; Vogiatzi et al.,2008), the degree 
of CMA in this process in physiological conditions might have been overestimated in prior studies. 
Our observations suggest that α-Synuclein could be regularly degraded by other proteolytic 
pathways different than CMA. Blocking degradation by CMA due to mutation of CMA therefore did 
not seem to dramatically affect the efficiency of α-Synuclein clearance in our experiments. 
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"Traditionally", two main proteolytic systems contribute to regulate expression of cytosolic proteins: 
ubiquitin-proteasome system (UPS) and autophagy- lysosomal pathways (ALP). The evidence for 
degradation of α-Synuclein by UPS remains conflicting since its inhibition failed to show the expected 
increase in cytosolic α-Synuclein levels in certain studies (Ancolico et al., 2000; Rideout et al., 2001). 
Another argument is that accumulated α-Synuclein found in LBs is mostly mono-ubiquitinated while 
proteasome preferentially degrades poly-ubiquitinated proteins. Recent findings have shown that 
mono-ubiquitinated α-Synuclein could also "exceptionnally" be targeted to proteasome (Rott et al., 
2011) but as long-lived protein, α-Synuclein is thought to be rather degraded by ALP than UPS 
(Cuervo, 2004). Among ALP, macroautophagy is known to be play a major role in removal of cytosolic 
proteins. Inhibition of macroautophagy by 3-MA led to accumulation of α-Synuclein in primary 
neurons as well as in cells overexpressing α-Synuclein (Vogiatzi et al.,2008). The role of another 
autophagic pathway, microautopahgy, in transporting α-Synuclein to lysosome is still poorly 
understood. Further studies using pharmacological inhibitors would be interesting to determine 
which pathway is dominant in regulation of α-Synuclein burden in our models. Recently, an elegant 
study using live imaging on cranial window proposed a distinct regulation: UPS might degrade α-
Synuclein under normal conditions whereas ALP is implicated to α-Synuclein degradation when 
protein burden is increased ("pathological" conditions) (Ebrahimi-Fakhari et al., 2011). 
The constructs of α-Synuclein chosen for this study might not be the appropriate structures for 
studying degradation by CMA in living systems. Mutation by substitution of 98DQ99 by AA might not 
be enough pertinent to affect the normal binding of Hsp70 chaperones in cellular systems although it 
was shown to reduce affinity of α-Synuclein to LAMP2-A in purified lysosomes (Cuervo, 2004). 
Additional PTMs might modulate the affinity of binding to Hsp70. Interestingly, in their recent 
findings, Choi et al. (2012) have identified that phosphorylation at different tyrosine residues in the 
region of C-terminus, especially Y136, was important to ensure the correct binding to Hsp70. 
Mutation of Y136A significantly reduced Hsp70 binding detected by immunoprecipitation. This Y136 
residue was absent in our constructs since we overexpressing C-terminal truncated α-Synuclein (1-
130). A53T-FL α-Synuclein in HEK-293 cell lines has shown a delay of ~10h compared to ∆CTα-
Synuclein and ~16h compared to WT-FL α-Synuclein (Figure 2.4 and Table 2.1). These data support 
the hypothesis that α-Synuclein might require the complete C-terminus to be properly translocated 
into the lysosome via CMA pathway.  
3.1.2 Absence of cellular toxicity mediated by overexpressing A53T mutant α-Synuclein 
Mutant α-Synuclein, especially A53T, exhibited a stronger affinity to LAMP2-A at membrane of 
purified lysosomes compared to WT α-Synuclein. A53T mutant was also found to be poorly 
internalized in lysosomal lumen as it might act as uptake blocker compromising the internalization of 
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other CMA substrates (Cuervo, 2004). Overexpression of A53T α-Synuclein was also reported to 
disrupt the normal functioning of CMA pathways and to induce cellular toxicity (Xilouri et al., 2009). 
Toxicity effects were variable as a function of culture conditions (A53T-∆CMA mutant rescued the 
toxicity effect in propagating culture but not in differentiation conditions in SHSY-5Y cells). In our 
cellular models, we found that A53T full-length but not A53T C-terminal truncated mutants showed a 
delay in degradation compared to WT full-length (Figures 2.3 and 2.4). This observation confirmed 
the earlier finding that A53T mutant half-life was longer than WT (Cuervo, 2004). No obvious change 
in degradation rate was observed between WT and A53T C-terminal truncated constructs in both 
HEK293 and BE(2)-M17 cells. In this regard, we also have not seen any toxic effect due to 
overexpression of α-Synuclein in proliferating (HEK293 and BE(2)-M17) as well as in differentiating 
conditions (BE(2)-M17, data not shown). Together, our results contradict previous findings that 
overexpression of A53T mutant could induce cellular toxicity. A part of explanation might come from 
different genetic background between our cell lines. Furthermore, we have detected the presence of 
mycoplasm in the SHSY-5Y lines used in the studies by Xilouri et al. (2009). We are not certain that 
contamination by mycoplasm is the origin of our different observation but it might also be 
considered as an element of interpretation. Indeed, microarray analysis on contaminated cultured 
human cells revealed that mycoplasma may alter the expression profile of hundreds of genes 
including genes encoding for transcription regulators, transporters or signal transducers (Miller et al., 
2003). We speculate that these alterations might interfere with protein degradation pahtways. A 
deeper investigation would be helpful to clarify the reasons of variability between these different cell 
models. 
3.2 In vivo studies: Generating and analyzing conditional mouse model 
expressing human pathogenic  α-Synuclein 3.2.1 Generation of animal models overexpressing α-Synuclein mutants in Purkinje cells  
In this part of the study we generated a novel conditional model specifically expressing human 
pathogenic mutant α-Synuclein in cerebellar PCs driven by the Pcp2 promoter. This model was 
expected to have several advantages compared to previous α-Synuclein transgenic models: (1) α-
Synuclein overexpression is cell-type specific; (2) it is a model to study the relationship between α-
Synuclein and neuropathology in cerebellum; (3) the expression of α-Synuclein is tightly controlled 
by Doxicycline; (4) it is the first in vivo model expressing α-Synuclein with CMA motif mutation 
(mutation by substitution of 98DQ99 by AA) providing a new tool to study the role of CMA in α-
Synuclein degradation. 
Most of α-Synuclein transgenic mouse models express α-Synuclein in more than one brain region. 
Expression of α-Synuclein driven by Thy-1 promoter is found throughout telencephalon, brain stem 
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and spinal cord (van der Putten et al., 2000). Inclusions of α-Synuclein have been found in deep 
neocortex layers, hippocampal CA3, olfactory bulb and occasionally in SN (PDGF mice, (Masliah et al., 
2000)) and in brain stem, spinal cord and deep cerebellar nuclei (Prion mice, Giasson et al., 2002). So 
far, generated animal models have not fully reproduced all PD features but just mimicked certain 
aspects of the diseases: they have not show the expected high expression in SN cells or PD-related 
phenotypes (reviewed in Chesselet et al., 2012). On the other hand, using TH promoter (Wakamatsu 
et al., 2008), the authors could drive α-Synuclein expression selectively in SN cells but expression of 
α-Synuclein was also seen in OB in another study using this promoter (Tofaris et al., 2006).  
Although cerebellum is not typically affected in PD, some studies revealed the existence of LBs in DLB 
patient cerebella (Mori et al., 2003). In this context, specifically targeting PCs using Pcp2 promoter in 
our model was hoped to give clear transgene expression in a specific neuron-type that would make 
the quantification of the overexpression and its related effects easier. Moreover, Pcp2-tTA mice are 
available for for-profit research structures like Boehringer Ingelheim Pharma GmbH &Co KG.  
Several models have been reported with expression of α-Synuclein in cerebellum and PCs (Giasson et 
al., 2002;Kahle et al., 2001;Lin et al., 2012) but no effect of α-Synuclein overexpression was 
specifically documented. α-Synuclein is endogenously expressed in PCs, its physiological role is 
however poorly understood although a role in interfering the DA transport and release have been 
suggested (Al-Wandi et al., 2010; Anwar et al., 2011). PCs are not DAergic neurons but GABAergic 
neurons. However, similar roles could also be expected in PCs. Having a clear transgene expression in 
PCs, we furnish an interesting model to further study the role of α-Synuclein in PCs. Our model 
abundantly express α-Synuclein in DCN, which is the main projection area of PC axons, and therefore 
is interesting for assessing α-Synuclein presynaptic functions. 3.2.2 Overexpression of α-Synuclein in PCs causes mild motor behavioral changes  
Our transgenic animals did not develop profound motor disabilities up to 23 months of age: no signs 
of paralysis, no obvious change in hind-limb clasping frequency or clear disproportional gait width 
(data not shown). However, they exhibited lower locomotion activities compared to non-transgenic 
animals in open-field and in pole test (Figures 2.12 and 2.13). Indeed, in open-field recordings, we 
observed lower locomotor activities, in particular rearing activities, in A53T-∆CMA line than non-
transgenic line Pcp2-tTA. This difference is less pronounced in A53T-∆CT line compared to non-
transgenic line (Figure 2.12). Interestingly, transgenic animals also showed lower motor coordination 
starting from 14 months of age in pole test reflected by increase of total time to descend the pole 
compared to the non-transgenic group Pcp2-tTA (Figure 2.13B). This result supports the impairment 
of vertical movement observed in open-field. A reserve one could make is that this impairment did 
not affect all animals in transgenic groups. Total locomotor activities (ambulatory and rearing) were 
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also stable over time indicating that there was no age-dependent decline (Figure 2.12). This feature 
does not mimic the progressive motor disabilities in PD patients. In pole test, the affected animals 
("symptomatic" group) did not show clear worsening between 14 and 23 months even though they 
exhibited a clear trend for decreased locomotor activity (rearing) (Figure 2.13B). Another reserve 
could be that motor coordination impairments of transgenic animals were not clearly reproduced in 
other tests (rotarod and beam-walk) (Figure 2.14). 
Our behavioral observations suggest that overexpression of α-Synuclein might lead to functional 
deficits of PCs due to increased intracellular levels of this protein (reviewed in (Eisbach and Outeiro, 
2013)) rather than being due to massive neurodegeneration. Due to specific location of transgene 
expression and the role of PCs as principal inhibitory neurons in cerebellum, we suppose that PC 
dysfunction might in consequence affect the integrity of cerebellar circuitries. Pathologies linked to 
PC dysfunction might differently affect the two transgenic lines as A53T-∆CMA showed constantly 
lower scores than A53T-∆CT line in open-field. Mutation of CMA motif reduces affinity of α-Synuclein 
to LAMP-2A and reduce the capacity of the cells to degrade α-Synuclein by this pathway (Cuervo, 
2004). Overexpression of A53T-∆CMA mutant might preserve the lysosomal system (since it does not 
block uptaking by LAMP-2A). However, extensive accumulation of non-degraded α-Synuclein by CMA 
in cytosol might interfere with other biological pathways resulting in lower locomotor activities of 
A53T-∆CMA line in open-fied recordings. 
We also emphasize that locomotor performance of Pcp2-tTA line was seen constantly lower than 
performance of other non-transgenic line (WT) (Annex 6) suggesting that genetic background might 
be involved in causing difference of locomotor behavior. It has been shown that overexpression of 
tTA might induce non desired toxicity effect as reported in previous studies (Gallia and Khalili, 
1998;Kuhnel et al., 2004).  3.2.3 CMA motif mutation does not lead to differential α-Synuclein steady state levels in 
vivo 
We wanted to examine the part of autophagy-lysosomal pathways (ALP), especially the implication of 
the emerging concept that CMA might be the major route for intracellular α-Synuclein degradation 
and that failure of this pathway might cause potential deleterious consequences on living organisms 
(Cuervo, 2004; Xilouri et al, 2009). From our general observations, we have not found a determinant 
role of CMA pathway in regulation of excess α-Synuclein protein burden in both cellular and animal 
models as the presence of CMA motif mutation of α-Synuclein sequence did not lead to increased 
steady state levels or changes in the clearance dynamics in cell culture (Figures 2.3, 2.4 and 2.7). Our 
transgenic animals also did not show a clear difference in disease-onset up to 23 months of age 
although significant differences in locomotor activities and motor coordination were observed 
(Figures 2.12 and 2.13).  
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One possible molecular explanation for that is the choice of the primary constructs of α-Synuclein. C-
terminal truncated α-Synuclein are known to promote aggregation in animal models leading (Tofaris 
et al., 2006; Wakamatsu et al., 2008). However, lacking residue components of C-terminus might lead 
to modify primary structure of α-Synuclein leading to missing PTMs required for degradation 
pathways (Choi et al., 2012).Our results on state protein level in vivo do not allow us, unfortunately, 
to explain the difference of behavioral scores. We agree that this statement is certainly limited by the 
absence of obvious pathologies. The different reasons of absence of toxicity will be discussed in more 
details in 3.2.6. 3.2.4 Overexpression of α-Synuclein in PCs did not lead to obvious neurohistopathology  
Despite interesting behavioral changes, we have not detected evident pathological changes in our 
transgenic animals up to the age of 23 months by immunohistochemichal or biochemical approaches. 
PC staining using Calbindin-D28K marker showed no significant difference of PC number between 
transgenic and non-transgenic (Pcp2-tTA) lines indicating that overexpression did not lead to 
significant PC loss. This result of PC counting was further confirmed by western-blot showing 
comparable expression levels of Calbindin between lines (Figure 2.15). Comparing cell numbers and 
expression of specific markers are not the sole criteria to analyze neurodegeneration. Multiple 
reports showed that beside diminution of cell numbers, PC degeneration might be manifested by a 
change of morphological characters including disorganization of dendritic trees in molecular layer 
(Donald et al., 2008;Unno et al., 2012), diminished synaptic density at dendritic spines (Giza et al., 
2010;Zu et al., 2004) or axon terminal atrophy (Komatsu et al., 2007). Interestingly, counting of 
visible main trunks of dendrites showed greater homogeneity in non-transgenic WT compared to 
non-transgenic Pcp2-tTA line and α-Synuclein transgenic lines (Figure 2.15B). Examination of DCN 
staining showed homogenous axonal density and no particular morphological change (Figure 2.17A). 
These observations suggest that the difference in genetic background between the animal lines, for 
example overexpression of tTA (Gallia et al, 1998; Kuhnel et al, 2004), might cause unexpected 
changes in mouse cerebellum architecture independent of the overexpression of α-Synuclein. These 
results of immunohistochemistry and western-blot support our observation in behavioral studies 
showing that WT line exhibited highest locomotor performance compared to the three other lines 
(Annex 6). 
Parallel to morphological aspects, PC physiological function seemed to be well preserved until the 
oldest age analyzed in these studies (23 months). Indeed, we did not observe clear-cut reductions of 
synaptic marker expression or change in distribution patterns (Figure 2.16). Synaptic marker staining 
was unchanged in regions of PCL, ML and DCN where the main communication activities between 
PCs and other cells in cerebellum are concentrated. According to these observations, the role of PC in 
regulation of cerebellar circuitries is not compromised even in case of overexpression of α-Synuclein. 
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However, we are aware that such interpretation should be made with care due to limits of 
methodological approaches used in these studies. Immunohistochemistry is not quantitative 
therefore observation on immunostained brain tissues might not reflect well the real activities of 
PCs. Synaptic markers are present at high density in communicating areas such as ML or DCN and 
therefore it might be difficult to detect minor changes of their density based on intensity of staining, 
although efforts have been made to analyze a large set of brain samples. 
We reported the absence of glial cell activation which was usually shown to be a feature of brain 
regions affected by neurodegeneration. The relationship between glial cell activation and 
neurodegeneration is not fully understood but both processes may act reciprocally in a vicious circle 
fashion (reviewed by Halliday and Stevens, 2011). Microglia typically exist in a resting state 
characterized by a ramified morphology. They are activated in response to pro-inflammatory stimuli 
such as neuronal damage signals of degenerating cells (Block and Hong, 2007;Marin-Teva et al., 
2004). Activation of microglia provides beneficial effects to eliminate pathogens and cells dying by 
apoptosis (Marin-Teva et al., 2004). However, microglia might be overactivated and activates in turn 
astrocytes under certain circumstances by producing excess of TNF-α and IL-β which initiates a 
perpetual cycle of neuron death (Zhang et al., 2010). Both immunostaining of astrocytes (GFAP 
marker) and microglia (Iba-1) in our animal models revealed similar density of these cells in 
cerebellum indicating that they were not recruited to this brain area to a significant degree. 
Examination of their morphology also did not show increases in activation state in transgenic animals 
compared to non-transgenic lines (WT and Pcp2-tTA) (Figure 2.19). 3.2.5 No obvious LB-like pathology in transgenic mice up to 23 months 
Our transgenic animals did not show accumulation of LB-like α-Synuclein aggregates as commonly 
characterized by resistance to PK digestion (Neumann et al., 2002) or phosphorylation at Ser129 
(Emmer et al., 2011;Neumann et al., 2002) or conjugation to ubiquitin (Masliah et al., 2000; Lim et 
al., 2011) (Figures 2.21 and 2.22). The choice of labeling phosphorylated α-Synuclein at Ser129 might 
be compromised by the truncation of α-Synuclein at 130 amino acids while the antibody recognizes 
specifically phospho-Ser129 epitope which is located close to our truncation site. Western-blotting 
confirmed absence of high-molecular-weight or ubiquitinated-α-Synuclein or both in triton soluble 
and insoluble fractions (data not shown). These observations indicate that overexpression of these 
two mutants in PCs did not result in α-Synuclein oligomerization. The absence of aggregation is 
concomitant with the absence of cellular toxicity induced by overexpression as observed in 
immunohistochemistry analysis.  
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3.2.6 Absence of toxicity caused by overexpression of α-Synuclein  
Several factors might explain the absence of toxicity in our models compared to previous 
observations in other studies, the most important of them would be the method used for the 
generation of our models. We would like to emphasize here that in order to minimize as much as 
possible differences in transgene transcription, we have chosen a specific, well-defined locus (FlipIn 
HEK293 cells and ROSA26 locus in animal models). Of course, consequences of suppression of these 
loci should not be neglected as their contribution to physiological functioning is poorly elucidated. 
However, by using this approach, we assure that our models are generated by isogenic insertion 
resulting in highly comparable expression (Figure 2.1). This condition is crucial, from our 
expectations, in order to compare protein steady-state levels for studies on the dynamics of protein 
degradation. Since any change of behavior or pathology cannot be due to deviation in mRNA 
transcription or translation, we also expect comparable physiological functioning in our systems as 
they should have homogenous genetic background.  
The level of protein overexpression compared to endogenous mouse α-Synuclein in our transgenic 
lines is the next critical point to explain absence of neurotoxicity. Indeed, using isogenic insertion 
method into ROSA26, we obtained a single integration of our  SNCA transgene. We could state from 
our experience in immunohistochemistry and western-blot using 157G antibody specific for human 
that our overexpression level is rather weak (Figures 2.10 and 2.11). Western-blotting using Syn-1 
specific for mouse and human α-Synuclein revealed very a low level of human α-Synuclein compared 
to endogenous mouse α-Synuclein (Annex 4). Furthermore, as the protein overexpression is variable 
between PCs (mosaic-like) the effects of overexpression might not be comparable between cells 
(Figure 2.9). Protein overexpression burden is a crucial condition in transgenic models of 
synucleopathies. Level of protein expression is determined by the combinaison of vector design, copy 
numbers of transgene integration or targeted cell areas (reviewed in Chesselet et al., 2010). So far, 
relevant transgenic models overexpressing α-Synuclein showing pathologies or strong phenotype 
have been found correlated with high expression level: two-fold higher than endogenous α-Synuclein 
in Thy-1 A30P mice (Kahle et al., 2000), 2.5-30 fold higher than endogenous α-Synuclein in mPrion 
(WT or A53T) mice (Giasson et al., 2002). However, too strong protein overexpression inducing 
robust and rapid phenotype (Giasson et al., 2002) might still not mimic the progressive development 
of PD symptoms. Recent animals models using CaM-tTA promoter have shown mild expression levels 
linking to interesting progressive phenotypes (Marxreiter et al., 2009;Nuber et al., 2008). 
Absence of α-Synuclein aggregation as discussed in 3.2.5 might also explain, in part, the lack of 
neurotoxicity in our models. Although the principal toxic species of α-Synuclein are still need to be 
identified, the presence of α-Synuclein is largely assumed to be linked to neurodegeneration 
(reviewed in (Oueslati et al., 2010)). Animals models exhibiting clear-cut phenotype also show 
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appreciable abundance of α-Synuclein oligomeric species (reviewed in Chesslet et al., 2010). Absence 
of aggregate formation in our transgenic animals might depend on our mode of generation of these 
models. Isogenic insertion allows comparable mRNA transcription but results in low expression level 
as only one copy of transgene is expressed compared to traditional transgenic with multiple insertion 
sites as discussed previously. 
A different argument for the absence of neurotoxicity effect in our transgenic animal models would 
be the choice of promoter to drive transgene expression. Indeed, we voluntary decided to drive 
expression of α-Synuclein in PCs instead of in the nigro-striatal system which is the main and 
"classical" target in generation of PD models. Even though PCs are not strongly affected in PD and 
other synucleopathies, several reasons argue in favor of our choice: (1) α-Synuclein inclusions have 
been observed in PC of DLB patients (Mori et al., 2003) and expression of α-Synuclein is seen in 
cerebellum and spinal cord e.g. in Thy-1 A30P mice (Kahle et al., 2001), which display a deleterious 
motor phenotype, (2) neurodegeneration of PCs are supposed to be more facile to be characterized 
by immunohistochemistry and has been chosen as reference of multiples neurodegeneration models 
(Reith et al., 2011; Unno et al., 2012; Zu et al., 2004), (3) the driver mouse line Pcp2-tTA is already 
available for for-profit research structures like Boehringer Ingelheim company. We speculate that the 
absence of neurotoxicity in PCs might be due to certain "properties" of these cells that help to resist 
better to toxicity mediated by α-Synuclein overexpression than other neuronal cell populations such 
as dopaminergic neurons. It has been actually shown that dopaminergic neurons are particularly 
vulnerable by dopamine-modified α-Synuclein. This PTM is able to block lysosomal degradation and 
causes cellular toxicity (Martinez-Vicente et al., 2008).  
3.3 Outlook 3.3.1 In vitro studies 
α-Synuclein remains central in PD research and reduction of α-Synuclein protein levels appears to be 
a viable therapeutic strategy, although results of our studies cannot confirm a large contribution of 
the CMA pathway in regulation of α-Synuclein protein burden under physiological condition since we 
failed to find a significant difference in half-lives of C-terminal truncated α-Synuclein in vitro. 
However, we are aware that α-Synuclein half-lives found in these studies were estimated based on 
normalization of kinetic curves that might not reflect the effective α-Synuclein half-life. Alternative 
methods such as "pulse-chase" with radioactive protein labeling might reveal different values of α-
Synuclein half-life (Vogiatzi et al., 2008). Nevertheless, α-Synuclein half-lives found in our studies for 
WT-FL and A53T-FL constructs are close to values found in some other studies using different 
approaches (Li et al., 2004). The way how α-Synuclein is degraded in our cellular models remains 
unexplored since we did not perform pharmacological studies. Inhibition of protein degradation 
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pathways such as macroautophagy (blocked by 3-MA) or lysosome (blocked by NH4Cl) could be 
interesting to determine the major pathway by which α-Synuclein is degraded. The role of 
proteasome (blocked by epoxomicin) could also be interesting to be re-explored since recent data 
have proposed an explanation for the role proteasome in degradation of mono-ubiquitinated α-
Synuclein (Rott et al.,2012, Abeywarnada et al., 2013). CMA remains an interesting route for 
reduction of α-Synuclein protein level. Indeed, several data including our own indicate that 
overexpression of A53T α-Synuclein mutant results in increased half-life of α-Synuclein (Figure 2.4). 
This result suggests that α-Synuclein could be targeted to lysosome membrane by the mean of CMA 
pathway and A53T mutant might act as a blocker at LAMP-2A receptor (Cuervo, 2004). In our studies, 
we have not however explored the consequence of overexpression of A53T-FL construct in 
degradation kinetics of other CMA substrates such as GAPDH that could provide substantial proofs 
for CMA implication in α-Synuclein pathogenesis. Furthermore, in these studies we have not 
generated cell lines overexpressing WT- ∆CMA-FL or A53T- ∆CMA- FL to reproduce experiments of 
determining kinetics of α-Synuclein turnover. This experiment would clarify whether α-Synuclein C-
terminus is really involved in CMA targeting mechanisms. 3.3.2  In vivo studies 
Lacks of clear phenotype and neuropathology in our animal models reflect the difficulties in 
generation of genetic PD models. Indeed, our transgenic animals show lower locomotor activities and 
motor coordination but with high variation of phenotype between animals. Moreover, we could not 
identify the link between neuropathology and behavioral changes supporting a link between α-
Synuclein overexpression and behavioral phenotype. The fact that we observed stable locomotor 
activities over time suggest that overexpressed α-Synuclein in cerebellum might induce rather 
functional impairment of PCs than massive neurodegeneration as discussed in 3.2.2. This hypothesis 
could be verified by a reverse experiment: as expression of α-Synuclein is induced by Tet-off system, 
this expression could be turned-off by addition of Dox. If overexpression of α-Synuclein induces 
behavioral changes, the locomotor activities of transgenic lines would be "rescued" when expression 
of α-Synuclein is suppressed.  
To further optimize our animal models using the same α-Synuclein constructs of this study, one could 
try to increase protein expression by increasing the copy number of the transgene or resort to other 
driver lines expressing at potentially higher levels of tTA such as CamKII-tTA (Nuber et al., 2008; Lim 
et al., 2007) or PITX3-tTA (Lin et al., 2012). The strategy of increasing the copy number by 
homozygozation is difficult as we did not observe appreciable increase of transgenic protein 
expression in homozygotics for tTA and/or TetO-SNCA (Annex 3). Moreover, the risk of higher 
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expression of tTA is not negligible due to its induction of unwanted effects shown in other studies 
(Morimoto and Kopan, 2009; Sanbe et al., 2003). 
Functional deficits in organization or physiology of PCs were not detected by immunohistostaining in 
our studies despite the large set of markers used. Pathological changes might be more subtle and 
require additional inestigations. Recent report showed that sub-cellular dysfunctions affecting cell 
compartments such as Golgi apparatus, endoplasmic reticulum, lysosomes or synaptic vesicles would 
be interesting to be explored (Lin et al., 2012). The physiological change of PCs might not be 
manifested by only morphology observation but also modifications of electrical activities or dynamic 
of neurotransmitter release. Additional studies using different technical approaches such as 
quantification of GABA releasing using in vivo microdialysis (Cauli et al., 2011; Manto et al., 2005) or 
ex-vivo whole cell patch-clamp recordings (Unno et al., 2012; Giza et al., 2010) would be interesting 
to bring complementary information about physiological functions in PC overexpressing α-Synuclein. 
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4 Materials and Methods 
4.1 Animal models  4.1.1 Animals 4.1.1.1 TetO-SNCA animals 
TetO-SNCA animals have been produced by Taconic Artemis (Germany). Methods (according to 
Taconic Artemis): ES cell RMCE (derived from mouse strain C57BL/6NTac-Gt(ROSA)26Sor tm596Arte) is 
grown on a mitotically inactivated feeder layer comprised of mouse embryonic fibroblasts (MEF) in 
DMEM high glucose medium containing 20% (w/v) FBS and 1200 u/mL Leukemia Inhibitory Factor 
(Milipore ESG 1107). 2x105 cells were placed on 3.5 cm dishes in 2 mL medium. For transfection: 3µl 
of Fugene Regeant (Roche) were mixed with 10µl serum free medium (OptiMEM I with Glutamax I, 
Invitrogen) and incubated for 5min at room temperature. 100 µl of the Fugene/OptiMEM solution 
was added to the DNA mixture containing 2 µg of circular vector and 2 µg CAGGS-Flp plasmid. 
Transfection complex was incubated for 20 min at room temperature and added dropwise to the 
cells. From 2 days onwards, the medium was replaced daily with medium containing 200 µg/mL of 
G418 (Invitrogen). Single clones ware isolated seven days later, expanded and analyzed by Southern 
blot. For diploid injection: after administration of hormones, super-ovulated BALB/c females were 
mated with BALB/c males. Blastocysts were isolated from the uterus at 3.5 days post coitum (dpc). 
Blastocysts were placed in a drop of DMEM with 15% FCS under mineral oil. A flat tip, piezo actuated 
microinjection-pipette with an internal diameter of 12-15 µm was used to inject 10-15 targeted 
C57BL/6NTac ES cells into each blastocyst. After recovery, 8 injected blastocysts were transferred to 
each uterine horn of 2.5 dpc, pseudopregnant females. Chimerism was measured in chimeras (G0) by 
coat color contribution of ES cells to the BALB/c host (black/white). Highly chimeric mice were bred 
to strain C57BL/6 females.  4.1.1.2 Driver Pcp2-tTA animals 
“Pcp2-tTA” mice (FVB-Tg(Pcp2-tTA)3Horr/J, JR# 005625) were purchased from Jackson laboratories 
(Germany). The mice are backcrossed to wild-type C57BL/6 mice (Charles River) to obtain C57BL/6 
background. The 10th backcrossing was considered to be pure for C57BL/6 background. 4.1.1.3 Animal housing 
Animals were housed in the Green Line IVC Sealsafe PLUS Mouse cages (GM500, Techniplast). Each 
cage, measured 391 x 199 x 160 mm (wide x deep x height), is covered by a 0.2 µm pore size filter 
and ventilated individually by connection to a closed air flow controlled by an automatic 
microprocessor. This allows circulating the air inside of the cages constantly and therefore reduces 
the risk of contamination and possible stress to the animals. The mice were housed in a 12 hours 
light/dark cycle and with free access to food and water. Cages, food and drink are renewed weekly. 
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All efforts are made to minimize animal suffering and reduce the number of animals use following 
the general guidelines approved by the animal healthcare officer of Boehringer Ingelheim.  4.1.2 Genotyping 4.1.2.1 DNA preparation 
Genomic DNA was prepared from tail biopsy (approximately 25 mg of tissue per animal were used) 
using DNeasy Blood & Tissue kit (Qiagen). Tissues are placed in 1.5 ml Eppendorf cups and digested 
from 5 hours to overnight at 56°C with Proteinase K in a thermomixer block (Eppendorf), thoroughly 
vortexed at 1000 rpm, until the samples are completely lysed. All steps of the DNA purification 
procedure using spin-column are fully automated processed by Qiagen cube (protocol DNA Tissue 
mini). DNA is eluted in 200 µl of AE buffer and the concentration is measured by UV 
spectrophotometer (NanoDrop, Thermo Scientific). Genomic DNA is stored at -20°C for further use.  4.1.2.2 Tet-O-SNCA transgene PCR 4.1.2.2.1 Standard genotyping 
Amplification of Tet-O SNCA transgene by PCR is performed using specific primers (ASYN-F, 
CATGAAAGGACTGAGCAAGGCT; ASYN-R, AAGCCTCATTGTCAGGATCC). PCR reagents are from Qiagen. 
Each 20µl PCR reaction contains: 1x PCR Buffer (containing 1.5 mM Mg2+), 1 mM MgCl2, 0.2 mM 
dNTPs, 0.6 µM  ASYN-F, 0.6 µM   ASYN-R, 1U Taq Polymerase, 10-20 ng DNA and nuclease-free water. 
PCR is programmed as following: 95°C 5 min- 95°C 30s, 60°C 30 s, 72°C 1 min (repeating 35 cycles)- 
72°C 10 min. PCR products are loaded onto e-Gel (2% (w/v) Agarose, Ethidium Bromide, Invitrogen) 
and visualized under UV light (ChemiDoc MP, Imaging System, Bio-Rad). 4.1.2.2.2 qPCR 
Relative quantification is the chosen method: gene expression levels are calculated by the ratio 
between the target gene and an endogenous reference gene. Amplification of SNCA transgene 
(target gene) is performed using specific primers (aSyn-F, 5’GGACTGAGCAAGGCTAAGGA; aSyn -R, 5’ 
CTTCAGCCACTCCCTGTTTG) and the Taq Man probe from the Universal Probe Library (UPL#66, 
Roche). PCR mastermix are from QuantiFast (Qiagen). Amplification of RNAPol II internal control 
gene (reference gene) is performed using specific primers (RNAPol-F, 5’ CATCAACCAGGTGGTACAGC; 
RNAPol -R, 5’GATTCTGGAACTCAACACTCTCC) and the Taq Man probe from the Universal Probe 
Library (UPL#68, Roche). Triplicate of 12 µl reaction for each sample is done. PCR performed in 
7500HT Fast System Thermocycler (ABI Prism) is programmed as following: 95°C 2 min- 95°C 15 s, 
60°C 1 min (repeating 40 cycles). Relative quantification is calculated by using the delta delta Ct 
(∆∆Ct) method. 
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4.1.2.2.3 ROSA26 locus amplification method 
To distinguish between heterozygote and homozygote Tet-O ASYN animals, an alternative method 
consisting of ROSA26 locus amplification is used (Soriano, 1999). Expected fragment of WT ROSA 
locus amplicon is 600 pb and of ROSA targeted locus amplicon is 331 pb. Amplification of ROSA26 
transgene by PCR is performed using 3 specific primers (ROSA26-wt-F, AAAGTCGCTCTGAGTTGTTAT; 
ROSA26-wt-R, GGAGCGGGAGAAATGGATATG; SA-mut-R, GCGAAGAGTTTGTCCTCAACC). PCR reactions 
are performed with Accuprime Taq Polymerase (Invitrogen). Each 25 µl PCR reaction contains: 1x PCR 
Buffer II, 0.2 µM ROSA26-wt-F, 0.2 µM ROSA26-wt-R, 0.2 µM SA-mut-R, 1U Taq Polymerase, 10-20 ng 
DNA and nuclease-free water. PCR is programmed as following: 94°C 2 min- 94°C 30 s, 55°C 30 s, 
68°C 1 min (repeating 35 cycles)- 4°C. PCR products are loaded onto e-Gel (2% (w/v) Agarose, 
Ethidium Bromide, Invitrogen) and visualized under UV light (ChemiDoc MP, Imaging System, Bio-
Rad). 4.1.2.3 Pcp2-tTA transgene PCR 4.1.2.3.1 Standard genotyping 
Amplification of Pcp2-tTA transgene by PCR is performed using specific primers (PCP-F, 
CGCTGTGGGGCATTTTACTTTAG; PCP-R, CATGTCCAGATCGAAATCGTC). PCR reagents are from Qiagen. 
Each 20µl PCR reaction contains: 1x PCR Buffer (containing 1.5 mM Mg2+), 0.2 mM dNTPs, 0.6 µM 
PCP-F, 0.6 µM PCP-R, 1U Taq Polymerase, 10-20 ng DNA and nuclease-free water. PCR is 
programmed as following: 94°C 3 min- 94°C 30 s, 57°C 1 min, 72°C 1 min (repeating 35 cycles)- 72°C 3 
min. PCR products are loaded onto e-Gel (2% (w/v) Agarose, Ethidium Bromide, Invitrogen) and 
visualized under UV light (ChemiDoc MP, Imaging System, Bio-Rad). 4.1.2.3.2 Quantitative PCR 
Relative quantification is the chosen method: gene expression levels are calculated by the ratio 
between the target gene and an endogenous reference gene. Amplification of Pcp2-tTA transgene 
(target gene) is performed using specific primers (PCP-F, CGCCATTATTACGACAAGCTATC; PCP-R, 
CAATTCAAGGCCGAATAAGAA) and the Taq Man probe from the Universal Probe Library (UPL#55, 
Roche). PCR mastermix are from QuantiFast (Qiagen). Amplification of RNAPol II internal control 
gene (reference gene) is performed using specific primers (RNAPol-F, 5’ CATCAACCAGGTGGTACAGC; 
RNAPol -R, 5’GATTCTGGAACTCAACACTCTCC) and the Taq Man probe from the Universal Probe 
Library (UPL#68, Roche). Triplicate of 12 µl reaction for each sample is done. PCR performed in 
7500HT Fast System Thermocycler (ABI Prism) is programmed as following: 95°C 2 min- 95°C 15 s, 
60°C 1 min (repeating 40 cycles). Relative quantification is calculated by using the delta delta Ct 
(∆∆Ct) method. 
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4.1.3 Biochemical methods 4.1.3.1 Brain homogenazition and protein extraction 
Brain tissue are homogenized in 10 volumes of Triton lysis buffer (50 mM Hepes pH7.5, 150 mM 
NaCl, 1.5 mM MgCl, 1 mM EGTA, 1% (w/v) Triton X-100) supplemented with protease inhibitor 
cocktail, EDTA free (Roche). Homogeneization is performed in Dispomix system (version V1.5, Medic 
Tools) during 45 s with gradually increasing rotation up to 10000 rpm. The homogenates are 
incubated at 4°C during 30 min with gentle rocking then clarified by centrifugation at 15000 x g for 15 
min at 4°C. The supernatant are quantified for total protein content using BCA kit (Thermo Fisher 
Scientific). Protein samples are diluted in NuPAGE LDS Sample Buffer supplemented with Reducing 
agent (Invitrogen) and deionized water then heated up at 70°C for 10 min. Samples are stored at -
20°C for further use. 4.1.3.2 Western-blot 
Total proteins are separated by 4-12% NuPAGE Bis-Tris PAGE gel (Invitrogen) using MES running 
buffer (Invitrogen) at constant voltage of 200V for 35 min. Proteins are transferred to nitrocellulose 
membrane using Semi-dry Transblot (Biorad) at constant current of 65 mA per gel for 2 hours. 
Immediately after transfer, membrane is placed in boiled PBS for 10 min then blocked with Odyssey 
blocking buffer (Licor Biosciences) for 1 hour at room temperature. Signals are visualized by infrared 
light using Odyssey scanning system (Licor Biosciences) at 780nm (green color) and 680nm (red color) 
wavelengths.  4.1.4 Immunohistochemistry 4.1.4.1 Standard immunohistochemistry 4.1.4.1.1 Tissue preparation 
Mice are anesthetized and perfused via cardiac infusion with formalin solution (4% 
paraformaldehyde in PBS). Brain tissues are removed and post-fixed in formalin at 4°C. 24 hours after 
post-fixation, tissues are processed for paraffinization and embedded in paraffin blocks.  
Processing for paraffinization (temperature of alcohol solution: 35°C; temperature of paraffin 
solution: 65°C):  
Alcohol 70% (v/v) 1 h 
Alcohol 80% (v/v) 1 h 
Alcohol 96% (v/v) 1 h 
Alcohol 96% (v/v) 1 h 
Alcohol 100% (v/v) 1 h 
Alcohol 100% (v/v) 1 h 
Alcohol 100% (v/v) + Xylol 100% (v/v) 1:1 1 h 
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Xylol 100%   1 h 
Xylol 100%   1 h 
Xylol 100%   1 h 
Paraffin 1 h 
Paraffin 1 h 
Paraffin 1 h 
Paraffin 1 h 
 
For immunostaining, 5-10 µm thick microtom sections (Leica) are made, tissues sections are loaded 
onto glass slides (SuperFrost Ultra plus, Thermo Scientific), dried out at 40°C overnight and stored at 
room temperature for further use. 4.1.4.1.2 Deparaffinization and immunostaining 
Tissue sections are progressively deparaffinized in 100% (v/v) xylol – 95% (v/v) ethanol – 70% (v/v) 
ethanol and washed in Tris buffered saline (TBS, Sigma-Aldrich). Depending on antigen of interest, 
tissue samples could be subject to a step of pre-treatment. The goal of this pre-treatment is to 
unmask antigen epitope. For certain antigen categories, this step is essential to break molecular 
cross-links induced by formalin fixation to increase in efficiency of primary antibody binding and 
enhance staining intensity. Most common antigen unmasking is done by heating in appropriate 
buffer (heat induced epitope retrieval). In some circumstances, reduction of protein cross-links could 
be sufficiently effective by reducing agents such as formic acid. Details of pre-treatment conditions 
for each antigen are listed below in Table IV.1. Blocking of unspecific binding sites using block buffer 
(TBS supplemented with 10% (v/v) of goat serum and 0.3% (w/v) of Triton X-100) is performed at 
room temperature for 1 hour. Incubation with primary antibodies diluted in antibody diluent solution 
(TBS supplemented with 5% (v/v) of goat serum) is performed overnight at 4°C. Before applying 
secondary antibodies, sections are washed 3 times in wash buffer (TBS supplemented with 0.1% 
(w/v) Tween 20) to remove primary antibodies.  
Antigen Antigen retrieval method 
α-Synuclein  Citrate+ Formic acid 
Calbindin Citrate 
mGluR1 Citrate (short) or EDTA 
Syntaxin Citrate (short)or EDTA 
GFAP Citrate 
Iba-1 Citrate 
VGAT Citrate 
Ubiquitin Formic acid 
pS129 α-Synuclein Formic acid 
Table 4.1. Optimal pre-treatment conditions of antigen retrieval after deparaffinization. 
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Citrate= Tissues are heated in sub-boiling citrate buffer (10mM citric acid, pH 6.0) (pre-heated at 95-100°C) 
during 30 min then cooled down to room temperature during 30min 
Citrate (short)= Tissues are heated in sub-boiling citrate buffer (10mM citric acid, pH 6.0) (pre-heated at 95-
100°C) during 10 min then cooled down to room temperature. 
EDTA= Tissues are heated in sub-boiling EDTA buffer (1mM EDTA, 0.05% (w/v) Tween 20, pH 8.0) (pre-heated 
at 95-100°C) during 30 min then cooled down to room temperature during 30min. 
Formic acid= Tissues are submerged in formic acid solution (88% (w/v) formic acid, pH 2.0) during 5 min at 
room temperature. 4.1.4.1.3 Revelation methods 
4.1.4.1.3.1 Fluorescence staining 
Alexa Fluor conjugated secondary antibodies (Molecular Probes) (Table 4.4) are used to visualize the 
staining. Incubation with secondary antibodies diluted in wash buffer is also performed overnight at 
4°C. Tissues are washed 3 times 10 min in wash buffer and DNA are stained with Hoechst 2 µM 
(Invitrogen), diluted in ultrapure water. Tissue samples are protected from light to avoid eventual 
degradation of fluorescence signals. 
4.1.4.1.3.2 Chromogenic staining 
The principle of chromogenic revelation method is based on the use of Avidin-Biotin Complex (ABC) 
to amplify the signal intensity. Primary antibody is first recognized by a biotinylated secondary 
antibody. Biotin molecule from secondary antibody binds to avidin which is conjugated itself with 
biotinylated horseradish peroxidase (HRP). HRP catalyzes oxidization of chormogenic substrates 
resulting in apparition of colorful signal detectable under light microscopy. Since each avidin 
molecule contains 4 binding sites for biotin, each avidin molecule could bring up to 3 enzyme 
molecules and increase the signal 3 times. 
The use of chromogenic stain is an alternative to fluorescence stain method. This represents 
advantages to avoid the auto-fluorescent signals emitted by accumulation of lipofusicin in old animal 
brain tissues. When using this technique, tissue sections need to be quenched of endogenous 
peroxidase (sections are incubated in 3% (w/v) H2O2 (Sigma Aldrich) during 10 min right after antigen 
retrieval steps). After incubation with primary antibodies, tissues are treated with biotinylated 
secondary antibodies (Vector laboratories) (Table 4.4) diluted in wash buffer during 1h at room 
temperature. After this incubation, excess of secondary antibodies is removed by 3-4 washes in wash 
buffer. Parallel to washing steps, biotinylated enzyme (HRP) is pre-incubated with free avidin to form 
large avidin-biotin-enzyme complexes (ABC) during 30min at room temperature (2 drops of regeant A 
and two drops of regeant B (from Vectastain kit,Vector laboratories) are mixed in 5 mL of wash 
buffer). Excess of ABCs are removed from sections by 3 washes of 10 min each. Chromogenic 
substrate solutions  are prepared during the last step of washing according to provider indications 
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(DAB (Dako) or VIP (Vector laboratories)). Chromogenic substrate is applied to sections until signals 
are sufficiently developped (5 to 10 min). Stained sections are washed thouroughly in distilled water 
until they are cleared of excess of chromogenic substrate.  4.1.4.1.4 Dehydration and storage 
After revelation, sections are dehydrated by washing progressively in 60% (v/v) ethanol 70% (v/v) 
ethanol – 80% (v/v) isopropanol – 100% (v/v) xylol and mounted with Etellan mounting media 
(Merck). Stained tissues are stored at room temperature and fluorescent stained tissues need to be 
well protected from light.  4.1.4.2 Proteinase K (PK) digestion  4.1.4.2.1 PK digestion on PVDF membrane  
Pathological deposits of α-Synuclein could be detected by PK digestion followed by immunostaining 
(Neumann et al., 2002). PVDF membrane is cut in small pieces (3 cm x 2 cm), one piece of membrane 
will contain one brain slice. Membranes are activated by a short wash in methanol (Sigma Aldrich) 
during 30 s followed by two washes in distilled water. Activated membrane could be stored in 
distilled water during the time of tissue cutting. 5 µm-thick brain tissues are cut as described in 
4.1.4.1.1. then brain sections are transferred to pre-activated membranes. Tissue sections are dried 
overnight at 40°C. Deparaffinization is made as for standard immunostaining described in 4.1.4.1.2. 
However, care should be taken when moving sections in and out of baths since they might go-off 
from the membranes. After deparaffinization steps, sections are incubated in PK solution (50 µg/mL). 
Stock PK aliquots (20 mg/mL) (Roche) are diluted in PK dilution buffer (10 mM Tris HCl pH 7.8, 100 
mM NaCl, 0.1% (w/v) Brij). Beforehand, membranes should be tightly retained between filter papers 
(pre-equilibrated in PK dilution buffer for 10 min) to ensure homogenous digestion. Digestion is 
performed at 55°C overnight (14 hours). The next day, membranes are removed from PK solution 
and transferred into 6-well plate (one membrane per well) to avoid sticking between the membranes 
during washing and staining steps. PK is removed by 3 times 5 min washes in TBS then incubated in 
3% (w/v) H2O2 (Sigma Aldrich) during 10 min for peroxidase quenching. H2O2 is removed by again 3 
times 5 min washes in TBS. The proteins on the membranes are denaturated with 3 M Guanidine 
isothiocyanate (in 10 mM Tris-HCl, pH7.8) during 15 min. This step is followed by 3 times 5 min 
washes in TBS. Membranes are blocked in Casein I-Block solution (Applied Biosystems) during 1 h at 
room temperature and processed for standard immunostaining (15G7 antibody, chromogenic 
revelation method). After dehydration, membranes are dried and stored at room temperature.  4.1.4.2.2 PK digestion on glass slides 
Protocol is adapted from Wagner et al., 2013. Thin sections (3µm) are cut and processed as described 
in 4.1.4.1.1. for deparaffinization. Tissues are pre-treated with 0.2M boric acid, pH 9 at 63°C during 
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25 min and stored in the same buffer at room temperature during 30 min. PK digestion is performed 
in 50 µg/mL of PK (Roche) diluted in PK buffer during 10-15 min at 37°C. Tissues are stained using 
standard immunostaining procedure (15G7 antibody, chromogenic revelation method).  4.1.5 Behavior analysis 4.1.5.1 Animal cohorts 
Male and female animals are both used for behavior studies but are separately housed in two 
different locations. Pcp2-tTA (n=22) from the 8th backcrossing and wild-type C57Bl/6 (n=16) are used 
as control groups. α-Synuclein transgenic mice are generated by crossing Pcp2-tTA mice from the 7th 
backcrossing to TetO-SNCA (A53T-∆CT) mice (n=16) and TetO-SNCA (A53T- ∆CMA) mice (n=18). 4.1.5.2 Rotarod  
The mice are trained the day preceding the test. 3 training runs per animal are performed, in a two-
hour interval, on a rotaring rod (RotaRod, TSE Systems) at constant rolling speed of 4 rpm for at least 
1 min. On the day of test, mice are habituated in the test room during at least two hours. For the 
test, mice are placed onto auto-acceleration rod from 0 to 40 rpm. Each line is controlled 
independently by its own timer and animal falls are detected by light-beam sensors. The length of 
time the mouse stays on the rod and the speed of fall are recorded by the RotaRod software.  4.1.5.3 Open-field test 
Locomotion activity during active phase is measured by recording the running distance and the 
frequence of rearing using open-field test (ActiMot, TSE Systems). The ActiMot frame is a square-
shaped frame (480 mm x 480 mm) which features two pair of light-beam strips, each pair consisting 
of one transmitter strip and one receiver strip. These light barriers strips are arranged at right angles 
to each other in the same plane. Each strip is equipped with 32 infra-red sensors. They are used to 
determine the X and Y coordinates of the animal and thus its location by calculating the center of 
gravity of the animal. Rearing is detected by additional uni-dimensional barrier strips with adjustable 
height which are used to determine Z1 coordinates. Experiments are carried on overnight in the dark 
(active phase) and separately for males or females. Animals are placed in the experiment room at 
least two hours before the run. The total time of recording is 840min. The total run distance (in m) 
and number of rearing (n) are calculated by the ActiMot software.  4.1.5.4 Pole climbing test 
The mice are placed facing upwards at the top of a wooden pole (50 cm long and 1 cm in diameter) 
planted in the middle of a square cage box. The mice are trained, three times per day during two 
consecutive days, to turn to orient downward and traverse the pole onto the floor of the box. On the 
day of test, mice are habituated in the test room during at least two hours. The mice were tested for 
the time to turn to orient downward and the total time to descend the pole from the time that the 
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animal is placed on the pole until it reaches the base of the pole in the cage box. Three trials were 
performed with each mouse and median data were taken across the trials. 4.1.5.5  Beam-walk 
Protocol is adapted from (Luong et al., 2011). All experiments are handled in a dark room. The beam 
apparatus consists of 1 m beams with a flat surface of 3.5 cm width at the starting point and 
graduatelly narrowed to 1 cm width at the finish point. The beam is resting 50 cm above the floor. A 
black box is placed at the end of the beam as the finish point. Nesting material from home cages is 
placed in the black box to attract the mouse to the finish point. A lamp (with 60 watt light bulb) is 
used to shine light above the start point and serves as an aversive stimulus. Another lamp (red bulb) 
is placed on the top of the black box and used to attract the animals stimulated by aversive light. The 
mice are trained, during two sessions the day before the test, to cross the whole beam. Four trials 
per session are given to each animal. On the day of test, mice are habituated in the test room during 
at least two hours. The time required per animal to cross successfully to whole beam is recorded. 
Falling-out of the beam is not counted as a successful trial. Four trials were performed with each 
mouse and median data were taken across the trials. 
4.2 Cell models 4.2.1 Generation of stable Tet inducible cell lines 4.2.1.1 Plasmid preparation  4.2.1.1.1 pTRE-Tight vectors 
α-Synuclein mutant constructs (C-terminus truncated, ∆CT 1-130) are generated by directed 
mutagenesis and subcloned into pTRE-Tight vector by Sloning BioTechnology GmbH (Germany). The 
subsequent vector is named “pTRE-Tight-ASYN vector”. Plamids are amplified in XL-1 Blue competent 
cells (Invitrogen) and purified using the NucleoBond Xtra Maxi (Macherey-Nagel). 1 ng of plasmid is 
used to transform 100 µl of bacterial cells. The mixture of vector and competent cells is incubated at 
42°C during 45 s, the heat-pulse is stopped by 2 min incubation on ice then the mixture is transferred 
into 0.9 mL of TB (“Terrific Broth”) medium pre-warmed at 42°C. Cells are allowed to grow during 1 h 
with constant shaking (250 rpm) at 37°C. Cells are spread on TB agar support containing 100 µg/mL 
of ampicillin in 10- cm Petri dish and incubated overnight at 37°C. Well transformed cells should give 
isolated, round and ampicllin-resistant colonies. Colonies will be picked the next day by a sterilized 
pipette tips and allowed again to grow in 300 mL of TB medium containing 200 µg/mL of ampicillin at 
37°C. Low-copy number plasmids (derived of pMB1/ColE1 such as pTRE-Tight, pBR322 etc.) might be 
difficult to amplified under normal antibiotic pressure since host chromosome continues to be 
replicated and chromosomal DNA can contaminate the plasmid preparation. Using an additional 
antibiotic, such as chloramphenicol, can inhibit host protein synthesis and prevents replication of the 
101 
 
host chromosome. Plasmid, however, continues to replicate and accumulates in the cell after several 
hours (Maniatis et al., 1982). According to this, 170 µg/mL of chloramphenicol is added to TB 
medium when the cell culture reaches the mid or late of log phase (OD600~ 0.7- 0.8) after around 8 h, 
then cells are allowed to further grow for 12 h. Cells are harvested and proceed to plasmid 
purification according to the protocol for low-copy plasmid (maxi-preparation) of NucleoBond kit. 
DNA is resuspended in steril water and stored at -20°C for further uses. 4.2.1.1.2 pcDNA/FRT/TO vectors 
All α-Synuclein mutant (C-terminus truncated, ∆CT 1-130) transgenes are subcloned from pTRE-
Tight-ASYN vectors (original vectors) to pcDNA/FRT/TO (host vectors, available in the lab). Original 
and host vectors are digested with AccGSI and EcoRV enzymes. Restricted host vectors are 
dephosphorylated by shrimp alkaline phosphatase. Insert and dephosphorylated host vectors are 
loaded on 2% (w/v) agarose gel and DNA is labeled with 0.001% (w/v) of blue methylen. DNA bands 
are extracted from the gel using Nucleo Spin Extract kit (Macherey-Nagel). The concentration of DNA 
is measured by Nanodrop. Inserts are ligated to 100 ng of host vectors at the molar ratio 1/1 
(amount of insert is calculated as following: Amount of Insert (ng) = [Amount of vector (ng) x Size of 
Insert (kB))/Size of vector (kB)) x molar ratio of (Insert/Vector)]. The ligation reaction is carried out at 
16°C overnight. Human wild-type and A53T α-Synuclein full-length are sub-cloned from pcDNA 3.1-
ASYN-Kozak vectors (available in the lab) to pcDNA/FRT/TO. Original and host vectors are digested 
with BamHI and ApaI enzymes and ligation is repeated as above. Ligation products are used to 
transform XL-1 Blue competent cells and proceed for plasmid preparation in the same manner as for 
pTRE-Tight vector using NucleoBond Xtra Maxi kit. However, since pcDNA/FRT/TO is high-copy 
plasmid, there is no need of adding chloramphenicol during the exponential phase in the growth 
medium. 4.2.1.2 Cell transfection and selection 4.2.1.2.1 Cell culture 
BE (2)-M17 cell clones stably expressing tTA (transfected with pUHD15.1neo, (Gossen and Bujard, 
1992)) were previously generated in the lab. HEK 293 Flp-In TRex TO cells were obtained from 
Invitrogen. The cells are cultured T75 flasks in presence of maintenance medium and incubated at 
37°C, 95% CO2 (Table 4.2). Passaging is repeated every 3-4 days when cells reach 80-90% of 
confluency, cells are washed twice with PBS then treated with EDTA solution (Sigma) to be detached 
from the bottom of the flask. A dilution 1/10 is routinely made for each passage. 4.2.1.2.2 Transfection and stable selection 
Prior generating stable lines, titration for optimal concentration of antibiotics was necessary. For 
that, 2x105 cells were plated in each well of a 6-well plate. Each well contains 2 mL of medium plus 
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varying amounts of antibiotic. Cells are incubated during 14-21 days depending on the drug to be 
tested and medium is refreshed every 2-3 days. The lowest concentration where massive cell death 
begins is chosen as optimal concentration used for selection culture. For generating stable cell lines, 
host cells are allowed to grow up to 80-90% of confluency at the day of transfection. Cells are 
transfected by electroporation using Neon®Transfection System (Invitrogen): cells are split and 
washed two times in PBS. After the second wash, cell pellets are resuspended the buffer “R” (Neon 
Transfection System kit, Invitrogen) and mixed with the appropriate amount of plasmids. The cells 
are then released in 10 mL pre-warmed medium (RPMI supplemented with 10% FCS) without 
antibiotics (37°C) contained in 10- cm Petri dish. The medium will be changed the next day and the 
selection will start at 3 days post-transfection with selection medium. Replacing of fresh selection 
medium occurs every 2-3 days until resistant colonies distinctly appear after 2-4 weeks. Isolated, 
large, healthy colonies are picked then aspired in 200 µl of medium and transferred to a single well in 
a 96-well plate. The next day cells are split and resuspended in 200 µl of fresh medium. Growing 
clones are expanded and screened for transgene expression by immunocytochemistry or western- 
blotting. Clones with comparable mRNA levels of α-Synuclein transgene (measured by qRT-PCR, see 
below) are chosen for the studies of kinetic of α-Synuclein degradation.  4.2.1.2.3 Cell storage 
Stock clones then are freezed in FCS supplemented with 10% DMSO at -80°C during 2-3 days then 
transferred to -150°C for long-term storage.Early passage working clones (passage 1) are expanded 
from stock clones and cryo-stored at a number o 10 vials/ clone.  4.2.1.2.4 Cell thawing 
Early passage working clones are thawed in incubator at 37°C during 5 min. Cells are diluted in pre-
warmed medium and cell pellets are collected by centrifugation at 700 g during 5 min. Supernatant 
containing DMSO is removed in specific waste. Thawed cells are washed twice in PBS (repeating 
centrifugation at 700 g during 5 min). After the last wash, cells were separated and transferred to 
appropriate culture medium.  
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Table 4.2: Recapitulation of conditions for generation of stable cell lines. 
4.2.1.3  Comparison of α-Synuclein mRNA levels by qRT-PCR 4.2.1.3.1 Total RNA extraction 
Cells are allowed to fully express α-Synuclein (~7 days of induction). 2x 105 cells per cell clone are 
used for RNA extraction using RNeasy Mini kit (Qiagen). All of the steps of RNA purification are 
handled in RNase-free conditions. Cells are harvested by centrifugation at 700 g during 5 min and 
washed twice with PBS to completely remove culture medium. Cell pellets can be proceed directly to 
lysis or store at-70°C for later uses. Cell pellets are disrupted in 350 µl of RTL buffer by thoroughly 
flicking and pipetting. Cell homogenates are processed for RNA purification according to the protocol 
from RNeasy Mini kit for animal cells. RNA are eluted in 30 µl RNase-free (Quiagen) water and stored 
at -20°C. 4.2.1.3.2 Reverse transcription (RT) 
To synthesize single-stranded cDNA from total RNA, a step of reverse transcription is necessary. 
Equal amount of 1 µg of total RNA per cell line taken up in 10 µl of RNase free water is used for a 20 
µl-reaction using High-capacity cDNA Reverse Transcription kit (Applied Biosystems). Total RNA is 
mixed with 10 µl of RT master mix containing 2 µl of 10X RT buffer, 0.8 µl of 25X dNTP mix (100mM), 
2 µl of RT Random primers, 1 µl of MultiScribe Reverse transcriptase, 1 µl of RNase inhibitor and 
completed with 3.2 µl of nuclease-free water. The RT reaction is programmed in the thermal cycler as 
 BE(2)-M17 HEK 293 Flp-In TRex  
Maintenance medium  RPMI (Invitrogen) + 10% (v/v) 
FCS+ 500 µg/mL G418 
RPMI (Invitrogen) + 10% (v/v) 
FCS+ 15 µg/mL Blasticidin S+ 
200 µg/mL Zeocin 
Selection drug Puromycin (1 µg/mL) Hygromycin (50 µg/mL) 
Culture surface Collagen I coated flasks Uncoated flasks 
Neon Transfection conditions 
(Pulse voltage [V]- Pulse 
width[ms]- Pulse number[n]) 
1600- 20- 1 1300- 30- 1 
Number of cells per pulse/ 
Total transfected cells per line 
1x 106/10x 106 1x 106/5x 106 
Plasmid amounts per pulse 2.5 µg pTRE-Tight-ASYN+ 0.5µg 
pIRES-Puromycin 
4 µg pcDNA/FRT/TO+ 0.5µg 
pOG44 
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following: 25°C 10 min- 37°C 120 min- 85°C 5 s- 4°C ∞. cDNA resulted from RT reaction can be stored 
at 4°C up to 24 h and then at -20°C for long-term use. 4.2.1.3.3 Quantitative PCR 
To determine and compare the expression of α-Synuclein mRNA between the cell lines, quantitative 
PCR approach was performed using cDNA template from the RT reaction. Amplification of ASYN 
transgene (target gene) is performed using specific primers (aSyn-F, 5’GGACTGAGCAAGGCTAAGGA; 
aSyn -R, 5’ CTTCAGCCACTCCCTGTTTG) and the Taq Man probe from the Universal Probe Library 
(UPL#66, Roche). The qPCR master mix is based on the protocol using TaqMan®GAPDH control 
regeants (human) (Applied Biosystems). Cycling program and relative quantification method is set up 
in the same manner as described in 1.3.2.2. 4.2.2 Cell lysis/ Protein extraction 
Medium are removed and cells are washed two times in cold PBS (Sigma-Aldrich) with gentle rocking 
for 5 min each. Then cells are lysed in Triton lysis buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 1.5 mM 
MgCl2, 1 mM EGTA, 1% Triton X-100) supplemented with protease inhibitors (Roche) or in RIPA lysis 
buffer (50 mM Tris pH 8.0, 150mM NaCl, 1% (v/v) Nonidet P40, 0.5% (w/v) Sodiumdeoxycholate, 
0.1% (w/v) SDS, 100mM NaF) supplemented with protease inhibitors (Roche) and 25 U/µl Benzonase. 
The cell lysates are incubated on ice during 5 min then clarified by centrifugation at 15000 x g for 15 
min at 4°C. The supernatant are quantified for total protein content using BCA kit (Thermo Fisher 
Scientific). Protein samples are diluted in NuPAGE LDS Sample Buffer (Invitrogen) and deionized 
water then heated up at 70°C for 10 min. Long-term storage at -20°C requires for further use. 4.2.3 Western-blot 
Total proteins are separated and blotted onto nitrocellulose or PVDF membrane following the same 
procedure as in 4.1.3.2 for protein extracts from brain tissue. Immunoblotting is performed using 
appropriate primary antibody dilutions in Roti block buffer (Roth) for overnight at 4°C. Revelation is 
done by Odyssey scanning. 4.2.4 Immunocytochemistry 
Cells are transferred from the culture dish to µ-slides VI (ibiTreat, ibidi) at 80% of density and 
incubated in culturing medium at 37°C for at least two hours that allow the cells to adhere onto the 
bottom of the slide. The cells are washed two times with PBS (100 µl per well) to remove medium, 
each wash step is performed with gentle rocking during 5 min, then fixed in formalin buffered 
solution (Sigma- Aldrich) (50µl per well) at room temperature for 15 min. Cells are washed two times 
for 5 min to remove the fixative and permeabilised with 0.1% Triton X diluted in PBS for 10 min at 
room temperature. After two washes in PBS to remove the Triton solution, cells are blocked with 
block buffer (5% (v/v) of goat serum, 0.5% (w/v) of BSA in PBG buffer which contains 0,045% (w/v) of 
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fishgelatine in PBS). The blocking can be done overnight at 4°C or 1 hour at room temperature.  After 
the blocking, cells are washed one time in PBG buffer and immunolabeled with the first antibody 
diluted in antibody diluent (5% (w/v) goat serum in PBG buffer) at room temperature for 1 hour. The 
first antibody is removed by three washing steps of 10 min each before applying the secondary 
antibody Alexa conjugated at room temperature for 45 min. Cells are again washed two times with 
PBG buffer then stained for DNA with 2µM Hoechst (Invitrogen) diluted in PBS for 10 min at room 
temperature. Finally, cells are washed two times with PBS and stored at 4°C. 
4.2.5 Kinetics of α-Synuclein degradation assay 
Assay of kinetic of α-Synuclein degradation consist of comparing the remaining α-Synuclein protein 
levels at different time-point after stopping the expression of α-Synuclein of inducible cell systems 
(Vogiatzi et al., 2008). Cells are allowed to fully express α-Synuclein: Tet- off cells BE(2)-M17 are 
cultured in absence of Dox, Tet-on cells HEK-293 TRex are cultured in presence of 15 ng/mL of Dox 
during 7 days with renewing of culture medium every 2-3 days to maintain Dox levels in medium. The 
day before starting experiment, 1x105 per well are seeded in 6-well plates in presence of 2 mL of 
induction medium (the number of wells per cell line depends on the different time points in function 
of experiment design, a triplicate for each time point is routinely made per experiment).  
To stop the expression of α-Synuclein in Tet-off cells (BE(2)-M17), culture medium are replaced with 
medium containing Dox (1 µg/mL). Time-point 0h is determined at the moment of adding Dox (1 
µg/mL) into Tet-off cells, cells are collected immediately for cell lysis.  
To stop the expression of α-Synuclein in Tet-on cells (HEK-293), cells are collected by centrifugation 
at 700 g during 5 min following by 2 washes with PBS to completely remove Dox in the medium. Cells 
are seeded into clean 6-well plates. Time-point 0h is determined as the moment after the second 
wash with PBS, the cells are collected immediately for cell lysis.  
The procedure of cell lysis is performed as described in 4.2 and α-Synuclein protein levels are 
determined by western-blotting using 15G7 antibody. The staining of β-Actin is used as loading 
control. The ratio of α-Synuclein/ β-Actin is calculated for each time-point.  
Protein level at each time point is measured by Odyssey software. Raw data are used to calculated 
relative protein level. All of statistic analysis and graphic design were performed with GraphPad 
Prism software, version 5. 
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 Primary 
antibody 
(antigen) 
Host 
species 
Concentration used in the studies Clone 
number 
Provider 
WB ICC IHC 
15G7 (α-Syn) Rat 500 ng/ mL 1 µg/ mL 1 µg/ mL 15G7 Supernatant 
received 
from 
C.Haas's lab 
Syn-1 (α-Syn) Mouse 500 ng/mL 500 ng/mL 500 
ng/mL 
42/α-
Synuclein 
BD 
Biosciences 
LB509 (α-Syn ) Mouse 1 µg/ mL n/a 1 µg/ mL LB 509 abcam 
GAPDH Chicken 100 ng/mL n/a n/a Polyclonal Sigma 
β-Actin Mouse 4 µg/ mL n/a n/a AC-74 Sigma 
Calbindin-D28K Mouse 200 ng/ mL  200 ng/ 
mL 
CB-955 Sigma 
VGAT Mouse 10 µg/ mL n/a 1 µg/ mL 117G4 Synaptic 
Systems 
mGluR1 Rabbit 20 µg/ mL n/a 20 µg/ mL 1630 Spring 
Bioscience 
Syntaxin Mouse 10 µg/ mL n/a 10 µg/ mL 
l 
HPC-1 Sigma 
Synaptophysin Rabbit 4 µg/ mL n/a 4 µg/ mL YE269 Milipore 
SNAP25 Rabbit 2 µg/ mL n/a 2 µg/ mL Polyclonal Sigma 
GFAP Rabbit 2 µg/ mL n/a 2 µg/ mL Polyclonal Dako 
Iba-1 Rabbit 500 ng/ mL n/a 1 µg/ mL Polyclonal Wako 
pS129 α-Syn Rabbit 500 ng/ mL n/a 1 µg/ mL EP1536Y Epitomics 
Ubiquitin Mouse 500 ng/ mL n/a 1 µg/ mL Ubi-1 (aka 
042691GS) 
Millipore 
LC3 Mouse 500 ng/ mL n/a n/a 5F10 Nano tools 
 
Table 4.3: List of primary antibodies used in the studies. Abbreviations: WB= western-blot, ICC= 
immunocytochemistry, IHC= immunohistochemistry, n/a= not applied 
 
 
Secondary antibody 
(antigen) 
Host 
specie
s 
Concentration used in the studies Provider 
WB ICC IHC 
Anti-rat IRD800 Goat 1.25 µg/ mL n/a n/a Rockland 
Anti-rat IRD700 Goat 1.25 µg/ mL n/a n/a Rockland 
Anti-mouse IRD800 Goat 1.25 µg/ mL n/a n/a Rockland 
Anti-mouse IRD700 Goat 400 ng/ mL n/a n/a Rockland 
Anti-chicken IRD800 Goat 1.25 µg/ mL n/a n/a Rockland 
Anti-chicken IRD700 Goat 200 ng/ mL n/a n/a Rockland 
Anti-mouse Alexa Fluor 488 Goat n/a 10 µg/ mL 10 µg/ mL Molecular 
probes 
Anti-mouse Alexa Fluor 594 Goat n/a 10 µg/ mL 10 µg/ mL Molecular 
probes 
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Anti-rabbit Alexa Fluor 488 Goat n/a 10 µg/ mL 10 µg/ mL Molecular 
probes 
Anti-rabbit Alexa Fluor 594 Goat n/a 10 µg/ mL 10 µg/ mL Molecular 
probes 
Anti-rat 488 Goat n/a 10 µg/ mL 10 µg/ mL Molecular 
probes 
Anti-rat 594 Goat n/a 10 µg/ mL 10 µg/ mL Molecular 
probes 
Anti-rat (biotinylated) Goat n/a n/a 7.5 µg/ mL Vector 
laboratories 
Anti-mouse (biotinylated) Goat n/a n/a 7.5 µg/ mL Vector 
laboratories 
Anti-rabbit (biotinylated) Goat n/a n/a 7.5 µg/ mL Vector 
laboratories 
 
Table 4.4: List of secondary antibodies used in the studies. Abbreviations: WB= western-blot, ICC= 
immunocytochemistry, IHC= immunohistochemistry, n/a= not applied 
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5 Annex figures 
 
A
B
Annex 1: Diagrams showing two steps of generation Tet-on stable cell lines using Flp-In T-REx systems
(Life technologies).
A. Step 1: Flp-In T-REx host cell line is generated by stable transfection of pFRT-LacZ-Zeocin then pcDNA6/TR
vectors. Host cell line contains the FRT sites and is resitant to Zeocin and Blasticidin.
B: Step 2: Flp-In T-REx expression cell line is generated by double stable transfection of pcDNA5/FRT/TO
(containing gene sequence of interest) and pOG44 vectors (expressing Flp recombinase which catalyzes
recombination between the FRT sites and pcDNA5/FRT/TO vector. Expression cell line looses Zeocin resistance
and gains Hygromycin resistance.
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Annex 2: Inducibility of LacZ transgene expression in cerebellum using of Pcp2-tTA driver line.
A: X-gal staining showing apparition of β-galactosidase expression level in cerebellum tissue homogenates from 
Pcp2-tTA/TetO-LACZ mice at 10, 15 and 20 days post-natal (P10, P15, P20),  pictures of paraffin sections of 7-
µm thickness.
B: Down-regulation of β-galactosidase expression by adding Dox (Dox chow 200mg/kg, Bioserve) to adult Pcp2-
tTA/TetO-LACZ mice during 2, 6 or 10 days, pictures of paraffin sections of 7-µm thickness. Food pellets were 
renwewed every week.
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Annex 3: Homozygotic animals does not show significant difference in α -Synuclein protein levels.
A, B: Western-blot showing in α-synuclein level in cerebellum tissue homogenates from TgA mice at 25 day-old
post-natal (P25), total protein loaded per lane: 20µg, antibody 15G7 anti- α-Synuclein, GAPDH is used as loading
control. C, D: Diagram representing the mean ±SEM of signal ratio α-synuclein/GAPDH of each genotype, n= 3
per genotype (Abbreviations: Ho/Ho: tTA homozgote/SNCA homozygote; Ho/He: tTA homozgote/SNCA
heterozygote; He/Ho: tTA heterozygote/SNCA homozgote; He/He: tTA heterozygote /SNCA heterozygote).
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Annex 4: Optimization of overexpressed α -Synuclein detection in adult mouse brain (~3mo)
homogenates.
A: Western-blots showing expression of α-Synuclein in three separate brain structures using different antibodies
(15G7 and LB509: human specific, Syn-1: human and mouse specific). Per lane: 20µg of total protein from each
brain structure homogenates are loaded (OB= Olfactory bulb, MB= Mid-brain (Cortex+ Basal ganglia), CB=
Cerebellum)
B: Western-blots showing signals detection when primary antibody is not applied (left) and when blot was
incubated with primary antibody (15G7). Background results from non-specific binding of secondary antibody.
A.
B.
GAPDH
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Non-specific 
detection
α-Synuclein
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Brain structure: OB MB CB OB MB CB OB MB CB
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- + (15G7)
15G7 LB509 Syn-1
Non-specific 
detection
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Annex 5: Overexpression of α -Synuclein does not lead to change of LC3 protein levels in cell lines. 
Western-blots showing LC3 and α-Synuclein protein levels in induced and non-induced conditions in HEK-293 
cells (left) and BE(2)-M17 cells (right), β-Actin is used as loading control. 
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Annex 6: Locomotor activities of animals recorded by Open-field test during active phase.
A: Total traveling distance from ages of 6 to 22.5 months.Data represent the mean ±SEM of traveling distance.
B: Total rearing activities from ages of 6 to 22.5 months.Data represent the mean ±SEM rearing activities.
(WT: n= 15, Pcp2-tTA: n=22, A53T-∆CT: n=16, A53T-∆CMA: n=18)
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Annex 7: Motor coordination and motor balance phenotyping.
Post-analysis of ambulatory movement for “symptomatic” (left) and “non-symptomatic” (right) groups . Data
represented the mean ±SEM of total traveling distance ages of 6 to 21 months (Pcp2-tTA: n=22, A53T-∆CT: n=7,
A53T-∆CMA:n=7).
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Annex 8: Motor coordination and motor balance phenotyping.
A: Latency of animals on rotarod. Data represent the mean of total time to stay on accelerating rod (in s) (Pcp2-
tTA: n=22, A53T-∆CT: n=16,A53T-∆CMA: n=18).
B: Post-analysis of latency on rotarod for “symptomatic” (left) and “non-symptomatic” (right) groups . Data
represented the mean ±SEM of latency ages of 5 to 19.5 months (Pcp2-tTA: n=22, A53T-∆CT: n=7, A53T-∆CMA:
n=7).
“Symptomatic” group “Non-symptomatic” group
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